# EDGAR Filing Document

**Accession Number:** 0001058307
**File Stem:** 0001437749-26-010668
**Filing Date:** 2026-3
**Character Count:** 362826
**Document Hash:** 3feebecb74e69fe7ea98adfab659cadc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-010668.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0001437749-26-010668

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 116

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NextPlat Corp
- **CENTRAL INDEX KEY:** 0001058307
- **STANDARD INDUSTRIAL CLASSIFICATION:** TELEPHONE COMMUNICATIONS (NO RADIO TELEPHONE) [4813]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 650783722
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40447
- **FILM NUMBER:** 26822316

**BUSINESS ADDRESS:**
- **STREET 1:** 400 ANSIN BLVD
- **STREET 2:** SUITE A
- **CITY:** HALLANDALE BEACH
- **STATE:** FL
- **ZIP:** 33009
- **BUSINESS PHONE:** 1-305-560-5381

**MAIL ADDRESS:**
- **STREET 1:** 400 ANSIN BLVD
- **STREET 2:** SUITE A
- **CITY:** HALLANDALE BEACH
- **STATE:** FL
- **ZIP:** 33009

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ORBSAT CORP
- **DATE OF NAME CHANGE:** 20190819

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Orbital Tracking Corp.
- **DATE OF NAME CHANGE:** 20150128

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Great West Resources, Inc.
- **DATE OF NAME CHANGE:** 20140514

?xml version='1.0' encoding='ASCII'? nxpl20251231_10k.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-K**

(Mark One)

☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the fiscal year ended December 31, 2025**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _______ to _______**

**Commission file number 001-40447**

**NEXTPLAT CORP**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **65-0783722** |
| *(State or other jurisdiction of* | *(I.R.S. Employer* |
| *incorporation or organization)* | *Identification No.)* |
| 400 Ansin Blvd, Suite A, Hallandale Beach, FL | **33009** |
| *(Address of principal executive offices)* | *(Zip Code)* |

---

Registrant's telephone number, including area code: **(305) 560-5381**

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: Common Stock, par value $0.0001

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," and "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Non-accelerated filer ☒ | Smaller reporting company ☒ |
|  | Emerging growth company ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of the last business day of the registrant's most recently completed second fiscal quarter (June 30, 2025), was approximately $11.2 million (based on a closing sale price of $0.74 per share as reported on the NASDAQ Stock Market).

The number of outstanding shares of the registrant's common stock, par value $0.0001 per share, as of March 27, 2026, was 27,026,215**.**

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant's definitive proxy statement for its 2026 Annual Meeting of Shareholders to be filed with the SEC no later than 120 days after the end of the registrant's fiscal year are incorporated by reference in Part III of this Annual Report on Form 10-K.

------

[**Table of Contents**](#toc)

**NEXTPLAT CORP**

**ANNUAL REPORT ON FORM 10-K**

**Fiscal Year Ended December 31, 2025**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **Page** |
| [**PART I**](#part_1) | [**PART I**](#part_1) |
| [Item 1. Business](#item1_business) | [3](#item1_business) |
| [Item 1A. Risk Factors](#item1A_riskfactors) | [18](#item1A_riskfactors) |
| [Item 1B. Unresolved Staff Comments](#item1B_unresolved) | [29](#item1B_unresolved) |
| [Item 1C. Cybersecurity](#Item_1C_Cybersecurity) | [29](#item1B_unresolved) |
| [Item 2. Properties](#item2_description) | [30](#item2_description) |
| [Item 3. Legal Proceedings](#item3_legal) | [31](#item3_legal) |
| [Item 4. Mine Safety Disclosures](#item4_minesafety) | [31](#item4_minesafety) |
| [**PART II**](#part_2) | [**PART II**](#part_2) |
| [Item 5. Market for Registrant<u>'</u><u>s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</u>](#item5_market) | [32](#item5_market) |
| [Item 6. \[RESERVED\]](#item6_reserved) | [34](#item6_reserved) |
| [Item 7. Management<u>'</u><u>s Discussion and Analysis of Financial Condition and Results of Operations</u>](#item7_mda) | [34](#item7_mda) |
| [Item 7A. Quantitative and Qualitative Disclosures About Market Risk](#item7a_quantitative) | [46](#item7a_quantitative) |
| [Item 8. Financial Statements and Supplementary Data](#item8_financial) | [47](#item8_financial) |
| [Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure](#item9_changes) | [48](#item9_changes) |
| [Item 9A. Controls and Procedures](#item9A_controls) | [48](#item9A_controls) |
| [Item 9B. Other Information](#item9B_other) | [51](#item9B_other) |
| [Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](#item9C_disclosure) | [52](#item9C_disclosure) |
| **[PART III](#part3)** | **[PART III](#part3)** |
| [Item 10. Directors, Executive Officers and Corporate Governance](#item10_directors) | [53](#item10_directors) |
| [Item 11. Executive Compensation](#item11_executive) | [53](#item11_executive) |
| [Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](#item12_security) | [53](#item12_security) |
| [Item 13. Certain Relationships and Related Transactions, and Director Independence](#item13_relationships) | [53](#item13_relationships) |
| [Item 14. Principal Accountant Fees and Services](#item14_principal) | [53](#item14_principal) |
| [**PART IV**](#part4) | [**PART IV**](#part4) |
| [Item 15. Exhibits and Financial Statement Schedules](#item15_exhibits) | [53](#item15_exhibits) |
| [Item 16. Form 10-K Summary](#item16_summary) | [57](#item16_summary) |
| [Signatures](#signatures) | [57](#signatures) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

[**Table of Contents**](#toc)

**PART I**

**Cautionary Statement Regarding Forward-Looking Statements**

*Portions of this Annual Report on Form 10-K (including information incorporated by reference) include* "*forward-looking statements*" *based on our current beliefs, expectations, and projections regarding our business strategies, market potential, future financial performance, industry, and other matters. This includes, in particular,* "*Item 7* — *Management*'*s Discussion and Analysis of Financial Condition and Results of Operations*" *of this Annual Report on Form 10-K, as well as other portions of this Annual Report on Form 10-K. The words* "*believe,*" "*expect,*" "*anticipate,*" "*project,*" "*could,*" "*would,*" *and similar expressions, among others, generally identify* "*forward-looking statements,*" *which speak only as of the date the statements were made. The matters discussed in these forward-looking statements are subject to risks, uncertainties, and other factors that could cause our actual results to differ materially from those projected, anticipated, or implied in the forward-looking statements. The most significant of these risks, uncertainties, and other factors are described in* "*Item 1A* — *Risk Factors*" *of this Annual Report on Form 10-K. Except to the limited extent required by applicable law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.*

**ITEM 1. BUSINESS**

NextPlat Corp ("NextPlat," "the Company," "we," "our," or "us") is a global e-commerce and healthcare services company that operates through two reportable segments: e-Commerce Operations and Healthcare Operations. Through these segments, the Company provides satellite-enabled communication products and services, global online distribution capabilities, pharmacy services, healthcare technology solutions, and data analytics services. Our platforms serve consumers, enterprises, healthcare providers, government organizations, and other institutions across multiple geographic markets. For the year ended December 31, 2025, approximately 27% of revenue was generated by our e-Commerce segment and 73% by our healthcare segment.

The Company operates internationally through a combination of proprietary e-commerce websites, third-party marketplace storefronts, physical pharmacy locations, and healthcare technology platforms. Our strategy is focused on expanding recurring revenue streams, increasing global e-Commerce distribution, and leveraging healthcare data and pharmacy services to improve patient outcomes while supporting healthcare providers and payors.

<u>**e-Commerce Operations**</u>

Our e-commerce segment provides satellite communications products, connectivity services, and related equipment to customers globally through proprietary online platforms and third-party marketplaces. Historically, the Company's core business has centered on the distribution of satellite-enabled communications equipment and services designed for use in remote or infrastructure-limited environments. These solutions provide voice, messaging, data connectivity, asset tracking, and emergency communications capabilities in locations where traditional telecommunications networks are unavailable or unreliable.

Our e-commerce operations currently include:

● Three proprietary global e-Commerce websites

● Approximately 25 third-party marketplace storefronts

● More than 10,000 product listings across multiple marketplaces

These platforms enable us to distribute products globally to customers located in more than 165 countries.

Our e-Commerce operations generate revenue from two primary sources: (i) product sales including satellite phones, tracking devices, broadband terminals, and related equipment and (ii) recurring service revenue including satellite airtime subscriptions, messaging plans, and connectivity services. Recurring airtime and service plans represent an increasing proportion of revenue as many products require ongoing connectivity subscriptions. A significant portion of our revenue is generated through third-party marketplaces, particularly Amazon, which represented approximately 31% of total e-Commerce revenue in 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

[**Table of Contents**](#toc)

<u>Satellite Communications Products and Services</u>

Through our subsidiaries Global Telesat Communications Ltd ("GTC"), Orbital Satcom Corp ("Orbital Satcom"), and Outfitter Satellite, Inc. ("Outfitter"), we provide Mobile Satellite Services ("MSS") solutions to fulfill the growing global demand for satellite-enabled voice, data, personnel and asset tracking, Machine-to-Machine ("M2M") and Internet of Things ("IoT") connectivity services. We provide these solutions for businesses, governments, military, humanitarian organizations, and individual users, enabling them to communicate, connect to the internet, track and monitor remote assets and lone workers, or request SOS assistance via satellite from almost anywhere in the world, even in the most remote and hostile of environments.

We provide voice, data communications, IoT and M2M services via Geostationary and Low Earth Orbit ("LEO") satellite constellations and offer reliable connectivity in areas where terrestrial wireless or wireline networks do not exist or are limited, including remote land areas, open ocean, airways, the polar regions and regions where terrestrial networks are not operational, for example due to political conflicts and natural or man-made disasters.

We generate revenue from both the provision of services and the sale of equipment. Higher margin recurring service revenue from the sale of monthly, annual, and prepaid airtime or messaging plans has historically represented an increasing proportion of our revenue, and we expect that trend to continue as we introduce new products requiring associated airtime or messaging plans.

We provide our products and services directly to end users and reseller networks located both in the United States and internationally through our subsidiaries: U.K. based GTC; U.S. based Orbital Satcom and Outfitter. We have a physical presence in the United States and the United Kingdom, as well as an e-Commerce storefront presence in 18 countries across five continents. We have a diverse geographical customer base having provided solutions for more than 60,000 customers located in more than 165 countries across most every continent in the world.

<u>MSS Products</u>

Our MSS products rely on satellite networks for voice, data and tracking connectivity and thus are not reliant on cell towers or other local infrastructure. As a result, our MSS solutions are suitable for recreational travelers and adventurers, government and military users, and corporations and individuals wishing to communicate or connect to the internet from remote locations, or in the event of an emergency such as a power outage, following a hurricane or other natural disaster during which regular cell phone, telephone and internet service may not be available.

Our satellite communications products enable users to make voice calls, send and receive text messages and emails, and transmit GPS location coordinates from virtually anywhere on the planet, no matter how remote the location and regardless of the availability of local communication infrastructure. Our range of satellite data products allows users around the world to connect to the internet, stream live video, and communicate via voice and data applications.

We are a provider of GPS enabled emergency locator distress beacons that can save lives, on land and at sea. Our distress beacons enable essential communication between our customers and search and rescue organizations during emergency situations and pinpoint locational information to Search and Rescue services, essential during an emergency.

We provide a wide range of satellite tracking devices used to monitor the location, movements, and history of almost anything that moves. We specialize in offering satellite tracking services through the Globalstar satellite network and have supplied tens of thousands of tracking devices which are used around the world to locate lone workers, track shipping containers, livestock, vehicles, and vessels along with many other types of assets.

<u>Mapping and Tracking Portal</u>

Our advanced subscription-based mapping and tracking portal, GTCTrack, is available for use by registered customers who pay a monthly fee to access it. This mapping portal provides a universal and hardware-agnostic, cloud-based data visualization and management platform that allows managers to track, command, and control assets in near-real-time. Asset location reports including position, speed, altitude, heading and past location and movement history reports for a wide range of tracking devices and other products sold by us are available through GTCTrack.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

[**Table of Contents**](#toc)

<u>Online Storefronts and e-Commerce Platforms</u>

We operate three e-Commerce websites offering a range of MSS products and solutions through our subsidiaries, Orbital Satcom, which targets customers in North and South America, and GTC which targets customers in the UK, EU, Middle East, Asia and the rest of the world. These websites produce sales and attract enquiries from customers and potential customers from all around the world. Over the long term, we plan to develop additional country-specific websites to target customers in South America, Asia, and Europe where we anticipate there will be substantial further demand for our products.

In addition to our three main e-Commerce websites, we make portable satellite voice, data and tracking solutions easier to find and buy online through our various third-party e-Commerce storefronts such as Alibaba, Amazon, Mercado Libre, OnBuy and Walmart. We currently operate 25 storefronts across various countries on five continents. We have invested in personnel to translate our listings correctly in the different countries we are represented in and intend to regularly improve and increase our listings on all e-Commerce sites. We currently have more than 10,000 product listings on all third-party sites and invest significantly in inventory to hold at Amazon's various fulfillment centers around the world to ensure that orders are shipped to customers as quickly as possible. The products include handheld satellite phones, personal and asset tracking devices, portable high-speed broadband terminals, and satellite Wi-Fi hotspots. Our Amazon online marketplaces represented approximately 31% and 33% of e-Commerce revenue for the years ended December 31, 2025, and 2024, respectively, and we anticipate that these marketplaces will continue to represent a significant portion of our revenue for the foreseeable future. Our e-Commerce storefronts enable us to attract a significantly diversified level of sales from all over the world, ensuring we are not overly reliant on any single market or sector for our sales revenue. Furthermore, many products we sell require subscription-based services which allow us to increase our recurring revenue from airtime sales.

*<u>Florida Sunshine Brands, LLC:</u>*

Florida Sunshine Brands, LLC ("Florida Sunshine") is a Florida limited liability company and incorporated December 6, 2023. Florida Sunshine operates under an operating agreement between NextPlat, with a 51% ownership, and Outer Brands FS, LLC, with a 49% ownership. Florida Sunshine's main objective is to source and sell vitamins and nutritional supplements.

**Industry and Market of our e-Commerce Operations Business**

We compete in the mobile satellite products and services sector of the global communications industry. The products and airtime that we sell are intended to meet users' needs for connectivity in all locations where existing terrestrial wireline and wireless communications networks do not exist, do not provide sufficient coverage, or are impaired. Government organizations, including military and intelligence agencies and disaster response agencies, non-governmental organizations and industrial operations and support teams depend on mobile voice and data satellite communications products and services on a regular basis. Businesses with global operations require reliable communications services when operating in remote locations around the world. Mobile satellite services users span many sectors, including emergency services, maritime, aviation, government, utilities, oil and gas, mining, recreation, forestry, heavy equipment, construction, and transportation, among others. We believe many of our customers view satellite communications products and services as critical to their daily operations.

We believe there is a fast-growing, multi-billion-dollar global market for a small and cost-effective solution for receiving and processing mobile voice and data communications from remote locations used in applications such as tracking vehicles or asset shipments, monitoring unattended remote assets or mobile security. Over the past two decades, the global mobile satellite services market has experienced significant growth. Increasingly, better-tailored, improved-technology products and services are creating new channels of demand for mobile satellite services. Growth in demand for mobile satellite voice services is driven by the declining cost of these services, the diminishing size and lower costs of the devices, as well as heightened demand by governments, businesses and individuals for ubiquitous global voice and data coverage. We believe our solutions are ideally suited for industries such as maritime, aviation, government/military, emergency/humanitarian services, mining, forestry, oil and gas, heavy equipment, transportation and utilities, as well as recreational users. We do not tailor our products and services to different types of customers as in our experience military, non-profit, government and recreational users tend to purchase the same types of products and services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5

------

[**Table of Contents**](#toc)

<u>Growth Strategy</u>

We intend to achieve our mission and further grow our business by pursuing the following strategies:

*<u>Increased product offerings and marketplace expansion</u>*: We are constantly increasing our product lines and offerings and will continue to do so in the future. Additionally, we intend to expand and open new global e-commerce storefronts around the world to develop revenue in new markets serving thousands of consumers, enterprises, and governments.

*<u>Government sourced revenue</u>*: We intend to target US government/GSA sales which have not historically represented a significant part of our revenue. We will also recruit experienced government sales professionals to assist with this plan. We plan to become an approved seller on the US Government's GSA Schedule ("Schedule"), which gives federal, and in some cases state and local buyers, access to a great number of commercial products and services at negotiated ceiling prices. Schedule purchases represent approximately 21% of overall federal procurement spending.

*<u>Future acquisitions</u>*: We will seek suitable acquisition opportunities to further increase our scale, expand revenue, and access new markets and sectors.

**Competition to our e-Commerce Operations Business**

The global satellite communications industry is highly competitive. In certain regions, such as North America, we currently face substantial competition from other service providers that offer a range of mobile and fixed communications options. In other regions, such as the UK and EU, we have a strong presence and are one of the leading providers of satellite communicators, emergency locator beacons and satellite tracking devices. We compete primarily on the basis of coverage, quality, portability, pricing and in the case of our e-commerce storefronts, availability of services and products.

The competitors for our satellite telecommunications services and products are other resellers of leading satellite networks such as Iridium, Inmarsat, Thuraya, Globalstar, and Starlink, some of which are also our suppliers. We expect the competition for our satellite telecommunications services and our satellite tracking and monitoring services to increase significantly as market demand accelerates.

We believe that we are well positioned to compete for the satellite telecommunications services business largely on a cost basis and our global e-commerce presence, which makes products more accessible to buy as compared to more traditional methods of purchasing e.g., bricks and mortar storefronts.

<u>Competitive</u> <u>Strengths</u>

We believe that the following strengths contribute to our success:

*<u>Global presence and expertise</u>*: Our global presence enables us to compete in various markets around the world, with our multi-lingual personnel allowing us to respond to global customer inquiries with 24/7/365 customer support. Our significant expertise in global e-commerce sales allows us to maintain a competitive advantage over traditional methods of purchase through "brick and mortar" stores. Additionally, our significant levels of inventory stored in fulfillment centers around the world enable us to quickly secure customer orders against competitors who may not hold available inventory.

*<u>Cost advantage through economies of scale</u>*: As a leading provider of MSS products, we benefit from significant economies of scale across our supply chain and distribution network that enable us to offer competitive prices for our products.

*<u>Strategic partnerships and industry expertise</u>*: Our long-standing contractual relationship and deep operational experience with Globalstar position us as a trusted and capable partner in satellite tracking and related connectivity solutions. These established partnerships provide us with privileged insight into system requirements, early access to upcoming opportunities, and a proven track record of performance.

*<u>Diverse customer base</u>*: No single customer represents more than 3% of our annual gross e-Commerce revenue and no single country represents more than 33% of our gross e-Commerce annual revenue as of December 31, 2025. This diversification reasonably permits the Company not to rely on any single customer, or group of customers, on any single product line, or any specific geographic area.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6

------

[**Table of Contents**](#toc)

<u>**Healthcare Operations**</u>

Our Healthcare segment operates through a wholly owned subsidiary, Progressive Care, LLC, ("Progressive") a Nevada Limited Liability Company, which includes wholly owned subsidiaries, Pharmco, LLC doing business as Pharmcorx and Pharmcorx LTC ("Pharmco 901"), Touchpoint RX, LLC doing business as Pharmco Rx 1002, LLC ("Pharmco 1002"), Family Physicians RX, Inc. doing business as PharmcoRx 1103 and PharmcoRx 1204 ("FPRX" or "Pharmco 1103" and "Pharmco 1204") (pharmacy subsidiaries collectively referred to as "Pharmco"), and ClearMetrX Inc. ("ClearMetrX"). Pharmco provides prescription pharmaceuticals, compounded medications, anti-retroviral and other specialty medications, medication therapy management, the supply of prescription medications to long-term care facilities, contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program, medication fulfillment services for contracted government facilities, and health practice risk management. ClearMetrX offers personalized healthcare services and technology that provides prescription pharmaceuticals and risk and data management services to healthcare organizations and providers.

We offer services in a variety of languages, including English, Spanish, French, Creole, Portuguese, Ukrainian, and Russian.

Our services are designed to provide satisfaction across all medication stakeholders and enhance loyalty and key performance metrics. We offer value-added services at no additional charge including prior authorization assistance, same-day home-medication delivery, on-site provider consultation services, primary care reporting and analytics, and customized packaging solutions. The pharmacies accept most major insurance plans and provide access to co-pay assistance programs to income qualified patients, discount and manufacturer coupons, and competitive cash payment options.

<u>Healthcare Products and Services</u>

We enhance patient adherence to complex drug regimens, collect and report data, and ensure effective dispensing of medications to support the needs of patients, providers, and payors. Our patient and provider support services ensure appropriate drug initiation, facilitate patient compliance and adherence, and capture important information regarding safety and effectiveness of the medications that we dispense.

Pharmco is rated by pharmacy benefit managers ("PBMs") based on its ability to adequately supply chronic care medications to patients during a measurement period. This score is then compared to the scores of other pharmacies in the network at which point a relative rating is issued. For the year ended December 31, 2025, per EQuIPP®, a performance information management tool that provides standardized, benchmarked data to help shape strategies and guide medication-related performance improvement, our performance score was Five Stars, ranking our pharmacy among the top pharmacies in the U.S. Primary care physicians may refer patients to pharmacies that have high performance scores, though patients retain the right to have their prescriptions dispensed by a network of pharmacies of their choice.

Through our wholly owned subsidiary, ClearMetrX, we offer data management and reporting services to support health care organizations. There are substantial restrictions in federal and state laws on the use and sharing of patient data and ClearMetrX is in compliance with such laws. ClearMetrX offerings include data management and Third-Party Administration ("TPA") services for 340B covered entities, pharmacy data analytics, and programs to manage HEDIS Quality Measures including Medication Adherence. These offerings cater to the glaring need for frontline providers to understand best practices, patient behaviors, care management processes, and the financial mechanisms behind these decisions. We provide data access and actionable insights that providers and support organizations can use to improve their practice and patient care.

Pharmco pharmacies provide contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program. Under the terms of these agreements, our pharmacies act as a pass-through for reimbursements on prescription claims adjudicated on behalf of the 340B covered entities in exchange for a dispensing fee per prescription. These fees vary by the covered entity and the level of services we provide.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7

------

[**Table of Contents**](#toc)

Pharmco also provides purchasing, special packaging, and dispensing of both prescription and non-prescription pharmaceutical products to long-term care ("LTC") facilities. Pharmco utilizes a unit-of-dose packaging system as opposed to the traditional vials as this method of distribution is the best practice standard in the industry. Pharmco is equipped for various types of unit-of-dose packaging options to meet the needs of LTC patients and retail customers. Pharmco uses the same robotic packaging systems currently used by chain, mail order, and large-scale pharmacies. Pharmco also provides computerized maintenance of patient prescription histories, third-party billing and consultant pharmacist services. Pharmco's consultant pharmacist services consist primarily of evaluation of monthly patient drug therapy and monitoring the LTC institution's drug distribution system.

Medication therapy management ("MTM") involves review and adjustment of prescribed drug therapies to improve patient health outcomes for patients with multiple prescriptions. This process includes several activities such as performing patient assessments, creating medication treatment plans, monitoring the effectiveness of and adherence to prescribed therapies, and delivering documentation of these services to the patient's physician to coordinate comprehensive care.

Pharmco pharmacies also provide medication fulfillment services of both prescription and non-prescription pharmaceutical products for contracted government facilities.

<u>Distribution Methods</u>

Pharmco pharmacies are full-service retail and specialty services pharmacies that offer same-day and next-day free delivery to Florida's diverse population and currently holds Florida Community Pharmacy Permits at all Florida pharmacy locations. Pharmco 901 is a pharmacy located in Hallandale Beach, Florida, and is licensed as a non-resident pharmacy in the following states: Arizona, Colorado, Connecticut, Georgia, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Texas, and Utah. Pharmco 1103 is a pharmacy located in Orlando, Florida that provides pharmacy services to the Orlando/Tampa corridor and the Treasure Coast of Florida. Pharmco 1204 is a pharmacy located in North Miami Beach that provides pharmacy services to Miami-Dade and Broward counties, Florida. Pharmco 1002 is a pharmacy located in Palm Springs, Florida that provides pharmacy services to Palm Beach, St. Lucie and Martin counties, Florida.

**Industry and Market of our Healthcare Operations Business**

<u>Pharmacy Operations</u>

The retail pharmacy and pharmaceutical wholesale industries are highly competitive and dynamic and have experienced consolidation and an evolving competitive landscape in recent years. Prescription drugs play a significant role in healthcare, constituting a first line of treatment for many medical conditions. New and innovative drugs will improve quality of life and control healthcare costs. In light of accelerating usage of mail order and delivery-based services, we believe the market for personalized and convenient care access is increasing. We have provided same-day and next-day home delivery services since the beginning of our operations. We are well positioned in Florida to gain additional market share among a broad demographic of patients due to our high-performance scores and value-added services. Additionally, we value opportunities that create strategic partnerships, acquire synergistic operations and expand current operations to round out pharmacy capabilities which could potentially include, but are not limited to, specialty medications, sterile compounding, and mail-order.

<u>Data Management Services</u>

The latest trend in healthcare is to use data to improve patient outcomes and quality of life - a practice known as "Applied Health Analytics". "Data analytics" refers to the practice of aggregating large data sets and analyzing them to draw important insights and recommendations. This process is increasingly aided by new software and technology that facilitates the examination of large volumes of data to detect hidden information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8

------

[**Table of Contents**](#toc)

A key objective within organizations with access to large data collections is to harness the most relevant data and use it to optimize decision making. ClearMetrX developed the 340MetrX platform that retrieves dispensing pharmacy data to provide physicians and 340B covered entities with valuable and insightful reports and analytics to manage their operations.

We also serve the following key constituents, to benefit our patients:

*<u>Physicians and Health Systems</u>:* Our team works with physician offices to manage prior-authorization and other requirements of managed care organization requirements, such as denial and appeal process, to ensure that complicated administrative tasks do not impair the delivery of quality patient care. We provide risk evaluation services, implement risk mitigation strategies, and collect patient adherence data to provide physicians and health systems with enhanced visibility. Our tools and processes improve physician performance metrics which in turn results in enhanced profitability of the physicians' practices.

*<u>Payors</u>:* We manage prescription regimens for chronically ill populations and help payors, including health insurance plans and PBMs, reduce costs through patient care management, reduction in readmission rates, decreased acute care spending for chronic care conditions, formulary compliance, and implementation of lowest cost-effective alternative therapies.

<u>Virtual Healthcare Services and Healthcare Technologies</u>

Virtual healthcare services, such as Telehealth, are a growing segment of the healthcare sector. It involves remotely exchanging patient data between locations for the purposes of obtaining assistance in monitoring and diagnosing. Telehealth allows the healthcare practitioner to easily offer their services on consultation, care management, diagnosis, and self-management services using information and communication technologies. These services are being offered through various modes of delivery, such as on-premises, web-based, and cloud-based delivery. A growing population over the age of 65, the increase in the number of chronic diseases, and a rise in demand for home monitoring devices are the major drivers which are likely to aid the growth of the telehealth market.

In the current environment, healthcare information is increasingly fragmented with numerous electronic healthcare record platforms, virtual care systems, pharmacy software, and data silos and transmitters which lack fundamental integration. Healthcare stakeholders are often at odds about proper care techniques, and this lack of alignment increases burdens on providers and patients alike and is associated with decreasing satisfaction with healthcare services and negative health outcomes.

<u>Growth Strategy</u>

We plan to grow our healthcare operations business by executing on the following key growth strategies:

*<u>Data Management Services</u>:* We believe that data management for frontline and independent providers, 340B covered entities, and pharmacies will have increasing importance as health systems evolve to become virtual and digitized. Increasing focus on performance, margins, and quality, means that our models and platforms will have strategic value through our roots in day-to-day care management. Data management services will become an increasing driver of growth and development for us with its higher margins and diverse monetization pathways.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9

------

[**Table of Contents**](#toc)

*<u>Invest in Sales and Marketing</u>:* Our pharmacies are based in Florida and will continue to grow our dispensing operations throughout the state, and there are opportunities to expand geographically throughout the rest of the country. Our data management services and health IT services can be used by customers across the U.S., and we expect to continue to invest in sales and marketing efforts for these services.

*<u>Selectively Pursue Growth Through Strategic Acquisition</u>s:* We believe the specialty pharmacy industry is highly fragmented and provides numerous opportunities to expand through acquisitions. While we will continue to focus on growing our business organically, we believe we can opportunistically enhance our competitive position through complementary acquisitions in both existing and new markets. We plan to selectively evaluate potential acquisition opportunities in other therapeutic categories, services, and technologies with the goal of preserving our culture, optimizing patient outcomes, enhancing value to other constituents, and building long-term value for our shareholders.

**Competition to our Healthcare Operations Business**

<u>Competitive Strengths</u>

We believe we are well positioned to continue to increase our market share based on the following competitive strengths:

*<u>Adding value to all constituents</u>*: The value we deliver to all constituents is based upon our thousands of daily patient interactions. We help patients adhere to complicated medication therapies, process refills, manage any side effects, and manage any insurance concerns ensuring that they get the best standard of care. The clinical efficacy of drug therapies, especially for acute and chronic conditions, is typically enhanced when patients precisely follow the prescribed treatment regimens, including dosing and frequency.

*<u>Performance</u>*: Pharmacies are measured against their peers to improve quality of patient care. We have dedicated staff to track performance metrics, ensuring high comparative adherence rates. Across the population, an average 50% of patients are adherent to prescribed medication protocols. We believe our high adherence rates are due to, among other things, our model of proactive patient engagement, direct communication with and connections to healthcare stakeholders, our patient training and education, patient behavior analysis and medication coaching, compliance packaging, tracking timing of refills, free home delivery, and language support. We also help identify third-party funding support programs to help cover expensive out-of-pocket costs.

*<u>Clinically trained operational professionals</u>*: Our licensed pharmacists and technicians have been trained on our patient care model and data management tools to conduct a full healthcare evaluation. These healthcare professionals not only dispense medications, but also analyze patients' needs, behaviors, lifestyles, healthcare services providers, and payor resources to optimize the medication therapies received. Our staff conducts this full healthcare evaluation while also communicating necessary care information to authorized providers and caregivers before medications are dispensed, which differentiates our pharmacy operations from our competitors' models.

*<u>Lean and nimble operational strategy</u>*: Healthcare is an industry where best practices are continuously evolving. With increasing emphasis on reducing healthcare costs which puts pressure on gross margins, we have identified new trends and opportunities pivoting to business processes better suited to future environments. Additionally, we have focused on diversifying our revenue streams within the pharmacy industry to identify complementary and associated revenue opportunities to keep the operation one step ahead of market forces.

*<u>Diversity and cultural awareness</u>*: We represent the fabric of the community from which we originate. Our employees consist of diverse faiths, races, ethnic origins, and sexual orientations. This provides us with the unique ability to speak the language that our patients and providers speak. It has also allowed us to be innovative in our approach to healthcare by leveraging the broad perspectives of our team to challenge our methodologies and be responsive to the unique needs of our patients, clients, and customers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10

------

[**Table of Contents**](#toc)

<u>Competitive Positions and Methods of Competition</u>

We compete with national and independent retail drug stores, supermarkets, convenience stores, mail order prescription providers, discount merchandisers, membership clubs, health clinics, provider dispensaries, and internet pharmacies. Competition is based on several factors including store location and convenience, customer service and satisfaction, product selection and variety, and price. Our primary competitive advantages lie in providing personalized service to the patients and facility operators, selectively adding labor saving and compliance enhancing processes and carrying inventory to provide rapid delivery of all pharmaceutical needs, free home delivery services, and data management and analytics.

In the United States, the provision of healthcare services of any kind is highly competitive. Our ability to recruit qualified personnel, attract new institutional and retail clients, and expand the reach of our pharmacy operations relies on our ability to quickly adapt to changing societal attitudes, market pressure, and government regulation.

We face substantial competition within the pharmaceutical healthcare services industry and in the past year have seen even more consolidation. We expect to see this trend continue in the coming year and it is uncertain what effect, if any, these consolidations will have on us or the industry. The industry includes several large, well-capitalized companies with nationwide operations and capabilities in the specialty services and PBM services arenas, such as CVS Caremark, Express Scripts, Humana, Walgreens, Optum, MedImpact Healthcare Systems and many smaller organizations that typically operate on a local or regional basis. In the Specialty Pharmacy Services segment, we compete with several national and regional specialty pharmacy companies that have substantial financial resources and which also provide products and services to the chronically ill, such as CVS Caremark, Express Scripts, Humana, Optum and Walgreens.

Some of our pharmacy service competitors are under common control with, or are owned by, pharmaceutical wholesalers and distributors or retail pharmacy chains and may be better positioned with respect to the cost-effective distribution of pharmaceuticals. Some of our primary competitors, such as Omnicare and Walgreens, have a substantially larger market share than our existing market share. Moreover, some of our competitors may have secured long-term supply or distribution arrangements for prescription pharmaceuticals necessary to treat certain chronic disease states on price terms substantially more favorable than the terms currently available to us. Because of such advantageous pricing, we may be less price competitive than some of these competitors with respect to certain pharmaceutical products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11

------

[**Table of Contents**](#toc)

**Intellectual Property**

Our success and ability to compete depends in part on our ability to maintain our trade secrets. The Company owns registered trademarks, including nextplat® and associated nextplat design marks registered with the United States Patent and Trademark Office ("USPTO"), which are used in connection with the Company's e-commerce and healthcare operations. All of our employees and consultants are subject to non-disclosure agreements and other contractual provisions to establish and maintain our proprietary rights. The Company actively monitors and enforces its intellectual property rights to prevent unauthorized use and protect brand value.

**Regulatory Matters**

Government contract laws and regulations affect how we will do business with our customers, and in some instances will impose added costs on our business. A violation of specific laws and regulations could result in the imposition of fines and penalties, and the termination of any contracts, or the inability to bid on future contracts. We intend Orbital Satcom to become qualified as a government contractor. Our products may also be subject to regulation by the National Telecommunications and Information Administration and the Federal Communications Commission that regulate wireless communications.

Government approval is necessary to open any new pharmacy or other health services location.

<u>**Effect of Existing or Probable Governmental Regulations**</u>

As a participant in the healthcare industry, our operations and relationships are subject to federal and state laws and regulations and enforcement by federal and state governmental agencies. Various federal and state laws and regulations govern the purchase, dispensing or distribution, and management of prescription drugs and related services we provide and may affect us. We believe that we are in substantial compliance with all legal requirements material to our operations.

We conduct ongoing educational programs to inform employees regarding compliance with relevant laws and regulations and maintain a formal reporting procedure to disclose possible violations of these laws and regulations to the Office of Inspector General ("OIG") of the U.S. Department of Health and Human Services.

<u>**Professional Licensure**</u>. Pharmacists, pharmacy technicians and certain other health care professionals employed by us are required to be individually licensed or certified under applicable state law. We perform searches in criminal, federal and state exclusion lists, and other background checks on employees and are required under state licensure to ensure that our employees possess all necessary licenses and certifications. We believe that our employees comply in all material respects with applicable licensure laws.

State laws require that each pharmacy location be licensed as an in-state or non-resident pharmacy to dispense pharmaceuticals in that state. State controlled substance laws require registration and compliance with state pharmacy licensure, registration or permit standards promulgated by the state's pharmacy licensing authority and federal authority, the U.S. Drug Enforcement Agency ("DEA"). Such standards often address the qualification of an applicant's personnel, the adequacy of its prescription fulfillment and inventory control practices and the adequacy of its facilities. In general, pharmacy licenses are renewed annually or biennial according to state laws. We believe that our pharmacies' present and future locations comply with all state licensing laws applicable to these businesses. If our pharmacy locations become subject to additional licensure requirements, are unable to maintain their required licenses or if states place burdensome restrictions or limitations on pharmacies, our ability to operate in the state would be limited, which could have an adverse impact on our business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12

------

[**Table of Contents**](#toc)

<u>**Other Laws Affecting Pharmacy Operations**.</u> We are subject to federal and state statutes and regulations governing the operation of pharmacies, repackaging of drug products, wholesale distribution, dispensing of controlled substances, medical waste disposal, and clinical trials. Federal and state statutes and regulations govern the labeling, packaging, advertising and adulteration of prescription drugs and the dispensing of controlled substances. Federal and state-controlled substance laws require us to register our pharmacies with the DEA and to comply with security, record keeping, inventory control, labeling standards and other requirements to dispense controlled substances.

<u>**Food, Drug, and Cosmetic Act**</u>. Certain provisions of the federal Food, Drug and Cosmetic Act govern the handling and distribution of pharmaceutical products. This law exempts many pharmaceuticals and medical devices from federal labeling and packaging requirements if they are not adulterated or misbranded and are dispensed in accordance with, and pursuant to, a valid prescription. We believe that we comply in all material respects with all applicable requirements.

<u>**Anti-Kickback Laws**</u>. Subject to certain statutory and regulatory exceptions (including exceptions relating to certain managed care, discount, bona fide employment arrangements, group purchasing and personal services arrangements), the federal "anti-kickback" law prohibits the knowing and willful offer or payment of any remuneration to induce the referral of an individual or the purchase, lease or order (or the arranging for or recommending of the purchase, lease or order) of healthcare items or services paid for in whole or in part by Medicare, Medicaid or other government-funded healthcare programs (including both traditional Medicaid fee-for-service programs as well as Medicaid managed care programs). Violation of the federal anti-kickback statute could subject us to criminal and/or civil penalties including suspension or exclusion from Medicare and Medicaid programs and other government-funded healthcare programs for not less than five years, or the imposition of civil monetary penalties. Exclusion from any of these programs or sanctions of civil monetary penalties could have a material adverse impact on our operations and financial condition.

The federal anti-kickback law has been interpreted broadly by courts, the OIG of the U.S. Department of Health and Human Services ("HHS"), and other administrative bodies. Because of the broad scope of those statutes, federal regulations establish certain safe harbors from liability. Safe harbors exist for certain properly reported discounts received from vendors, certain investment interests held by a person or entity, and certain properly disclosed payments made by vendors to group purchasing organizations, as well as for other transactions or relationships. Nonetheless, a practice that does not fall within a safe harbor is not necessarily unlawful but may be subject to scrutiny and challenge. In the absence of an applicable exception or safe harbor, a violation of the statute may occur even if only one purpose of a payment arrangement is to induce patient referrals or purchases. Among the practices that have been identified by the OIG as potentially improper under the statute are certain "product conversion" or "switching" programs in which benefits are given by drug manufacturers to pharmacists or physicians for changing a prescription (or recommending or requesting such a change) from one drug to another. Anti-kickback laws have been cited as a partial basis, along with state consumer protection laws discussed below, for investigations and multi-state settlements relating to financial incentives provided by drug manufacturers to retail pharmacies about such programs.

Several states also have enacted anti-kickback laws that sometimes apply not only to state-sponsored healthcare programs but also to items or services that are paid for by private insurance and self-pay patients. State anti-kickback laws can vary considerably in their applicability and scope and sometimes have fewer statutory and regulatory exceptions than federal law. Management understands the importance of anti-kickback laws and has helped structure our operations in a manner believed to be compliant with these laws.

<u>**The Stark Law**</u>. The federal self-referral law, commonly known as the "Stark Law", prohibits physicians from referring Medicare or Medicaid patients for "designated health services" (which include, among other things, outpatient prescription drugs, durable medical equipment and supplies and home health services) to an entity with which the physician, or an immediate family member of the physician, has a direct or indirect financial relationship, unless the financial relationship is structured to meet an applicable exception. Several states have enacted laws similar to the Stark Law. These state laws may cover all, not just Medicare and Medicaid, patients and exceptions or safe harbors may vary from the Stark Law and vary significantly from state to state. Many federal healthcare reform proposals in the past few years have attempted to expand the Stark Law to cover all patients as well. Possible penalties for violation of the Stark Law include denial of payment, refund of amounts collected in violation of the statute, civil monetary penalties, and program exclusion. Noncompliance with the Stark Law could adversely affect our financial results and operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13

------

[**Table of Contents**](#toc)

<u>**Statutes Prohibiting False Claims and Fraudulent Billing Activities**</u>. A range of federal civil and criminal laws target false claims and fraudulent billing activities. One of the most significant is the federal False Claims Act (the "False Claims Act"), which imposes civil penalties for knowingly making or causing to be made false claims to secure a reimbursement from government-sponsored programs, such as Medicare and Medicaid. Investigations or actions commenced under the False Claims Act may be brought either by the government or by private individuals on behalf of the government, through a "whistleblower" or "qui tam" action. The False Claims Act authorizes the payment of a portion of any recovery to the individual suing. Such actions are initially required to be filed under seal pending their review by the Department of Justice. If the government intervenes in the lawsuit and prevails, the whistleblower (or plaintiff filing the initial complaint) may share with the federal government in any settlement or judgment. If the government does not intervene in the lawsuit, the whistleblower plaintiff may pursue the action independently. The False Claims Act generally provides for the imposition of civil penalties and for treble damages, resulting in the possibility of substantial financial penalties for small billing errors that are replicated in many claims, as each individual claim could be deemed to be a separate violation of the False Claims Act.

Some states also have enacted statutes like the False Claims Act which may include criminal penalties, substantial fines, and treble damages. In recent years, federal and state governments have launched several initiatives aimed at uncovering practices that violate false claims or fraudulent billing laws. Under Section 1909 of the Social Security Act, if a state false claim act meets certain requirements as determined by the OIG in consultation with the U.S. Attorney General, the state is entitled to an increase of ten percentage points in the state medical assistance percentage with respect to any amounts recovered under a state action brought under such a law. Some of the larger states in terms of population that have had the OIG review such laws include California, Florida, Indiana, Massachusetts, Michigan, Nevada, Tennessee and Texas. We operate in several of these states and submit claims for Medicaid reimbursement to the respective state Medicaid agency. This legislation has led to increased auditing activities by state healthcare regulators. As such, we have been the subject of an increased number of audits. While we believe that we are following Medicaid and Medicare billing rules and requirements, there can be no assurance that regulators would agree with the methodology employed by us in billing for our products and services and a material disagreement between us and these governmental agencies on the way we provide products or services could have a material adverse effect on our business and operations, our financial position, and our results of operations.

The False Claims Act also has been used by the federal government and private whistleblowers to bring enforcement actions under so-called "fraud and abuse" laws like the federal anti-kickback statute and the Stark Law. Such actions are not based on a contention that an entity has submitted claims that are facially invalid. Instead, such actions are based on the theory that when an entity submits a claim, it either expressly or impliedly certifies that it has provided the underlying services in compliance with applicable laws, and therefore that services provided and billed for during an anti-kickback statute or Stark Law violation result in false claims, even if such claims are billed accurately for appropriate and medically necessary services. The availability of the False Claims Act to enforce alleged fraud and abuse violations has increased the potential for such actions to be brought, and which often are costly and time-consuming to defend.

<u>**Confidentiality and Privacy**</u>. Most of our activities involve the receipt, use and disclosure of confidential medical, pharmacy or other health-related information concerning individual members, including the disclosure of the confidential information to the member's health benefit plan.

On April 14, 2003, the final regulations issued by HHS, regarding the privacy of individually identifiable health information (the "Privacy Regulations") pursuant to the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") took effect. The Privacy Regulations are designed to protect the medical information of a healthcare patient or health plan enrollee that could be used to identify the individual.

The requirements imposed by the Privacy Regulations, the Transactions Standards, and the Security Standards are extensive and can require substantial cost and effort to assess and implement. We have taken and will continue to take steps that we believe are reasonable to ensure that our policies and procedures are following the Privacy Regulations, the Transactions Standards, and the Security Standards. The requirements imposed by HIPAA have increased our burden and costs of regulatory compliance, altered our reporting to Plan Sponsors and reduced the amount of information we can use or disclose if members do not authorize such uses or disclosures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14

------

[**Table of Contents**](#toc)

<u>**Medicare Part D**</u>. The Medicare Part D program, which makes prescription drug coverage available to eligible Medicare beneficiaries, regulates various aspects of the provision of Medicare drug coverage, including enrollment, formularies, pharmacy networks, marketing, and claims processing. The Centers for Medicare & Medicaid Services ("CMS") imposed restrictions and consent requirements for automatic prescription delivery programs and further limited the circumstances under which Medicare Part D plans may recoup payments to pharmacies for claims that are subsequently determined not payable under Medicare Part D. CMS sanctions for non-compliance may include suspension of enrollment and even termination from the program.

The Medicare Part D program has undergone significant legislative and regulatory changes since its inception. The Inflation Reduction Act of 2022 contains several provisions that could have the effect of reducing the prices we can charge and the reimbursement we receive for the drugs we dispense, thereby reducing our profitability, and could adversely affect our financial condition and results of operations. These provisions include the establishment of a Medicare Drug Price Negotiation Program, which requires the government to negotiate and set a "maximum fair price" for select high-expenditure drugs covered under Medicare Part D (starting in 2026) and Part B (starting in 2028), and the implementation of changes to Medicare Part D benefits designed to limit patient out-of-pocket drug costs and shift program liabilities from patients to other stakeholders, including health plans, manufacturers and the government.

Medicare Part D continues to attract a high degree of legislative and regulatory scrutiny, and applicable government rules and regulations continue to evolve. For example, CMS may issue regulations that limit the ability of Medicare Part D plans to establish preferred pharmacy networks.

<u>**Any Willing Provider Statutes and Narrow Networks**</u>. Any Willing Provider ("AWP") statutes are laws that require health insurance carriers to permit providers to join those networks so long as the provider is willing to accept the terms and conditions of that carrier's plan. Numerous states have some form of AWP law, though nearly all prohibit insurance carriers from limiting membership within their provider networks based on geography or other characteristics. The laws in each state addressing the legality of narrow networks vary widely. Some laws address plans only while other laws address non-insurers, like a PBM. Some laws address all types of health benefits while other laws only address a single type of benefit, like pharmacy. The risk to a pharmacy would be in those states that do not have an applicable AWP statute, a provider can be excluded from a narrow network.

While the offering of narrow and preferred networks is common across the country, there have been many lawsuits challenging the use of these types of arrangements due to the fact that they exclude certain providers from participating. The outcome of the challenges has varied, primarily based upon the interpretation of the state laws under which the challenges are made. This is an evolving area of law. Given the intense scrutiny of drug pricing and arrangements, and the ongoing lawsuits that are being filed in response to narrow networks, there remains risk in developing narrow networks, which will vary by state, depending on each state's laws and legal precedent. Additionally, state laws are subject to change at any time, resulting in uncertainty for pharmacy operations in a given state.

<u>**Health Reform Legislation**</u>. Congress passed major health reform legislation, including the Patient Protection and Affordable Care Act ("ACA"), as amended by the Healthcare and Education Reconciliation Act of 2010 (the "Health Reform Laws"), which enacted a number of significant healthcare reforms. There have been executive, judicial, and Congressional challenges to certain aspects of the Health Reform Laws. For instance, the Tax Cuts and Jobs Act of 2017 included a provision that repealed the tax-based shared responsibility payment imposed by the Health Reform Laws on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the "individual mandate." On June 17, 2021, the Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the "individual mandate" was repealed by Congress. Further, on August 16, 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program.

In addition, on July 4, 2025, the One Big Beautiful Bill Act of 2025 ("OBBBA") was signed into law. Among other things, the OBBBA includes significant policy changes affecting federal healthcare programs, including modifications to Medicaid eligibility, financing and program integrity requirements, changes to Affordable Care Act marketplace subsidies and other coverage provisions, and various Medicare-related reforms. The legislation also includes measures intended to reduce federal healthcare spending and may result in reduced coverage levels or increased eligibility verification and work requirements for certain beneficiaries. The OBBBA further provides funding intended to support certain healthcare providers, including rural healthcare initiatives. Many of the law's provisions will be implemented over several years and will require federal and state rulemaking and guidance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15

------

[**Table of Contents**](#toc)

It is possible that the ACA and other federal healthcare programs will be subject to additional judicial, regulatory or Congressional challenges or modifications in the future. It remains uncertain how the implementation of the OBBBA, potential future healthcare reform measures, or actions by the current administration may affect the ACA, other federal healthcare programs, or our business.

**Costs and Effects of Compliance with Environmental Laws**

Not applicable.

**Employees**

As of December 31, 2025, we had 121 full-time employees and 9 part-time employees.

**Sources and Availability of Components and Raw Materials**

Certain materials and equipment for our products are custom-made for those products and are dependent upon either a single or limited number of suppliers. A supplier failure could cause delays in product delivery if another supplier cannot be found promptly, or if the quality of such replacement supplier's components is inferior or unacceptable. As a result of supply chain constraints, we have experienced shortages in inventory due to manufacturing and logistical issues.

We obtain pharmaceutical and other products from wholesale drug distributors. We have maintained a relationship with a primary supplier that accounted for 98% of pharmaceutical purchases for the year ended December 31, 2025, and several supplementary suppliers. Our primary supplier for the years ended December 31, 2025 and 2024 was McKesson. The loss of a supplier could adversely affect our business if alternate sources of drug supply are unavailable. We believe that our relationships with our suppliers, overall, are good, and that there are alternative suppliers in the marketplace.

**Our Risks and History of Losses**

Our ability to achieve our mission and execute our strategies is subject to certain challenges, risks and uncertainties, including, among others:

● Our ability to obtain sufficient funding to expand our business and respond to business opportunities

● Our ability to acquire new customers or retain existing customers in a cost-effective manner

● Our ability to successfully improve our production efficiencies and economies of scale

● Our ability to manage our supply chain to continue to satisfy our future operation needs

● Our ability to retain our market share in our industry

We have incurred net losses since our inception. For the years ended December 31, 2025, and 2024, we have incurred net losses of approximately $10.5 million and $22.5 million, respectively. As of December 31, 2025, we had an accumulated deficit of approximately $60.1 million. We expect to incur additional losses prior to recording sufficient revenue from our operations as a result of the costs associated with maintaining public company status as well as expanding and seeking additional sources of revenue to our current revenue base.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16

------

[**Table of Contents**](#toc)

**Corporate Information**

NextPlat Corp, formerly Orbsat Corp, is a Nevada corporation and was originally incorporated in Florida in 1997. Our headquarters and principal executive offices are located at 400 Ansin Blvd, Suite A, Hallandale Beach, FL 33009. Our telephone number is (305) 560-5381 and our corporate website is <u>www.nextplat.com</u>.

**Available Information**

We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC also maintains an Internet site that contains annual, quarterly and current reports, proxy and information statements and other information that we (together with other issuers) file electronically. The SEC's Internet site is www.sec.gov. We make available free of charge on or through our website our annual, quarterly and current reports and amendments to those reports as soon as reasonably practicable after we electronically file such material with or furnish it to the SEC.

The contents of our website or any other website are not incorporated by reference into this Annual Report on Form 10-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17

------

[**Table of Contents**](#toc)

**ITEM 1A. RISK FACTORS**

*An investment in our securities involves a high degree of risk. You should consider carefully all of the risks described below, together with the other information contained in this Annual Report on Form 10-K, before making a decision to invest in our securities. The risk factors in this section describe the material risks to our business, prospects, results of operations, financial condition or cash flows, and should be considered carefully. In addition, these factors constitute our cautionary statements under the Private Securities Litigation Reform Act of 1995 and could cause our actual results to differ materially from those projected in any forward-looking statements (as defined in such act) made in this Annual Report on Form 10-K. Investors should not place undue reliance on any such forward-looking statements. Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as* "*will likely result,*" "*are expected to,*" "*will continue,*" "*is anticipated,*" "*estimated,*" "*intends,*" "*plans,*" "*believes*" *and* "*projects*"*) may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements.*

*Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.*

<u>**Risks Related to Our Business Generally**</u>

***We have incurred significant net losses, have accumulated deficit, and may require additional capital to continue operations and execute our business strategy.***

We have incurred significant net losses since inception. For the years ended December 31, 2025, and 2024, we have incurred net losses of approximately $10.5 million, and $22.5 million, respectively, and as of December 31, 2025, we had an accumulated deficit of approximately $60.1 million. We expect to continue to incur operating losses as we invest in expanding our e-Commerce and healthcare operations, develop new platforms and services, and pursue potential acquisitions.

Our ability to achieve profitability depends on numerous factors, many of which are outside of our control, including growth in revenue, management of operating expenses, the stability of supply chains, reimbursement levels within our healthcare segment, competitive pressures, and overall economic conditions. If revenue growth does not occur at the pace we anticipate, or if our operating expenses increase more rapidly than expected, we may be unable to achieve or sustain profitability.

We may require additional capital to support our operations, fund working capital needs, make strategic acquisitions, expand our healthcare footprint, enhance our technology platforms, and service any indebtedness. We cannot assure you that additional financing will be available on favorable terms, or at all. If we raise funds through the issuance of equity securities, existing stockholders may experience significant dilution. If we incur additional indebtedness, such debt may contain restrictive covenants that limit our operational flexibility and could increase our exposure to interest rate risk.

If we are unable to obtain sufficient capital when needed, we may be required to delay, reduce, or eliminate certain business initiatives, scale back operations, sell assets, or seek protection under applicable bankruptcy laws. Any of these outcomes could materially and adversely affect our business, financial condition, results of operations, and the value of our common stock. Even if we achieve profitability in future periods, we may not be able to sustain or increase profitability on a quarterly or annual basis, and our results from operations and cash flows may fluctuate significantly from period to period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18

------

[**Table of Contents**](#toc)

***Unfavorable global economic conditions, inflation, rising interest rates and financial market volatility could materially adversely affect our business.***

Our operations are sensitive to general economic conditions in the United States and globally. Economic downturns, recessions, government shutdowns, credit tightening, inflationary pressures, rising interest rates, supply chain constraints, and volatility in equity and foreign exchange markets could reduce consumer spending on discretionary products, increase our operating costs, impair access to capital, and negatively affect our results of operations and cash flows.

Inflation has increased our operating costs, including product sourcing, freight, fuel, labor and pharmaceutical acquisition costs. We may not be able to pass these increased costs through to customers or reimbursement sources in a timely manner, which may result in margin compression. Increases in benchmark interest rates may increase our cost of capital and reduce our ability to raise additional funds.

Geopolitical conflicts, including the Russia-Ukraine conflict and Middle East hostilities, may contribute to supply chain disruptions, fuel price volatility, currency fluctuations and broader economic uncertainty. The cumulative impact of these macroeconomic conditions could materially adversely affect our business, financial condition, results of operations, and cash flows.

***Our business may be adversely affected by pandemics, public health crises, natural disasters, acts of war or other events beyond our control.***

Public health crises, including pandemics, as well as natural disasters, severe weather events, terrorist acts, civil unrest and acts of war, could disrupt global supply chains, impair logistics providers, limit workforce availability, reduce consumer demand, restrict travel, and interrupt our operations or those of our suppliers and customers. Such events may also increase credit risk, cause financial market volatility, and impair access to capital. The occurrence of any of these events could materially adversely affect our business and financial condition.

***We rely heavily on a single pharmaceutical wholesale distributor for substantially all of our pharmaceutical purchases.***

Approximately 98% of our pharmaceutical purchases for the year ended December 31, 2025 were obtained from a single wholesale distributor. The loss of, or material change in, this relationship could result in drug shortages, higher acquisition costs, unfavorable credit terms, or operational disruptions.

Transitioning to alternative suppliers could require regulatory approvals, system integrations, renegotiation of contracts and DEA compliance measures and may not be completed on commercially reasonable terms or within acceptable timeframes. Any disruption in pharmaceutical supply could materially adversely affect our healthcare operations, profitability and cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19

------

[**Table of Contents**](#toc)

***We may fail to maintain compliance with applicable continued listing standards of The Nasdaq Stock Market.***

Our common stock is listed on The Nasdaq Stock Market and we must satisfy continued listing requirements, including minimum stock price, public float, stockholders' equity and other corporate governance standards. If we fail to satisfy these requirements, Nasdaq may issue a deficiency notice and ultimately delist our securities. Any delisting could materially adversely affect the liquidity and market price of our common stock, reduce our ability to raise capital, limit institutional investor participation, and adversely affect our reputation. Even if we are able to regain compliance, the process may be costly and disruptive to management.

***We have been notified by The Nasdaq Stock Market LLC of our failure to comply with certain Nasdaq continued listing requirements and if we are unable to regain compliance with all applicable Nasdaq continued listing requirements and standards, our Common Stock could be delisted from Nasdaq.***

Our Common Stock is listed on the Nasdaq Capital Market and to maintain our listing, we are required to satisfy continued listing requirements. There can be no assurance we will continue satisfying such continued listing requirements, which include among other requirements, that the closing bid price of our Common Stock be at least $1.00 per share (the "Minimum Bid Price Requirement") and that that the market value of our publicly held shares of Common Stock be at least $1 million (the "Market Value Requirement").

On April 28, 2025, we received a letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying us that, for the previous 30 consecutive business days, the closing bid price for the Common Stock had been below the minimum $1.00 per share required for continued listing on the Nasdaq Capital Market under the Minimum Bid Price Requirement. The Staff provided the Company with an initial period of 180 calendar days, or until October 27, 2025, to regain compliance with the Minimum Bid Price Requirement.

On October 28, 2025, we received a letter from the Staff notifying us that the Company is eligible for a second 180-day period, or until April 27, 2026 (the "Second Grace Period") to regain compliance with the Minimum Bid Price Requirement. According to the notification, the Staff's determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Minimum Bid Price Requirement, and (ii) the Company's written notice to Nasdaq of its intention to cure the deficiency during the Second Grace Period by effecting a reverse stock split, if necessary.

To regain compliance with the Minimum Bid Price Requirement, the Company scheduled a special meeting of shareholders (the "Special Meeting") that occurred on March 27, 2026. At the Special Meeting, the shareholders considered a proposal (the "Reverse Stock Split Proposal") for the Company to implement one or more reverse stock splits in a range between 1-for-5 to 1-for-50 shares at the discretion of the Board of Directors (the "Reverse Stock Split"). The Reverse Stock Split Proposal, if passed, is intended to increase our stock price to an amount that we expect will allow our common stock to stay trading above the $1.00 minimum threshold in the long term. If the Reverse Stock Split is successful and if we can maintain a trading price above $1.00 for at least ten (10) consecutive trading days, then we expect to be able to regain compliance with the Minimum Bid Price requirement. Maintaining our Nasdaq listing as a publicly traded listed company has numerous benefits to the Company, including our ability to procure more financing for ongoing operations, our ability to further our business strategy and our ability to attract more investor and business partner interest, among others. On March 27, 2026, the shareholders voted to approve the Reverse Stock Split Proposal. Also, on March 27, 2026, the Board of Directors voted to approve a reverse stock split at a ratio of 1-to-10.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20

------

[**Table of Contents**](#toc)

There can be no assurance that the Company will be able to comply with all of the obligations placed on us by Nasdaq in order to regain compliance with such Nasdaq Capital Market continued listing standards, and, assuming that we are able to comply with such obligations, that we will be able to continue to comply with such Nasdaq Capital Market continued listing standards in the future, including the Minimum Bid Price Requirement and the Market Value Requirement. If we fail to regain compliance by the end of the Second Grace Period, we may not be successful in any appeal to Nasdaq to grant additional extensions, or in the event that we are successful, we may not be able to regain compliance by such additional extension date. In the event that we are not successful in such appeal or we are not able to regain compliance with such requirements by any applicable date, our Common Stock will be subject to delisting from Nasdaq. Additionally, assuming we are able to comply with all such obligations, but we fail to comply with all applicable Nasdaq listing requirements in the future, our Common Stock may be subject to delisting from Nasdaq.

In the event of such a delisting and that the Common Stock is not eligible for trading on another national securities exchange, trading of our Common Stock could be conducted in the over-the-counter market operated by the OTC Markets Group, Inc. ("OTC"). In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our Common Stock, and it would likely be more difficult to obtain coverage by securities analysts and the news media, which could cause the price of our Common Stock to decline further. Also, it may be difficult for us to raise additional capital if we are not listed on a national exchange. Additionally, in the event of such delisting, we may be subject to penalties or defaults under certain of our material agreements, which could materially and adversely affect our business, operating results, cash flows, and financial condition.

***The Reverse Stock Split may incentivize stockholders to sell their holdings of our common stock following the effectiveness of the Reverse Stock Split and depress the stock price, which could lead to our delisting from Nasdaq.***

Similar with what has happened to our stock price in the past, if a significant number of shares of our common stock are sold into the market over a period of time, the increase in supply could lead to a depression of the stock price and it may be difficult to recover from such depression. Since our common stock has been trading at significantly lower prices than what we expect the stock price will be immediately following the effectiveness of the Reverse Stock Split, some stockholders may take the opportunity to sell some or all of their shares of common stock following the effectiveness of the Reverse Stock Split. If this happens, our stock price could decrease quickly from the opening trading market price on the day of effectiveness of the Reverse Stock Split. If we are not successful in mitigating the volatility to our stock price following that date and over time, then we may not recognize any of the intended benefits of completing the Reverse Stock Split. If the stock price dips below $1.00 again following the completion of the Reverse Stock Split at any point in the ten trading days following the effectiveness of the Reverse Stock Split, then we will be subject to delisting from Nasdaq. Even if we are able to maintain a stock price above $1.00 for ten (10) trading days following the effectiveness of the Reverse Stock Split (or some longer period as Nasdaq may designate at their discretion) or if the Company falls out of compliance with the Minimum Bid Price requirement (*i.e.*, our stock price falls below $1.00 for a period of thirty (30) consecutive trading days) in the year following the effectiveness of the Reverse Stock Split, then we will be subject to immediate delisting from Nasdaq.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21

------

[**Table of Contents**](#toc)

***If the results of the Reverse Stock Split are different than expected and we are delisted from Nasdaq, the delisting will have a significant adverse impact on our business, operations, cash flows, and financial condition.***

While we expect the Reverse Stock Split to increase our stock price and allow us to regain compliance with the Minimum Bid Price Requirement and remain listed on Nasdaq, the effect of the Reverse Stock Split on the market price of our common stock cannot be predicted with certainty, and the results of reverse stock splits by companies under similar circumstances have varied. It is not uncommon for the market capitalization of a company's common stock to decline in the period following a reverse stock split. Factors unrelated to the number of shares of our common stock outstanding, such as negative financial results or negative developments regarding our product development program or the commercializing and scaling efforts of our products, could adversely affect the market price of our common stock and jeopardize our ability to regain compliance with the Minimum Bid Price requirement. If we cannot maintain our stock price above $1.00 for at least ten consecutive trading days prior to April 27, 2026, then we will be subject to delisting from Nasdaq. Even if the Reverse Stock Split is successful in increasing our stock price above $1.00, we may have challenges in maintaining compliance with other Nasdaq continued listing rules. For example, the Reverse Stock Split may result in a lesser number of round lot holders (holders of at least 100 shares), which could cause us to be noncompliant with a Nasdaq rule requiring that we have at least 300 round lot holders to maintain continued listing compliance. Once a company has been delisted, its stock can trade on OTC, but such companies will have significantly fewer opportunities to attract financing partners and less leverage to negotiate terms for such financing instruments and arrangements that are not overly burdensome or expensive to the company. If our stock trades on OTC, we will not be able to maintain S-3 shelf eligibility. Our S-3 shelf eligibility greatly increases our access to the capital markets and other financing opportunities. If we lose access to this source of capital raising and financing avenues, then we may not be able to source enough capital to finance our business plans and operations, which will materially adversely impact our business, operations, cash flows, and financial condition.

***The Reverse Stock Split may not increase the price of our common stock over the long term***.

As noted above, the purpose of the Reverse Stock Split is to help regain compliance with the Minimum Bid Price Requirement for continued listing on Nasdaq, as well as to increase the trading price of our common stock to enhance overall liquidity of the common stock by facilitating future financing and attracting new investors. However, the effect of the Reverse Stock Split on the market price of our common stock cannot be predicted with any certainty, and we cannot assure you that the Reverse Stock Split will accomplish these objectives for any meaningful period of time, or at all. While we expect that the reduction in the number of outstanding shares of common stock will proportionally increase the market price of our common stock, we cannot assure you that the Reverse Stock Split will increase the market price of our common stock by a multiple of the Reverse Stock Split ratio, or result in any permanent or sustained increase in the market price of our common stock. The market price of our common stock may be affected by other factors which may be unrelated to the number of shares outstanding, including our business and financial performance, general market conditions, and prospects for future success. Once we have effected a Reverse Stock Split, we must ensure that our stock price trades above $1.00 in the long term. Under a Nasdaq rule that was amended in January 2025, if the Company falls out of compliance with the Minimum Bid Price Requirement (i.e., our stock price falls below $1.00 for a period of thirty (30) consecutive trading days) within one year of the completion of a Reverse Stock Split, then we will be immediately subject to delisting from Nasdaq and we will not be afforded another 180-day compliance period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22

------

[**Table of Contents**](#toc)

***The Reverse Stock Split may decrease the liquidity of our common stock***.

The Board of Directors ("Board") believes that the Reverse Stock Split may result in an increase in the market price of our common stock, which could lead to increased interest in our common stock and possibly promote greater liquidity for our stockholders. However, the Reverse Stock Split may also reduce the total number of outstanding shares of common stock, which may lead to reduced trading and a smaller number of market makers for our common stock, particularly if the price per share of our common stock does not increase as a result of the Reverse Stock Split.

***The Reverse Stock Split may result in some stockholders owning*** "***odd lots***" ***that may be more difficult to sell or require greater transaction costs per share to sell.***

If the Reverse Stock Split is implemented, it may increase the number of stockholders who own "odd lots" of less than 100 shares of common stock. A purchase or sale of less than 100 shares of common stock (an "odd lot" transaction) may result in incrementally higher trading costs through certain brokers, particularly "full service" brokers. Therefore, those stockholders who own fewer than 100 shares of common stock following the Reverse Stock Split may be required to pay higher transaction costs if they sell their common stock.

***The Reverse Stock Split may lead to a decrease in our overall market capitalization***.

The Reverse Stock Split may be viewed negatively by the market and, consequently, could lead to a decrease in our overall market capitalization. If the per share market price of our common stock does not increase in proportion to the Reverse Stock Split ratio, then the value of our Company, as measured by our market capitalization, may be reduced. Additionally, any reduction in our market capitalization may be magnified as a result of the smaller number of total shares of common stock outstanding following the Reverse Stock Split.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23

------

[**Table of Contents**](#toc)

***Our business requires significant working capital, and we are exposed to inventory and receivables risk.***

Our e-Commerce and healthcare operations require significant working capital to purchase inventory, including satellite communication devices and pharmaceuticals. We may be required to make substantial upfront inventory purchases before corresponding revenues are realized. If we overestimate demand, experience obsolescence due to technological advances, encounter product recalls, or are unable to sell inventory at anticipated margins, we may be required to record inventory write-downs. In addition, delays in reimbursement from payors or payment disputes could increase accounts receivable balances and negatively impact cash flow. Any significant working capital shortfall, inventory impairment or receivable collection issue could materially adversely affect our financial condition, results of operations, and cash flows.

***We may not have adequate insurance coverage to protect against all operational and product liability risks.***

Our business includes the sale of communications equipment and the dispensing of pharmaceuticals. Product defects, equipment malfunctions, adverse health outcomes or misuse of products could result in claims for personal injury, property damage or other losses. Although we maintain insurance coverage, our policies may not be sufficient to cover all potential liabilities, and certain types of claims may be excluded. Any uninsured or underinsured claim, or a claim exceeding policy limits, could materially adversely affect our financial condition, results of operations, and cash flows.

<u>**Risks Related to Our e-Commerce Business**</u>

***We depend significantly on Amazon marketplaces and fulfillment services, and adverse changes to our relationship with Amazon could materially harm our business.***

Amazon marketplaces represented approximately 31% and 33% of our total e-Commerce revenue for the years ended December 31, 2025 and 2024, respectively. We expect Amazon to remain a significant distribution channel.

Amazon may suspend or terminate seller accounts, modify fee structures, alter search algorithms, impose additional compliance requirements, or withhold payments at its discretion. Any limitation, suspension, increased fees, or adverse algorithm changes could significantly reduce our revenues, profitability, and cash flows.

We also rely on Amazon's fulfillment services to provide expedited shipping. Any disruption in these services or failure to meet Amazon's performance metrics could negatively impact our marketplace visibility and customer satisfaction.

Amazon may withhold or delay payments to sellers in connection with performance investigations, chargebacks, customer claims or alleged policy violations. Because a significant portion of our revenue is generated through Amazon marketplaces, any extended payment hold or account suspension could materially impact our short-term liquidity. In addition, Amazon competes directly with third-party sellers by offering its own private label products and may use data derived from marketplace activity to inform competitive offerings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24

------

[**Table of Contents**](#toc)

***Our e-Commerce operations depend on global suppliers, manufacturers and logistics providers.***

We rely on third-party manufacturers and suppliers for satellite phones, tracking devices, broadband terminals and other products. Certain products or components are sourced from limited suppliers. Disruptions due to production delays, financial distress, geopolitical events, tariffs, port congestion, customs delays or transportation interruptions could lead to inventory shortages and increased costs.

If we cannot obtain sufficient inventory at commercially reasonable prices or pass increased costs through to customers, our margins, results of operations, and cash flows could be materially adversely affected.

***We operate in highly competitive markets and technological advances may render our products less competitive.***

We face intense competition from established e-Commerce platforms, satellite communications providers, and emerging technologies such as Low Earth Orbit ("LEO") satellite systems that may reduce demand for certain of our products.

Failure to innovate, adapt to new technologies, or effectively compete on price, service, or product offerings could materially adversely affect our business.

<u>**Risks Related to Healthcare and Regulation**</u>

***Changes in reimbursement rates, healthcare regulations, or pharmacy benefit manager practices could materially adversely affect our healthcare segment.***

Our healthcare operations are subject to complex federal and state regulations, including reimbursement from Medicare, Medicaid and PBMs. Changes in reimbursement methodologies, pricing pressure, generic drug deflation, clawbacks, DIR fees, or modifications to the 340B program could reduce margins.

In addition, failure to comply with healthcare laws and regulations could result in fines, penalties, exclusion from government programs, or suspension of operations.

***We are subject to extensive and evolving domestic and international laws and regulations.***

Our operations are subject to numerous laws relating to commerce, consumer protection, product safety, intellectual property, privacy, anti-corruption, trade compliance, export controls and taxation. Failure to comply could result in fines, penalties, litigation, reputational harm and operational disruption.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25

------

[**Table of Contents**](#toc)

***Our healthcare operations are subject to audits, investigations and potential recoupment actions by government agencies and pharmacy benefit managers.***

Our pharmacy operations are subject to audits and reviews by Medicare, Medicaid, PBMs, third-party payors, state boards of pharmacy, the DEA, and other federal and state agencies. These audits may result in payment recoupments, penalties, fines, exclusion from reimbursement programs, or other corrective actions.

PBMs may conduct routine or targeted audits and may assert overpayment claims, impose clawbacks, reduce reimbursement rates, or terminate network participation agreements. Government investigations or enforcement actions could result in civil or criminal penalties, suspension of operations, or reputational harm.

Any significant audit finding, reimbursement recoupment, network termination or regulatory action could materially adversely affect our healthcare segment and overall results of operations and cash flows.

***Failure to comply with laws and regulations governing controlled substances could materially adversely affect our operations.***

To the extent we dispense controlled substances, we are subject to federal and state laws administered by the DEA and other regulatory authorities. These laws impose strict recordkeeping, reporting, security and dispensing requirements. Violations, whether intentional or inadvertent, could result in civil penalties, loss of controlled substance registrations, fines, or criminal liability.

The loss or suspension of any required license or registration could materially impair our ability to operate our pharmacy business.

***A significant portion of our pharmacy segment gross profit is derived from participation in the federal 340B Drug Pricing Program, and adverse changes to the program could materially adversely affect our profitability and cash flows** **.***

A material portion of our pharmacy segment gross profit is derived from participation in the federal 340B Drug Pricing Program, including revenues generated through contract pharmacy arrangements. Prescriptions dispensed under the 340B program generally carry significantly higher margins than non-340B prescriptions. As a result, although 340B prescriptions may represent a smaller percentage of total prescription volume, they contribute a disproportionately significant portion of our pharmacy segment gross profit.

The 340B program has been subject to increased regulatory scrutiny, manufacturer restrictions on contract pharmacy arrangements, litigation, legislative proposals, and evolving guidance from the Health Resources and Services Administration ("HRSA"). Pharmaceutical manufacturers have imposed limitations on the distribution of 340B-priced drugs through contract pharmacies, and additional restrictions may be implemented in the future.

Federal or state regulatory changes, judicial decisions, or manufacturer policies that reduce 340B eligibility, limit contract pharmacy arrangements, alter reimbursement methodologies, or otherwise decrease the margin associated with 340B prescriptions could materially reduce our pharmacy segment profitability. In addition, noncompliance with 340B program requirements, whether intentional or inadvertent, could result in repayment obligations, civil monetary penalties, exclusion from the program, termination of covered entity relationships, or reputational harm.

Any material reduction in our ability to generate gross profit from 340B prescriptions could materially adversely affect our business, financial condition, results of operations, and cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26

------

[**Table of Contents**](#toc)

<u>**Risks Related to Data Security and Technology**</u>

***Security breaches or failures in our information systems could materially harm our business.***

We process and store sensitive customer, supplier and business information. Cyberattacks, data breaches, ransomware incidents, employee misconduct or system failures could result in data loss, regulatory penalties, litigation and reputational harm. Despite security measures, no system is immune from attack. A significant cybersecurity incident could materially adversely affect our operations and financial condition.

***We may incur significant costs and liabilities in connection with data privacy and cybersecurity regulations.***

We are subject to evolving data protection and privacy laws and regulations, including federal and state privacy laws, data breach notification requirements and healthcare privacy regulations such as HIPAA, to the extent applicable. A data breach or failure to comply with applicable privacy laws could result in regulatory investigations, fines, penalties, litigation, mandatory notification costs, credit monitoring expenses, and reputational harm. Compliance with evolving cybersecurity and privacy regulations may require substantial investment in administrative, technical and physical safeguards. Any failure to comply with these requirements could materially adversely affect our business and financial condition.

<u>**Risks Related to Acquisitions and Growth**</u>

***Our growth strategy involves acquisitions and strategic investments that may not achieve expected benefits.***

We may pursue acquisitions, investments and joint ventures. These transactions involve integration risks, potential hidden liabilities, management distraction, regulatory approvals and financial exposure. Failure to successfully integrate acquired businesses could materially adversely affect our results of operations and cash flows.

<u>**Risks Related to International Operations and China**</u>

***Our operations in China expose us to political, economic and regulatory risks.***

We market products in China and may expand operations there. The regulatory environment in the PRC is evolving and subject to significant government discretion. Changes in trade policy, tariffs, foreign exchange controls, licensing requirements, data security laws or geopolitical tensions between the United States and China could increase costs, restrict operations or reduce demand for our products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27

------

[**Table of Contents**](#toc)

Retaliatory tariffs imposed by China in response to tariffs enacted by the United States expose us to significant trade-policy risk. Elevated tariff rates and other non-tariff barriers imposed on U.S.-origin goods may adversely affect the competitiveness of certain of our products in the Chinese market. Chinese authorities possess broad discretion to modify tariff rates or impose additional trade restrictions with limited advance notice and may target specific U.S. industries or product categories in response to geopolitical developments.

In response to the current tariff environment, we have paused certain initiatives within our e-Commerce development program that were intended to expand U.S.-origin product sales into China, including the introduction of certain products under our Florida Sunshine brand. For the year ended December 31, 2025, our revenue in China represented less than 1% of our consolidated revenues and did not have a material impact on our results of operations. If elevated tariffs persist, expand, or are reinstated following any temporary easing, our ability to profitably sell certain U.S.-origin products in China could be materially adversely affected. While we continue to sell certain non-U.S.-origin products in China that are not currently subject to additional tariffs, future changes in trade policy could alter the tariff treatment of those products as well.

We cannot predict whether the current trade environment will persist or whether new quotas, duties, tariffs, exchange controls, sanctions, or other restrictions will be imposed by either government. Any such actions could materially adversely affect our business, financial condition, results of operations and cash flows.

<u>**Risks Related to Corporate Governance and Public Company Status**</u>

***Being a public company increases our costs and administrative burdens.***

We incur substantial legal, accounting and compliance costs as a public company, including Sarbanes-Oxley compliance. Failure to maintain effective internal controls could impair investor confidence and adversely affect our stock price.

***Concentration of ownership may limit other stockholders**' **ability to influence corporate matters.***

Our principal stockholders, executive officers and directors collectively own a significant percentage of our outstanding shares, which may allow them to influence corporate actions, including election of directors and approval of major transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28

------

[**Table of Contents**](#toc)

**ITEM 1B. UNRESOLVED STAFF COMMENTS**

Not applicable.

**ITEM 1C. CYBERSECURITY**

NextPlat uses, stores, and processes data for and about our customers, employees, partners and suppliers. We have implemented a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats to this data, our systems, and our business operations.

**Cyber Risk Management and Strategy**

Our cybersecurity risk management processes are integrated into our overall risk management processes. Our strategy consists of utilizing a combination of employee education, preventative controls, detective controls, and periodic third-party cybersecurity testing. We engage with external cybersecurity experts, including assessors, consultants, and auditors, to enhance our cybersecurity measures and ensure compliance with industry best practices. We have established processes to oversee and manage cybersecurity risks associated with our use of third-party service providers, ensuring they adhere to our security standards. We review third-party service provider contracts to ensure they contain data privacy and security provisions, aligning with our standards and regulatory requirements. We use the National Institute of Standards and Technology Cybersecurity Framework to guide our approach, ensuring a structured and comprehensive strategy for managing cybersecurity risks. As of the date of filing this Annual Report on Form 10-K, we are not aware of any cybersecurity threats or incidents that have materially affected or are reasonably likely to materially affect the Company, including our business strategy, results of operations, cash flows, or financial condition.

**Risk Management Oversight and Governance**

Our Chief Compliance Officer and the Chief Financial Officer lead the oversight of company-wide cybersecurity strategy, policy, standards and processes. We utilize third-party IT consultants to help manage cybersecurity risks. Our Chief Compliance Officer and Chief Financial Officer have the requisite experience in risk assessment and a strong understanding of business operations, including experience with security frameworks, compliance regulations, and the ability to communicate effectively with both technical and non-technical stakeholders. Our consultants have the requisite combination of technical experience in network security, system administration, and incident response.

Our Audit Committee liaises with our management team to communicate with and monitor management's mitigation efforts to reduce cybersecurity risks by monitoring incident response, discussing and assisting with identifying potential cyber threats, analyzing vulnerabilities, and prioritizing risks.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *29*

------

[**Table of Contents**](#toc)

**ITEM 2. PROPERTIES**

***Corporate Office***

In August 2025, we relocated our corporate office from approximately 4,141 square feet of leased office space in Coconut Grove to a Company-owned facility located at 400 Ansin Blvd., Suite A, Hallandale Beach, Florida, which is co-located with Pharmco 901. The Company-owned facility consists of approximately 11,000 square feet.

***e-Commerce locations***

We lease a facility in Poole, England for office and warehouse space. Our lease has a three-year term and expires on July 31, 2027. The annual rent is approximately £14,000 through July 31, 2025, approximately £30,000 through July 31, 2026, and approximately £26,000 through July 31, 2027.

Outfitter rents office space at 2727 Old Elm Hill Pike, Nashville, Tennessee. The lease was entered into and commenced in April 2024 with an expiration date of April 2026. The lease agreement calls for monthly payments of approximately $4,800. In December 2025, a First Amendment to Lease Agreement was executed extending the lease through April 1, 2027 and revising lease payments effective January 1, 2026.

***Pharmacy locations*** 

**Pharmco 901**

We own an approximately 11,000 sq. ft. facility at 400 Ansin Blvd, Suite A, Hallandale, Florida. The monthly mortgage payment is approximately $12,000.

**Pharmco 1002**

We rent pharmacy space at 3208 2<sup>nd</sup> Avenue North, Bays 2, 3 and 4, Palm Springs, FL 33461. The original lease expired in March 2021 and automatically renewed for an additional 48 months through February 2025. The lease agreement calls for monthly payments of approximately $4,300, with an escalating payment schedule each year thereafter. During January 2025, the lease was extended for an additional 12 months through February 2026 with monthly payments of approximately $5,600.

**Pharmco 1103**

We rent pharmacy space at 1160 South Semoran Blvd, Suites D, E, F, Orlando, Florida. The lease was entered into and commenced on August 1, 2020 with a 66-month term and expires on February 1, 2026. The lease agreement calls for monthly payments beginning February 1, 2021 of $4,310, with an escalating payment schedule each year thereafter. In January 2026, the Company executed a First Amendment to the lease agreement for its Orlando, Florida pharmacy location (1160 S. Semoran Blvd., Suites D, E & F), extending the lease term through January 31, 2031 and revising monthly base rent to $8,914 (Feb 2026–Jan 2027), $9,182 (Feb 2027–Jan 2028), $9,457 (Feb 2028–Jan 2029), $9,741 (Feb 2029–Jan 2030), and $10,033 (Feb 2030–Jan 2031).

**Pharmco 1204**

We rent approximately 2,200 square feet of retail and pharmacy space at 901 North Miami Beach Blvd., North Miami Beach, Florida. The lease is for five years and commenced on September 1, 2021. The lease agreement calls for monthly payments of approximately $5,200, with an escalating payment schedule each year thereafter.

We believe that we have adequate space for our anticipated needs and that suitable additional space will be available at commercially reasonable prices as needed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30

------

[**Table of Contents**](#toc)

**ITEM 3. LEGAL PROCEEDINGS**

On March 17, 2025, a former employee of Pharmco LLC, a wholly owned subsidiary of the Company, filed a lawsuit against Pharmco LLC, asserting claims under the Equal Employment Opportunity Commission (EEOC) regulations. On October 14, 2025, the Company reached a Settlement Agreement with the plaintiff to resolve all claims. The settlement was fully covered by the Company's insurance policy, and the insurer remitted payment directly to the plaintiff on the Company's behalf.

On October 28, 2024, Alan Jay Weisberg, the former Chief Executive Officer and Chairman of Progressive Care Inc. ("RXMD"), filed a putative class action suit on behalf of himself and all other former RXMD stockholders against NextPlat, Charles M. Fernandez, the former Chief Executive Officer and director of NextPlat, and Rodney Barreto, a director of NextPlat. The complaint purports to allege a breach of fiduciary duty by NextPlat and Messrs. Fernandez and Barreto in connection with the merger of RXMD with and into a wholly owned subsidiary of NextPlat (the "Merger"), which Merger was completed on October 1, 2024 following approval by the stockholders of each of NextPlat and RXMD in stockholder meetings held on September 13, 2024 by NextPlat and RXMD. Among other things, the complaint asserts that the consideration paid to Mr. Weisberg and the other RXMD stockholders in connection with the Merger was insufficient. The monetary relief requested in the complaint includes compensatory and rescissory damages in an unspecified dollar amount. The complaint is pending in the Court of Chancery of the State of Delaware. The caption is *Alan Jay Weisberg v. Charles M. Fernandez, Rodney Barreto and Nextplat Corp.,* and the case number is C.A. No. 20. 24-1097-MTZ.

The Company believes the claims asserted in the action are without merit and intends to continue to vigorously defend against the lawsuit. The Company has filed a motion to dismiss the complaint. Although the parties have engaged in discussions regarding a potential resolution of the matter, no agreement has been reached and there can be no assurance that the matter will be resolved on acceptable terms or at all. Based on currently available information and after consultation with legal counsel, management determined that a loss associated with this matter is probable and reasonably estimable in accordance with applicable accounting guidance. Accordingly, as of December 31, 2025, the Company recorded an accrual of approximately $1.75 million, which represents management's current estimate of loss exposure and corresponds to the Company's applicable insurance retention under its directors' and officers' liability insurance coverage. The ultimate outcome of the matter remains uncertain, and the actual loss could differ materially from the amount accrued. Any such difference could have a material effect on the Company's consolidated financial condition, results of operations, and cash flows in the period in which the matter is resolved.

On June 17, 2024, Progressive Care was notified of a potential claim that a former employee (the "Claimant") allegedly suffered a loss due to an alleged breach by Progressive Care of an employment contract with the Claimant. Following receipt of the notice of claim, Progressive Care filed a petition for arbitration against the Claimant, asserting that it was the Claimant who breached the employment contract. On November 7, 2025, Progressive Care entered into a Settlement Agreement (the "Settlement Agreement") with the Claimant to resolve all disputes related to the employment and the arbitration proceeding. The details of the Settlement Agreement are disclosed below in the section entitled "*Item 9B. Other Information.*"

From time to time, the Company may become involved in litigation relating to claims arising out of our operations in the normal course of business. Other than the matters described above, the Company is not currently involved in any pending legal proceeding or litigation, and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which the Company is a party or to which any of the Company's properties is subject, which would reasonably be likely to have a material adverse effect on the Company's business, financial condition, operating results, and cash flows.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 31

------

[**Table of Contents**](#toc)

 **PART II**

**ITEM 5. MARKET FOR REGISTRANT**'**S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES**

**Market Information**

Our common stock has been listed on the Nasdaq Capital Market since May 28, 2021. Our common stock and warrants have been trading on the Nasdaq Capital Market under the symbols "NXPL" and "NXPLW," respectively, since January 21, 2022.

**Holders of Common Equity**

As of March 27, 2026, we had 27,026,215 shares of our common stock issued and outstanding held by approximately 739 stockholders of record.

**Dividend Policy**

We have never paid any cash dividends on our capital stock and do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain future earnings to fund ongoing operations and future capital requirements. Any future decision to pay cash dividends will be at the discretion of our Board of Directors and will be dependent upon financial condition, results of operations, capital requirements and such other factors as the Board of Directors deems relevant.

**Issuer Purchases of Equity Securities**

On December 16, 2024, the Board of Directors authorized a $2.0 million share repurchase program valid for one year. The Company may repurchase shares from time to time under the program through various methods, including in open market transactions, block trades, privately negotiated transactions, and otherwise. The timing, as well as the number and value of shares repurchased under the program, will depend on a variety of factors. The Company is not obligated to purchase any shares under the repurchase program, and the program may be suspended, modified, or discontinued at any time without prior notice. The repurchased shares are held as treasury stock. The authorized share repurchase program expired on December 16, 2025 and has not been extended as of the date of filing this Annual Report on Form 10-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32

------

[**Table of Contents**](#toc)

The following table provides information with respect to purchases by the Company of shares of its Common Stock during the fourth quarter of 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  |  | **Approximate Dollar Value** |
|  | **Total Number of** |  | **Total Number of Shares** | **of Shares that May Yet Be** |
|  | **Common Shares** | **Average Price** | **Purchased as Part of Publicly** | **Purchased Under the** |
| **Period** | **Purchased** | **Paid per Share** | **Announced Plan or Program** | **Plan or Program** |
|  | **(in thousands, except shares and per share data)** | **(in thousands, except shares and per share data)** | **(in thousands, except shares and per share data)** | **(in thousands, except shares and per share data)** |
| October 1, 2025 through October 31, 2025 |  | $— |  | $1900 |
| November 1, 2025 through November 30, 2025 |  | $— |  | $1990 |
| December 1, 2025 through December 31, 2025 |  | $— |  | $1900 |
| Total |  | $— |  | $1900 |

---

**Equity Compensation Plan Information**

The following table outlines our Equity Compensation Plan information:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Plan category** | **Number of securities to be issued upon exercise of outstanding options, warrants and rights** |  | **Weighted- average exercise price of outstanding options, warrants and rights** |  | **Number of securities remaining available for future issuance under equity compensation plans** |  |
| *Equity compensation plans approved by security holders:* |  | |  | |  | |
| Equity compensation plans 2020 Incentive Plan | 523000 |  | $0.26 |  | 50600 |  |
| Equity compensation plans 2021 Incentive Plan | 295000 |  | 0.32 |  | 1351726 |  |
| *Equity compensation plans not approved by security holders:* |  | |  | |  | |
| 2018 Incentive Plan |  |  |  |  | 1333 |  |
| Equity compensation issued pursuant to individual compensation arrangements | 1697421 |  | 2.51 |  |  |  |
| Total | 2515421 |  | $3.09 |  | 1403659 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 33

------

[**Table of Contents**](#toc)

**ITEM 6. [RESERVED]**

**Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Cautionary Notice Regarding Forward Looking Statements**

This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to our liquidity, our expectations regarding the sufficiency of our cash and borrowing capacity to meet our working capital needs for the next 12 months, our expectations regarding acquisitions and new lines of business, gross profit, gross margins and capital expenditures. Additionally, words such as "expects," "anticipates," "intends," "believes," "will," "would," "plan," "vision" and similar words are used to identify forward-looking statements.

Some or all the results anticipated by these forward-looking statements may not occur. Important factors, uncertainties and risks that may cause actual results to differ materially from these forward-looking statements include, but are not limited to, the Risk Factors which appear in our filings and reports made with the Securities and Exchange Commission (the "SEC"), our lack of working capital, the value of our securities, the impact of competition, the continuation or worsening of current economic conditions, technology and technological changes, a potential decrease in consumer spending and the condition of the domestic and global credit and capital markets. Additionally, these forward-looking statements are presented as of the date this Form 10-K is filed with the SEC. We do not intend to update any of these forward-looking statements.

*This discussion should be read in conjunction with the other sections of this Report, including* "*Risk Factors,*" "*Description of Business*" *and the Financial Statements attached hereto pursuant and the related exhibits. The various sections of this discussion contain a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risk factors described throughout this Annual Report on Form 10-K.*

The following discussion provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our financial statements and notes thereto contained elsewhere in this Annual Report on Form 10-K. The following discussion and analysis contains forward-looking statements, which involve risks and uncertainties. Our actual results may differ significantly from the results, expectations and plans discussed in these forward-looking statements.

**Executive Overview** 

NextPlat Corp operates through two primary business segments: e-Commerce Operations and Healthcare Operations. Our strategy is focused on expanding global e-Commerce distribution of satellite communication products and services while continuing to grow our healthcare platform through pharmacy services and healthcare data analytics solutions.

Our e-Commerce Operations segment distributes satellite communications equipment, connectivity solutions, and related services through proprietary websites and third-party marketplaces. These products enable voice, data, tracking, and emergency communications in remote environments where traditional terrestrial communications infrastructure may be unavailable or unreliable. We generate revenue primarily from the sale of satellite communication devices and related equipment, as well as recurring revenue from satellite airtime and connectivity service plans.

Our Healthcare Operations segment operates through Progressive Care LLC and its pharmacy and healthcare technology subsidiaries. This segment provides prescription pharmaceuticals, medication therapy management services, long-term care pharmacy support, and healthcare analytics solutions. The segment also participates in the federal 340B Drug Pricing Program through contract pharmacy arrangements, which contributes meaningfully to pharmacy segment margins.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 34

------

[**Table of Contents**](#toc)

<u>2025 Operating Environment</u>

During 2025, we continued to expand our global e-commerce distribution capabilities and healthcare services platform. Our operations were influenced by several factors, including evolving global supply chain conditions, inflationary pressures affecting product sourcing and logistics costs, and ongoing regulatory developments affecting healthcare reimbursement and pharmaceutical pricing.

In our e-Commerce segment, growth continues to be driven by increasing demand for satellite communications solutions among commercial enterprises, government organizations, and individual users operating in remote or infrastructure-limited environments. The expansion of global e-Commerce marketplaces has allowed us to broaden our international customer base while increasing the availability of our products across multiple geographic markets.

In our healthcare segment, pharmacy operations continue to focus on improving medication adherence among patients with chronic conditions, expanding long-term care pharmacy services, and increasing utilization of healthcare analytics and data management solutions provided through our ClearMetrX platform.

<u>Results of Operations</u>

During 2025, we continued to execute on our strategy of expanding our global e-Commerce distribution platform while maintaining our healthcare services operations. Our results for the year reflect modest growth in our e-Commerce segment and significant improvement in our overall net loss, despite lower revenues in our healthcare segment.

For the year ended December 31, 2025, we generated net revenues of approximately $54.3 million, compared with $66.1 million for year ended December 31, 2024, representing a decrease of approximately $11.8 million, or 18%, year over year. The decline in revenue was primarily attributable to a reduction of approximately $12.6 million in Healthcare Operations, largely reflecting lower pharmacy 340B contract revenue and reduced pharmacy prescription revenues during the year. These decreases were partially offset by continued growth in our e-Commerce Operations segment, where revenues increased by approximately $0.8 million, reflecting ongoing demand for satellite communications products and related connectivity services across our global e-commerce platforms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 35

------

[**Table of Contents**](#toc)

Gross margins were approximately 20% for the year ended December 31, 2025, compared with 26% in 2024. The decrease in gross margin primarily reflects lower 340B contract revenues within the healthcare segment as well as higher airtime service costs in the e-Commerce segment following the expiration of a service provider airtime contract at the end of 2024.

Despite the decline in overall net revenues and gross margins, our operating performance improved significantly during 2025. Loss before other income decreased by approximately $14.0 million compared with the prior year, primarily due to the absence of significant non-recurring impairment charges that were recognized during 2024. As a result, net loss declined substantially year-over-year, reflecting improved operating efficiency and the non-recurrence of these impairment-related charges.

<u>Liquidity, Capital Resources, and Strategic Focus</u>

Our operations require significant working capital to support inventory purchases, pharmaceutical procurement, and the continued development of our technology platforms. While we have historically funded operations through a combination of available cash and equity issuances, we may require additional capital to support future growth initiatives, including potential acquisitions and expansion of our healthcare and e-commerce operations. Management continues to evaluate strategic alternatives and operational initiatives intended to strengthen our liquidity position and support long-term growth. Our strategy is focused on expanding our global e-Commerce distribution of satellite communications products and services while continuing to grow our healthcare platform through pharmacy services and healthcare analytics capabilities. We intend to pursue growth through a combination of organic expansion and selective acquisitions that complement our existing operations and enhance our technology-enabled service offerings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36

------

[**Table of Contents**](#toc)

**Critical Accounting Policies and Estimates**

Our consolidated financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, estimated asset lives, impairments and bad debts. These estimates and assumptions are affected by management's applications of accounting policies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe the following critical accounting policies, grouped by our activities, affect our more significant judgments and estimates used in the preparation of our consolidated financial statements. For additional information, see Item 8 of Part II, "Financial Statements and Supplementary Data – Note 3 – Summary of Significant Accounting Policies."

**Revenue Recognition and Unearned Revenue**

***<u>e-Commerce Operations:</u>***

The Company recognizes revenue from satellite services when earned, as services are rendered or delivered to customers. Equipment sales revenue is recognized when the equipment is delivered to and accepted by the customer. Only equipment sales are subject to warranty. Historically, the Company has not incurred significant expenses for warranties. Equipment sales which have been prepaid before the goods are shipped are recorded as contract liabilities and once shipped and delivered is recognized as revenue. The Company also records as contract liabilities, certain annual plans for airtime, which are paid in advance. Once airtime services are incurred, they are recognized as revenue. Unbilled revenue is recognized for airtime plans whereby the customer is invoiced for its data usage the following month after services are incurred.

The Company's customers generally purchase a combination of our products and services as part of a multiple element arrangement. The Company's assessment of which revenue recognition guidance is appropriate to account for each element in an arrangement can involve significant judgment. This assessment has a significant impact on the amount and timing of revenue recognition.

The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. The five-step model is applied to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services transferred to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assess whether each promised good or service is distinct. We then recognize revenue in the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 37

------

[**Table of Contents**](#toc)

***<u>Healthcare Operations:</u>***

We recognize product revenue from prescriptions dispensed to patients (customers) at the time the drugs are physically delivered to a customer or when a customer picks up their prescription, which is the point in time when control transfers to the customer. 340B dispensing fees are a component of 340B contract revenue, which are recognized at the time the drugs are received by the patient, by either delivery or customer pick up. Payments are received directly from the customer at the point of sale, or the customers' insurance provider is billed electronically. For third-party medical insurance and other claims, authorization is obtained to ensure payment from the customer's insurance provider before the medication is dispensed to the customer. Authorization is obtained electronically and a corresponding authorization number is issued by the customer's insurance provider.

We record unearned revenue for prescriptions that are filled but not yet delivered at period-end. Billings for most prescription orders are with third-party payers, including Medicare, Medicaid, and insurance carriers. Customer returns are nominal.

We recognize revenue from TPA services as we satisfy the services under the TPA contract with a 340B covered entity. TPA services provided to covered entities include consulting services, accounting and reconciliation of contract pharmacy billings, and various compliance services.

**Stock-Based Compensation**

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The Company's determination of the fair value using the option-pricing model is affected by the stock price as well as assumptions regarding the number of highly subjective variables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38

------

[**Table of Contents**](#toc)

**Goodwill and Intangible Assets**

Goodwill represents the excess of the purchase price of over the value assigned to net tangible and identifiable intangible assets. We perform the required annual impairment tests of goodwill at the end of each fiscal year on our reporting unit. To determine the fair value of the reporting unit, we use a discounted cash flow model with market-based support as our valuation technique to measure the fair value for our reporting unit. The discounted cash flow model uses five-to-ten-year forecasted cash flows plus a terminal value based on a multiple of earnings or by capitalizing the last period's cash flows using a perpetual growth rate. Our significant assumptions in the discounted cash flow models include, but are not limited to: the weighted average cost of capital ("WACC"), revenue growth rates, including perpetual revenue growth rates, and operating margin percentages of the reporting unit's business. We consider the current market conditions when determining assumptions. The total forecasted cash flows are discounted based on ranges included in assumptions regarding our WACC. Lastly, we reconcile the aggregate fair values of our reporting units to our market capitalization, which include a reasonable control premium based on market conditions. The use of estimates and the development of assumptions results in uncertainties around forecasted cash flows.

A change in any of these estimates and assumptions used in the annual test, a degradation in the overall markets served by these reporting units, among other factors, could have a negative material impact to the fair value of the reporting units and could result in a future impairment charge. There can be no assurance that our future goodwill impairment testing will not result in a charge to earnings. This impairment charge could have a negative material impact on our results of operations.

Acquired intangible assets other than goodwill are amortized over their useful lives unless the lives are determined to be indefinite. For intangible assets purchased in a business combination, the estimated fair values of the assets received are used to establish their recorded values. Valuation techniques consistent with the market approach, income approach, and/or cost approach are used to measure fair value. Goodwill and other indefinite-lived intangible assets are assessed annually for impairment in the fourth fiscal quarter and in interim periods if events or changes in circumstances indicate that the assets may be impaired.

**Use of Estimates**

In preparing the Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the statements of financial condition, and revenues and expenses for the years then ended. Actual results may differ significantly from those estimates. Significant estimates made by management include, but are not limited to, assumptions used to calculate stock-based compensation, fair value of net assets acquired in business combinations, common stock warrants and options issued for services, net realizable value of accounts receivables and other receivables, the useful lives of property and equipment and intangible assets, assumptions used in determining the potential impairment of long-lived assets, including intangible assets and goodwill, the estimate of the fair value of the lease liability and related right of use assets, inventory reserve estimates, and the estimates of the valuation allowance on deferred tax assets and corporate income taxes.

**Effect of Exchange Rate on Results**

The Company's reporting currency is U.S. Dollars. The accounts of one of the Company's subsidiaries, GTC, is maintained using the appropriate local currency, Great British Pound, as the functional currency. All assets and liabilities are translated into U.S. Dollars at balance sheet date, shareholders' equity is translated at historical rates and revenue and expense accounts are translated at the average exchange rate for the year or the reporting period. The translation adjustments are reported as a separate component of stockholders' equity, captioned as accumulated other comprehensive (loss) gain. Transaction gains and losses arising from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the statements of operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39

------

[**Table of Contents**](#toc)

**Results of Operations**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** | | |
|  | **2025** | **2024** | **$ Change** | **% Change** |
| Revenue, net | $54322 | $66082 | $(11760) | (18)% |
| Cost of revenue | 43416 | 49074 | (5658) | (12)% |
| Gross profit | 10906 | 17008 | (6102) | (36)% |
| Operating expenses | 19906 | 40033 | (20127) | (50)% |
| Loss before other income | (9000) | (23025) | 14025 | (61)% |
| Other expense (income) | 1463 | (570) | 2033 | (357)% |
| Loss before income taxes | (10463) | (22455) | 11992 | (53)% |
| Income taxes |  | (71) | 71 | (100)% |
| Net loss | (10463) | (22526) | 12063 | (54)% |
| Deemed dividend | (1249) |  | (1249) | —% |
| Net loss attributable to non-controlling interest |  | 9100 | (9100) | (100)% |
| Net loss attributable to common stockholders | $(11712) | $(13426) | $1714 | (13)% |

---

For the years ended December 31, 2025 and 2024, we recognized overall net revenue from operations of approximately $54.3 million and $66.1 million, an overall decrease of approximately $11.8 million for the year ended December 31, 2025, when compared to the year ended December 31, 2024, respectively. The decrease in revenue was primarily attributable to a decrease of approximately $12.6 million from Healthcare Operations, which was partially offset by an increase of approximately $0.8 million as from e-Commerce Operations.

Gross margins for the years ended December 31, 2025 and 2024 were approximately 20% and 26%, respectively. The decrease in gross margin was attributable to the overall decline in gross profit in both operating segments. The gross margin for Healthcare Operations decreased during 2025 to approximately 19% from 26% when compared to 2024 and was primarily attributable to the decrease in pharmacy 340B contract revenue. The gross margin for e-Commerce Operations decreased during 2025 to approximately 23% from 25% when compared to 2024 due to a service provider airtime contract that expired on December 31, 2024, which introduced new airtime costs beginning January 1, 2025, and temporary rate reductions for some customers affected by ongoing service interruptions.

Our loss before other income decreased by approximately $14.0 million for the year ended December 31, 2025, when compared to the year ended December 31, 2024, primarily as a result of the decrease in non-recurring impairment losses of approximately $13.7 million for the year ended December 31, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40

------

[**Table of Contents**](#toc)

***Revenue, net***

Our net revenues were as follows (in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** | **Years Ended December 31,** | **Years Ended December 31,** | | |
|  | **2025** | **2025** | **2024** | **2024** |  |  |
|  | **Dollars** | **% of Revenue** | **Dollars** | **% of Revenue** | **$ Change** | **% Change** |
| e-Commerce revenue | $14608 | 27% | $13791 | 21% | $817 | 6% |
| Pharmacy prescription and other revenue, net of PBM fees | 35704 | 66% | 41907 | 63% | (6203) | (15)% |
| Pharmacy 340B contract revenue | 4010 | 7% | 10384 | 16% | (6374) | (61)% |
| Revenues, net | $54322 | 100% | $66082 | 100% | $(11760) | (18)% |

---

Our net revenues consist of e-Commerce sales of satellite phones, tracking devices, accessories, and airtime plans; pharmacy prescription revenues; and pharmacy 340B contract revenues. For the year ended December 31, 2025, overall revenues were approximately $54.3 million compared to $66.1 million for the year ended December 31, 2024, a decrease of approximately $11.8 million or 17.8%.

Total e-Commerce revenues were approximately $14.6 million and $13.8 million for the years ended December 31, 2025 and 2024, respectively, an increase of approximately $0.8 million primarily due to an increase in airtime and hardware sales of approximately $0.4 million and a favorable foreign currency impact of approximately $0.4 million.

Total pharmacy prescription and other revenue, net of PBM fees, were approximately $35.7 million and $41.9 million for the years ended December 31, 2025 and 2024, respectively, a decrease of approximately $6.2 million. The decrease was attributable to the decrease in the number of total prescriptions filled of approximately $11.3 million, which was offset by the increase in reimbursement rates per prescription filled of approximately $5.1 million. During the year ended December 31, 2025, we filled approximately 374,000 prescriptions versus 473,000 in the prior year period. The decline in prescription volume during the current year period was influenced in part by the continued changes in provider relationships and shifts in patient flow due to insurance network adjustments or provider decisions to align with different pharmacy partners.

Pharmacy 340B contract revenue was approximately $4.0 million and $10.4 million for the years ended December 31, 2025 and 2024, respectively, a decrease of approximately $6.4 million, due to certain relationships transitioning to other pharmacy partners, some covered entities opened in-house pharmacies, and another covered entity no longer participates in the 340B program.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41

------

[**Table of Contents**](#toc)

***Operating Expenses***

Our operating expenses were as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** |  |  |
|  | **2025** | **2024** | **$ Change** | **% Change** |
| Selling, general and administrative | $6043 | $6179 | $(136) | (2)% |
| Salaries, wages and payroll taxes | 10707 | 13303 | (2596) | (20)% |
| Impairment loss |  | 13653 | (13653) | (100)% |
| Professional fees | 2264 | 4401 | (2137) | (49)% |
| Depreciation and amortization | 540 | 788 | (248) | (31)% |
| Intangible asset amortization | 102 | 1709 | (1607) | (94)% |
| Loss on settlement of litigation | 250 |  | 250 | —% |
| Total operating expenses | $19906 | $40033 | $(20127) | (50)% |

---

Total operating expenses for the year ended December 31, 2025 were approximately $19.9 million, a decrease of approximately $20.1 million or 50.3% from total operating expenses for the year ended December 31, 2024, of approximately $40.0 million. Factors contributing to the decrease are described below.

Selling, general and administrative expenses remained relatively consistent at approximately $6.0 million and $6.2 million for the year ended December 31, 2025 and 2024, respectively. The $0.2 million decrease was primarily due to a decrease in computer equipment purchases.

Salaries, wages and payroll taxes were approximately $10.7 million and $13.3 million for the years ended December 31, 2025 and 2024, respectively, a decrease of approximately $2.6 million or 19.5%. The decrease was attributable to the decrease of stock-based compensation for non-recurring grants fully vested of approximately $1.1 million, a decrease in executive compensation of approximately $0.4 million, and a decrease of approximately $1.1 million resulting from a reduction in total headcount.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42

------

[**Table of Contents**](#toc)

No impairment loss was recognized during the year ended December 31, 2025. Impairment loss for the year ended December 31, 2024 of approximately $13.7 million was related to a goodwill impairment of approximately $0.7 million, long-lived assets, primarily intangible assets, impairment of approximately $12.8 million, and the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future of approximately $0.1 million.

Professional fees include expenses for legal fees, accounting services fees, consulting fees, and public company expenses. Professional fees were approximately $2.3 million and $4.4 million for the years ended December 31, 2025 and 2024, respectively, a decrease of approximately $2.1 million or 48.6%. The decrease was mainly attributable to the decrease in accounting services fees of approximately $0.2 million, a decrease in director fees of approximately $0.2 million, and a decrease in legal and consulting fees of approximately $1.7 million.

Depreciation and amortization was approximately $0.5 million and $0.8 million for the years ended December 31, 2025 and 2024, respectively.

Intangible asset amortization was approximately $0.1 million and $1.7 million for the years ended December 31, 2025 and 2024, respectively, a decrease of approximately $1.6 million or 94.0%. The decrease was attributable to the decrease in the carrying amount of intangible assets when compared to the prior year period. Intangible assets related to our Healthcare Operations were fully impaired throughout the year ending December 31, 2024. Intangible assets, net as of December 31, 2025 were related to our e-Commerce Operations due to the Outfitter acquisition in April 2024.

Loss on settlement of litigation was approximately $0.3 million for the year ended December 31, 2025 - for further information regarding litigations see "Note 20. Commitments and Contingencies" included in the Notes to Consolidated Financial Statements.

***Total Other (Expense) Income***

Our total other (expense) income changed by approximately $2.0 million for the year ended December 31, 2025 when compared to the same period in 2024. The change was primarily due to a loss on sale or disposal of property and equipment recognized in the amount of approximately $0.2, compared to a gain on sale or disposal of property and equipment in the amount of approximately $0.1 million in the prior year period; a decrease in interest earned of approximately $0.4 million due to the decrease in cash on hand; a contingent loss on settlement of litigation of approximately $1.8 million; an asset write-off of approximately $0.1 million in the prior year period; and a favorable change in foreign currency rates of approximately $0.3 million.

***Net Loss***

We recorded net losses of approximately $10.5 million and $22.5 million for the years ended December 31, 2025 and 2024, respectively. The change in the net loss was a result of the factors described above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 43

------

[**Table of Contents**](#toc)

**Liquidity and Capital Resources**

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. As of December 31, 2025, we had a cash balance of approximately $13.7 million. Our working capital was approximately $15.0 million at December 31, 2025. Our principal uses of cash include (i) purchases of pharmaceutical inventory and e-Commerce product inventory, (ii) operating expenses, including payroll, professional services, and public company expenses, (iii) technology development and platform investments, and (iv) potential acquisitions and strategic investments. We continue to closely monitor our cash position and operating expenditures. In response to recent trends and in alignment with our long-term strategic goals, we continue to implement a series of cost reduction measures aimed at improving operational efficiency and preserving liquidity. These measures include optimizing our delivery process and renegotiating certain vendor agreements. While we remain committed to investing in key growth initiatives, we are prioritizing financial discipline to ensure we maintain adequate liquidity to support ongoing operations and strategic objectives. In addition, management is exploring various options with respect to strategic alternatives to diversify our business operations, including opportunities in additional services, joint ventures, and other collaborative structures.

As of the date of filing this Annual Report on Form 10-K, the Company's existing cash resources are sufficient to support planned operations for the next 12 months. As a result, management believes that the existing financial resources are sufficient to continue operating activities for at least one year past the issuance date of the financial statements.

&nbsp;&nbsp;&nbsp;&nbsp; Our long-term cash requirements (beyond the next 12 months from filing this Annual Report on Form 10-K) include lease obligations, note payable obligations, and potential capital investments in technology development and strategic acquisitions. We anticipate funding these long-term requirements through cash generated from operations, available cash on hand, and, if necessary, proceeds from future equity or debt financings. We do not have any material commitments for capital expenditures as of December 31, 2025.

The following table summarizes our cash flows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** |
|  | **2025** | **2024** |
| Net change in cash from: |  |  |
| Operating activities | $(6130) | $(5464) |
| Investing activities | 163 | (953) |
| Financing activities | (225) | 72 |
| Effect of exchange rate on cash | (59) | (2) |
| Change in cash | (6251) | (6347) |
| Cash at end of year | $13709 | $19960 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44

------

[**Table of Contents**](#toc)

**Cash Flow from Operating Activities**

Net cash used in operating activities totaled approximately $6.1 million and $5.5 million for the years ended December 31, 2025 and 2024, respectively, and changed by approximately $0.7 million period-over-period. The unfavorable change of approximately $0.7 million was primarily attributable to the following:

● an increase in cash received from e-Commerce Operations of approximately $5.3 million due to year-over-year revenue increase;

● a decrease in cash received from Healthcare Operations of approximately $17.6 million due to year-over-year revenue decrease;

● a decrease in cash received from interest income and other sources of approximately $0.4 million;

● a decrease in cash paid for inventory purchases and other costs of revenue of approximately $1.8 million;

● a decrease in cash paid for salaries and related expenses of approximately $1.1 million due to the decrease in executive compensation and decreased headcount;

● a decrease in cash paid for other recurring operating expenses of approximately $6.5 million due to the timing of payables and decreases in general legal and consulting fees; and

● a decrease in cash paid for other non-recurring expenses of approximately $2.6 million due to litigation matters and merger costs in the prior year period.

**Cash Flow from Investing Activities**

Net cash provided by investing activities for the year ended December 31, 2025 was approximately $0.2 million, and was attributable to sales of vehicles for our Healthcare Operations delivery fleet. Net cash used in investing activities for the year ended December 31, 2024 was approximately $1.0 million, primarily attributable to the acquisition of Outfitter.

**Cash Flow Financing Activities**

Net cash used in financing activities was approximately $0.2 million for the year ended December 31, 2025, primarily attributable to the repayment of notes payable and repurchases of common shares. Net cash provided by financing activities was approximately $0.1 million for the year ended December 31, 2024, primarily attributable to the repayment of notes payable, offset by capital contributions received.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45

------

[**Table of Contents**](#toc)

***Share Repurchase Program***

On December 16, 2024, our Board of Directors authorized a $2.0 million share repurchase program valid for one year. We may repurchase shares from time to time under the program through various methods, including in open market transactions, block trades, privately negotiated transactions, and otherwise. The timing, as well as the number and value of shares repurchased under the program, will depend on a variety of factors. We are not obligated to purchase any shares under the repurchase program, and the program may be suspended, modified, or discontinued at any time without prior notice. During the year ended December 31, 2025, we repurchased approximately $0.1 million of common stock and had approximately $1.9 million remaining under the share repurchase program as of that date. The repurchased shares are held as treasury stock. The authorized share repurchase program expired on December 16, 2025 and has not been extended as of the date of filing this Annual Report on Form 10-K.

**Off-balance Sheet Arrangements**

We have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered any derivative contracts that are indexed to our shares and classified as stockholder's equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity.

**ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Consistent with the rules applicable to "Smaller Reporting Companies" we have omitted information required by this Item.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 46

------

[**Table of Contents**](#toc)

**ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA**

**Recent Accounting Pronouncements**

**Accounting Pronouncements Recently Adopted**

In November 2024, the FASB issued ASU 2024-03, "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses", ("ASU 2024-03"), which is intended to enhance transparency into the nature and function of expenses. The amendments to Subtopic 220-40 require that on an annual and interim basis, entities disclose disaggregated operating expense information about specific categories, including purchases of inventory, employee compensation, depreciation, amortization and selling expense. The Company early adopted this ASU, effective January 1, 2025, on a retrospective basis. The amendments are presentation matter revisions and did not have an impact on the Company's financial condition, results of operations, or cash flows.

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740)—Improvements to Income Tax Disclosure" ("ASU 2023-09"), which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements primarily relating to the rate reconciliation and income taxes paid. This includes a tabular reconciliation using both percentages and reporting currency amounts, covering various tax and reconciling items, and disaggregated summaries of income taxes paid during the period. ASU 2023-09 is required to be adopted for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this accounting standard update effective January 1, 2025 and did not have an impact on the Company's financial condition, results of operations, or cash flows.

**Accounting Pronouncements Issued but not yet Adopted**

In December 2025, the FASB issued ASU 2025-11, "Interim Reporting (Topic 270): Narrow-Scope Improvements," which is intended to clarify and improve the guidance in Topic 270, Interim Reporting. The amendments clarify the applicability of interim reporting guidance, the types of interim reporting, the form and content of interim financial statements and notes prepared in accordance with U.S. GAAP, and establish a principle for disclosing events and changes since the end of the last annual reporting period that have a material impact on the entity. The amendments are not intended to change the fundamental nature of interim reporting or expand or reduce current interim disclosure requirements. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, for public business entities, with early adoption permitted. The Company has not yet adopted ASU 2025-11 and does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.

In December 2025, the FASB issued ASU 2025-12, "Codification Improvements," which includes numerous amendments across a broad range of Topics to clarify existing guidance, correct errors, and otherwise improve the usability and consistency of the Accounting Standards Codification. Key areas addressed include clarifications to the diluted earnings per share calculation when a loss from continuing operations exists, clarification of disclosure requirements for lease receivables arising from certain leases, revisions to the reference amount for beneficial interests, and other technical improvements. ASU 2025-12 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. The Company does not expect the adoption of ASU 2025-12 to have a material impact on its consolidated financial statements.

***Income Tax Legislation***

On July 4, 2025, the United States enacted the OBBBA, which included amendments to certain provisions of the Internal Revenue Code. OBBBA included provisions that affect research and development expenditures, bonus depreciation, the Section 163(j) business interest expense limitation, and the calculation of the Corporate Alternative Minimum Tax. In addition, the OBBBA imposes a 1% excise tax on certain stock repurchases, which is accounted for as a non-income tax expense and recognized within operating expenses when incurred.

In accordance with ASC 740, the Company evaluated, at the enactment date, the impact of the legislation on its income tax accounting, including the measurement of deferred tax assets and deferred tax liabilities and valuation allowance. Because the Company maintains a full valuation allowance against its net deferred tax assets, the enactment of the OBBBA did not have a material effect on the Company's consolidated financial statements for the year ended December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 47

------

[**Table of Contents**](#toc)

**ITEM 9. CHANGES IN AND DISAGREEMENT WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE**

None.

**ITEM 9A. CONTROLS AND PROCEDURES**

(a) *Evaluation of Disclosure Controls and Procedures.* Our management, with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), as of December 31, 2025. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were not effective as of December 31, 2025 to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms. This conclusion was primarily due to the material weaknesses in our internal control over financial reporting described below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) *Inherent Limitation on Controls.* Management, including the CEO and CFO, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and fraud. Any control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that its objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Accordingly, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to errors or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) *Management*'*s Report on Internal Control over Financial Reporting.* Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Our internal control over financial reporting includes policies and procedures that: (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of assets; (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and Board of Directors; and (c) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements. Management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2025 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in the *Internal Control*—*Integrated Framework (2013)*. Based on this evaluation, management concluded that our internal control over financial reporting was not effective as of December 31, 2025 due to the material weaknesses described below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 48

------

[**Table of Contents**](#toc)

**Material Weakness in Internal Control Over Financial Reporting**

A material weakness is a deficiency or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim consolidated financial statements will not be prevented or detected on a timely basis.

<u>Previously Identified Material Weakness - Inventory Valuation (Remediated)</u>

As previously disclosed, we identified a material weakness related to controls over the valuation of inventory during 2024. This material weakness resulted from deficiencies in the design and operations of controls over net realizable value ("NRV") assessments, including insufficient formal policies, inadequate review controls, and limitation in the accuracy and completeness of data used in valuation analyses. During the year ended December 31, 2025, we implemented enhances controls including (i) formalized policies and procedures to perform comprehensive NRV assessments for inventory at each reporting period; (ii) quarterly documented review controls performed by senior management to evaluate the accuracy and completeness of NRV calculations; and (iii) improvements to the accuracy and reliability of pricing and cost data used in NRV calculations by integrating reliable internal tracking mechanisms. Based on management's evaluation, including the operations of these controls for a sufficient period of time, management concluded that this material weakness was remediated as of December 31, 2025.

<u>Material Weakness - Accounting Estimate of PBM Performance Bonus Receivable (Unremediated)</u>

As of December 31, 2025, management identified a material weakness related to the accounting for the estimation and recording of a performance-based bonus receivable recorded at December 31, 2024 in connection with incentive arrangements with pharmacy benefit managers ("PBMs"). This material weakness resulted from deficiencies in the design and operations of controls over significant accounting estimates, including the development and review of assumptions and inputs used to estimate performance-based receivables.

<u>Material Weakness - PIPE Warrant Modification (Unremediated)</u>

As of December 31, 2025, management identified a material weakness related to the accounting for the valuation of the modification of certain PIPE warrants. This material weakness resulted from deficiencies in the design and operation of controls over the identification, evaluation, and accounting for modifications of equity-linked financial instruments. Specifically, the Company did not maintain effective controls to ensure (i) timely identification of warrant modifications, (ii) appropriate evaluation of the accounting implications of such modifications, including the determination of whether the modification should be accounted for as an equity or liability transaction, and (iii) accurate valuation of the modified warrants using appropriate valuation techniques and assumptions. In addition, the Company lacked sufficient technical accounting expertise to appropriately evaluate complex and non-routine transactions involving equity-linked instruments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 49

------

[**Table of Contents**](#toc)

**Remediation Plans**

Management is committed to improving its internal control over financial reporting and remediating the material weaknesses described above as quickly as possible. Management has outlined a remediation plan to ensure that the control deficiencies are remediated. Management will continue to evaluate the design and operating effectiveness of the controls. The material weaknesses will not be considered remediated until the controls have operated effectively for a sufficient period of time and management has completed testing to conclude that the controls are effective.

<u>Accounting Estimate of PBM Performance Bonus Receivable</u>

To address the material weakness related to the estimation of performance-based bonus receivables, management has initiated the following actions: (i) establishing a standardized quarterly process for estimating performance-based bonus receivables, including documented estimates retrieved timely from third-party adherence data and performance metrics and (ii) designing and implementing documented review controls performed by senior management to evaluate the reasonableness of the estimate.

<u>PIPE Warrant Modification</u>

To address the material weakness related to the accounting for the valuation of the modification of certain PIPE warrants, specifically the extension of expiration dates, management has initiated the following actions: (i) establishing controls to ensure timely identification of modifications to outstanding warrants, including enhanced coordination and communication protocols between finance, legal, and executive management when contractual terms are amended; (ii) implementing valuation controls requiring the preparation of detailed valuation analyses for modified warrants; (iii) engaging qualified third-party valuation specialists to assist in the valuation of warrant modifications and to support management's accounting conclusions for complex or non-routine transactions; and (iv) designing and implementing documented review controls performed by individuals with appropriate technical expertise to evaluate classification conclusions, valuation methodologies and assumptions, and the completeness and accuracy of financial statement impacts.

This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by our registered public accounting firm pursuant to rules from the SEC that permit us to provide only management's report in this annual report.

(d) *Changes in Internal Control Over Financial Reporting.* Other than the material weaknesses and the remediation plans described above, there were no other changes in our internal control over financial reporting during our fourth fiscal quarter ended December 31, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50

------

[**Table of Contents**](#toc)

**ITEM *9B.* OTHER INFORMATION**

*<u>Amendment to PIPE Warrants</u>*

On *November 5, 2025,* the Company entered into a Universal Amendment to PIPE Warrants (the "Amendment") with holders of the Company's Common Stock Purchase Warrants (the "Warrants") representing greater than *fifty* percent of the outstanding Warrants (based on the number of underlying warrant shares). The Warrants were originally issued pursuant to a Securities Purchase Agreement dated *December 8, 2022,* and provided for an exercise period ending on *December 14, 2025.*

Pursuant to the Amendment, the exercise period of each Warrant was extended by *twenty-four* (*24*) months, such that the Warrants will now expire on *December 14, 2027,* instead of *December 14, 2025.* All other terms and conditions of the Warrants remain unchanged and in full force and effect. The Company determined the modification resulted in an incremental increase in fair value of the warrants of approximately *$1.2* million, calculated using the Black-Scholes model immediately before and after the change. As the modification was considered an inducement to holders to retain their investment, the incremental value of *$1.2* million was recognized as a reduction of additional paid-in capital and recorded as a deemed dividend, impacting net income attributable to common stockholders for the year ended *December 31, 2025.* The modified warrants remain classified as equity instruments in stockholders' equity.

As consideration for the extension of the exercise period of the Warrants, each holder agreed to a release in favor of the Company and its related persons. Specifically, each holder released and waived any and all claims, demands, obligations, liabilities, and causes of action, whether known or unknown, arising prior to the execution of the Amendment and relating to the Securities Purchase Agreement, the Registration Rights Agreement, the Warrants, any other transaction document, and the administration thereof. The release extends to the Company and its parents, affiliates, participants, and their respective officers, directors, employees, agents, attorneys, accountants, consultants, successors, and assigns.

*<u>Settlement of Arbitration Proceeding</u>*

As previously disclosed, on *June 17, 2024,* Progressive Care was notified of a potential claim that a former employee (the "Claimant") allegedly suffered a loss due to an alleged breach by Progressive Care of an employment contract with the Claimant. Following receipt of the notice of claim, Progressive Care filed a petition for arbitration against the Claimant, asserting that it was the Claimant who breached the employment contract.

On *November 7, 2025,* Progressive Care entered into a Settlement Agreement (the "Settlement Agreement") with the Claimant to resolve all disputes related to the employment and the arbitration proceeding. Pursuant to the Settlement Agreement, Progressive Care paid the Claimant a total sum of *$150,000* within *seven* days of execution. In addition, Progressive Care transferred to the Claimant *128,205* shares of NextPlat common stock valued at *$100,000.* The Settlement Agreement provides the Claimant with a *one*-time reverse stock-split protection mechanism, whereby, if the aggregate value of the transferred shares declines by more than *20%* within *sixty* calendar days following a reverse stock split, Progressive Care will issue additional shares of NextPlat common stock to the Claimant to restore the aggregate value to the pre-split level, with such shares to be issued within *ten* days after the *sixty*-day period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *51*

------

[**Table of Contents**](#toc)

The Settlement Agreement includes mutual releases of all claims between the parties related to the arbitration and underlying disputes, with each party denying any admission of liability. Within *three* days of execution, the parties will file a joint stipulation of dismissal of the arbitration with prejudice, with each party bearing its own fees and costs. The Settlement Agreement contains mutual confidentiality and non-disparagement provisions, limiting disclosure of the Settlement Agreement and related information except as required by law or regulatory authorities. The Settlement Agreement also includes standard provisions regarding amendments, venue, waiver of jury trial, severability, execution in counterparts, binding effect on successors, and a requirement for good faith cooperation.

In addition, the Settlement Agreement provides that simultaneously with the execution of the Settlement Agreement, the parties entered into a *one* year Consulting Agreement pursuant to which Progressive Care engaged the Claimant as a consultant with an annual base fee of *$150,000.* Pursuant to the Consulting Agreement, the Claimant will also be eligible for incentive compensation for a percentage of new gross revenue with positive gross margins generated by the pharmacy's long-term care business and gross collections from *340B* eligible business generated by the Claimant.

A copy of the Settlement Agreement is filed with this Form *10*-K as Exhibit *10.40* and is incorporated herein by reference. The foregoing description of the Settlement Agreement is qualified in its entirety by reference to the full text thereof.

*Rule *10b5*-*1* Trading Arrangements*

During the *three* months ended *December 31, 2025*, no director or officer of the Company adopted or terminated any "Rule *10b5*-*1* trading arrangement" or "non-Rule *10b5*-*1* trading arrangement," as each term is defined in Item *408*(a) of Regulation S-K.

**ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS**

Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52

------

[**Table of Contents**](#toc)

**PART III**

**ITEM *10.* DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE**

The information required by this item is incorporated by reference to our Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within *120* days of the fiscal year ended *December 31, 2025*.

Our Board of Directors has adopted a written Code of Conduct and Ethics applicable to all officers, directors and employees, which is available on our website (www.nextplat.com) under "Governance Documents" within the "Corporate Governance" section. We intend to satisfy the disclosure requirement under Item *5.05* of Form *8*-K regarding amendment to, or waiver from, a provision of this Code and by posting such information on the website address and location specified above.

**ITEM *11.* EXECUTIVE COMPENSATION**

The information required by this item is incorporated by reference to our Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within *120* days of the fiscal year ended *December 31, 2025*.

**ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS**

The information in Item 5 of this Form 10-K regarding our Equity Compensation Plans is incorporated herein by reference. The remainder of the information required by this item is incorporated by reference to our Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2025.

**ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE**

The information required by this item is incorporated by reference to our Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2025.

**ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES**

The information required by this item is incorporated by reference to our Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2025.

**PART IV**

**ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES**

(a) Documents filed as part of this Annual Report on Form 10-K.

(1) Financial Statements. See Index to Consolidated Financial Statements, which appears on page F-1 hereof. The financial statements listed in the accompanying Index to Consolidated Financial Statements are filed herewith in response to this Item.

(2) Financial Statements Schedules. None.

(3) Exhibits

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 53

------

[**Table of Contents**](#toc)

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 3.1 | [<u>Amended and Restated Articles of Incorporation (Incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2014).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000141588914001013/ex3-2.htm) |
| 3.2 | [<u>Certificate of Amendment to Amended and Restated Articles of Incorporation (Incorporated by reference to Exhibit 3.3 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2014).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000141588914001013/ex3-3.htm) |
| 3.3 | [<u>Certificate of Amendment to Amended and Restated Articles of Incorporation (Incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2016).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000141588916004990/ex3-1.htm) |
| 3.4 | [<u>Certificate of Change to the Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.7 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on May 28, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221013155/ex3-7.htm) |
| 3.5 | [<u>Certificate of Amendment of the Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on January 20, 2022).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315222001696/ex3-1.htm) |
| 3.6 | [<u>Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on January 20, 2022).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315222001696/ex3-2.htm) |
| 4.1 | [<u>Description of NextPlat Corp'</u><u>s Securities Registered Under Section 12 of the Exchange Act.</u> <u>(Incorporated by reference to Exhibit 4.1 to the Company</u><u>'</u><u>s Annual Report on Form 10-K filed with the SEC on March 31, 2022).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315222008346/ex4-1.htm) |
| 4.2 | [<u>Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company'</u><u>s Registration Statement on Form S-1/A filed with the SEC on April 7, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221008222/ex4-1.htm) |
| 4.3 | [<u>Form of Warrant Agent Agreement (incorporated by reference to Exhibit 4.2 to the Company'</u><u>s Registration Statement on Form S-1/A filed with the SEC on April 7, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221008222/ex4-2.htm) |
| 4.4 | [<u>Form of Underwriter'</u><u>s Warrant (incorporated by reference to Exhibit 4.3 to the Company</u><u>'</u><u>s Registration Statement on Form S-1/A filed with the SEC on April 7, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221008222/ex4-3.htm) |
| 4.5 | [<u>Form of Warrant Agreement issued in offering (incorporated by reference to Exhibit 4.1 to the Company'</u><u>s Current Report on Form 8-K filed with the Commission on December 13, 2022)</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315222035214/ex4-1.htm) |
| 4.6 | [<u>Form of Placement Agent Warrant Agreement issued in offering (incorporated by reference to Exhibit 4.2 to the Company'</u><u>s Current Report on Form 8-K filed with the Commission on December 13, 2022)</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315222035214/ex4-2.htm) |
| 4.7 | [<u>Form of Universal Amendment to PIPE Warrants, dated as of November 5, 2025, by and among the Company and various holders of the PIPE Warrants</u> (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on November 13, 2025).](http://www.sec.gov/Archives/edgar/data/1058307/000143774925034525/ex_885905.htm) |
| 10.1<sup>+</sup> | [<u>David Phipps Employment Agreement (Incorporated by reference from the Current Report on Form 8-K filed with the SEC on March 11, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221005818/ex10-3.htm) |
| 10.2<sup>+</sup> | [<u>2020 Equity Incentive Plan (Incorporated by reference from the Current Report on Form 8-K filed with the SEC on December 31, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315220024699/ex10-1.htm) |
| 10.3 | [<u>Debenture by and among Global Telesat Communications LTD and HSBC UK BANK PLC, dated July 16, 2020 (Incorporated by reference from the Company'</u><u>s Current Report on Form 8-K filed on July 21, 2020).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315220013728/ex10-1.htm) |
| 10.4 | [<u>Coronavirus Business Interruption Loan Agreement by and among Global Telesat Communications LTD and HSBC UK BANK PLC, dated July 16, 2020 (Incorporated by reference from the Company'</u><u>s Current Report on Form 8-K filed on July 21, 2020).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315220013728/ex10-2.htm) |
| 10.5<sup>+</sup> | [<u>David Phipps Employment Agreement (incorporated by reference to Exhibit 10.3 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on March 11, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221005818/ex10-3.htm) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 54

------

[**Table of Contents**](#toc)

---

| | |
|:---|:---|
| 10.6<sup>+</sup> | [<u>Form of Director Offer Letter (incorporated by reference to Exhibit 10.17 to the Company'</u><u>s Registration Statement on Form S-1/A filed with the SEC on April 7, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221008222/ex10-17.htm) |
| 10.7<sup>+</sup> | [<u>Hector Delgado Independent Director Agreement (incorporated by reference to Exhibit 10.21 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on June 7, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221013704/ex10-21.htm) |
| 10.8<sup>+</sup> | [<u>Louis Cusimano Independent Director Agreement (incorporated by reference to Exhibit 10.22 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on June 7, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221013704/ex10-22.htm) |
| 10.9<sup>+</sup> | [<u>David Phipps Employment Agreement (incorporated by reference to Exhibit 10.25 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on June 7, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221013704/ex10-25.htm) |
| 10.10 | [<u>Alibaba.com Supplemental Services Agreement (incorporated by reference to Exhibit 10.29 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on July 13, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221016675/ex10-29.htm) |
| 10.11 | [<u>Alibaba.com Transaction Services Agreement (incorporated by reference to Exhibit 10.30 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on July 13, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221016675/ex10-30.htm) |
| 10.12 | [<u>Alibaba.com Terms of Use (incorporated by reference to Exhibit 10.31 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on July 13, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221016675/ex10-31.htm) |
| 10.13<sup>+</sup> | [<u>Amended and Restated 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on October 1, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221024305/ex10-5.htm) |
| 10.14<sup>+</sup> | [<u>Director Services Agreement, dated January 11, 2022, between Orbsat Corp and Rodney Barreto (incorporated by reference to Exhibit 10.1 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on January 11, 2022).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315222000920/ex10-1.htm) |
| 10.15<sup>+</sup> | [<u>Orbsat Corp Amended and Restated 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on December 22, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221032262/ex10-1.htm) |
| 10.16<sup>+</sup> | [<u>Orbsat Corp 2021 Incentive Award Plan (incorporated by reference to Exhibit 10.2 to the Company'</u><u>s Current Report on Form 8-K filed with the SEC on December 22, 2021).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315221032262/ex10-2.htm) |
| 10.17 | [<u>Employment Agreement, dated as of November 7, 2022, by and between the Company and Robert Bedwell (incorporated by reference to Exhibit 10.6 the Company'</u><u>s Quarterly Report on Form 10-Q filed with the SEC on November 14, 2022).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315222032082/ex10-6.htm) |
| 10.18<sup>+</sup> | [<u>Stock Option Agreement dated December 5, 2022, and effective as of November 7, 2022, by and between the Company and Robert Bedwell (incorporated by reference to Exhibit 10.1 to the Company'</u><u>s Current Report on Form 8-K Filed on December 5, 2022).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315222034416/ex10-1.htm) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 55

------

[**Table of Contents**](#toc)

---

| | |
|:---|:---|
| 10.19 | [<u>Merchant Sourcing Agreement, dated as of April 20, 2023, by and between the Company and Alibaba.com Singapore E-Commerce Private Limited, a company organized under the laws of Singapore\*</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315223013713/ex10-1.htm)[<u>(incorporated by reference from Exhibit 10.1 to the Company's Current Report on Form 8-K filed on April 26, 2023)</u>](http://www.sec.gov/Archives/edgar/data/1058307/000149315223013713/ex10-1.htm) |
| 10.20 | [<u>Promissory Note, dated July 7, 2023, in the original principal amount of $250,000 made by Next Borough Capital Management to the order of NextPlat Corp.</u> (incorporated by reference to Exhibit 10.9 to the Company's Quarterly Report on Form 10-Q filed on August 14, 2023)](http://www.sec.gov/Archives/edgar/data/1058307/000143774923023378/ex_556929.htm). |
| 10.21 | [<u>Distribution Agreement, dated as of October 12, 2023, by and between OPKO Health Spain, S.L.U. and NextPlat Corp (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on October 18, 2023)</u>](http://www.sec.gov/Archives/edgar/data/1058307/000143774923028516/ex_581742.htm). |
| 10.22+ | [Employment Agreement, dated as of August 11, 2024, by and between the Company and David Phipps (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on August 14, 2024).](http://www.sec.gov/Archives/edgar/data/1058307/000143774924026477/ex_712694.htm) |
| 10.23+ | [Amended Director Agreement, dated as of October 1, 2024, by and between the Company and Hector Delgado (incorporated by reference to Exhibit 10.36 to the Company's Annual Report on Form 10-K filed on March 24, 2025)](http://www.sec.gov/Archives/edgar/data/1058307/000143774925008787/ex_785732.htm). |
| 10.24+ | [Independent Director Agreement, dated as of October 1, 2024, by and between the Company and Douglas Ellenoff (incorporated by reference to Exhibit 10.37 to the Company's Annual Report on Form 10-K filed on March 24, 2025).](http://www.sec.gov/Archives/edgar/data/1058307/000143774925008787/ex_785733.htm) |
| 10.25+ | [Independent Director Agreement, dated as of October 1, 2024, by and between the Company and Anthony Armas (incorporated by reference to Exhibit 10.38 to the Company's Annual Report on Form 10-K filed on March 24, 2025).](http://www.sec.gov/Archives/edgar/data/1058307/000143774925008787/ex_785734.htm) |
| 10.26+ | [Director Agreement, dated as of August 13, 2025, by and between the Company and Lauren Sturges Fernandez (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on August 14, 2025).](http://www.sec.gov/Archives/edgar/data/1058307/000143774925026604/ex_852870.htm) |
| 10.27† | [Settlement Agreement, dated November 7, 2025, by and between Progressive Care, LLC and Claimant (incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q filed on November 13, 2025.](http://www.sec.gov/Archives/edgar/data/1058307/000143774925034525/ex_885909.htm) |
| 10.28+ | [<u>Employment Agreement, dated as of January 9, 2026, between NextPlat Corp and Amanda Ferrio</u> (incorporated by reference from Exhibit 10.1 to the Company's Current Report on Form 8-K/A filed on January 13, 2026)](http://www.sec.gov/Archives/edgar/data/1058307/000143774926001144/ex_906559.htm). |
| 10.29+ | [<u>David Phipps Stock Award Agreement (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K/A filed with the Commission on October 3, 2024).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000143774925030380/ex_865988.htm) |
| 10.30+ | [<u>Amendment No. 1 to David Phipps Employment Agreement (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K/A filed with the Commission on October 3, 2024).</u>](http://www.sec.gov/Archives/edgar/data/1058307/000143774925030380/ex_865989.htm) |
| 10.31+ | [Consulting Agreement, dated as of December 1, 2025, by and between NextPlat Corp and Barreto Group, Inc. (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on December 9, 2025).](http://www.sec.gov/Archives/edgar/data/1058307/000143774925037261/ex_896737.htm) |
| 19.1 | [Insider Trading Policy](ex_939006.htm) |
| 21.1 | [Subsidiaries of NextPlat Corp.](ex_892254.htm) |
| 23.1 | [Consent of RBSM LLP.](ex_892255.htm) |
| 31.1 | [Certification of Principal Executive Officer, pursuant to Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_892256.htm) |
| 31.2 | [Certification of Principal Financial Officer, pursuant to Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_892257.htm) |
| 32.1 | [Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_892258.htm) |
| 97.1 | [Policy Relating to Recovery of Erroneously Awarded Compensation (incorporated by reference from Exhibit 97.1 to the Company's Annual Report on Form 10-K filed on April 11, 2024).](http://www.sec.gov/Archives/edgar/data/1058307/000143774924011806/ex_629016.htm) |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101 | The following financial statements from the Company's Annual Report on Form 10-K for the year ended December 31, 2025, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations and Comprehensive (Loss) Income, (iii) Consolidated Statements of Equity, (iv) Consolidated Statements of Cash Flows and (v) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |

---

------

(1) Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule or exhibit so furnished.

&nbsp;&nbsp;&nbsp;&nbsp; + Management contract or compensatory plan or arrangement.

&nbsp;&nbsp;&nbsp;&nbsp; † Certain portions of this exhibit have been *redacted* pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company hereby undertakes to furnish an unredacted copy of the exhibit upon request by the SEC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 56

------

[**Table of Contents**](#toc)

**ITEM 16. FORM 10-K SUMMARY**

None.

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: March 31, 2026 | **NEXTPLAT CORP** | **NEXTPLAT CORP** |
|  | By: | */s/ David Phipps* |
|  |  | David Phipps |
|  |  | Chief Executive Officer and President (Principal Executive Officer) |
|  | By: | */s/ Amanda Ferrio* |
|  |  | Amanda Ferrio |
|  |  | Chief Financial Officer (Principal Financial and Accounting Officer) |

---

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following person on behalf of the registrant and in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ David Phipps* | Chief Executive Officer and President, Director | March 31, 2026 |
| David Phipps | (Principal Executive Officer) |  |
| */s/ Amanda Ferrio* | Chief Financial Officer | March 31, 2026 |
| Amanda Ferrio | (Principal Financial and Accounting Officer) |  |
| */s/ Rodney Barreto* | Chairman | March 31, 2026 |
| Rodney Barreto |  |  |
| */s/ Douglas S. Ellenoff* | Vice Chairman | March 31, 2026 |
| Douglas Ellenoff |  |  |
| */s/ Hector Delgado* | Director | March 31, 2026 |
| Hector Delgado |  |  |
| */s/ Anthony Armas* | Director | March 31, 2026 |
| Anthony Armas |  |  |
| */s/ Lauren Sturges Fernandez* | Director | March 31, 2026 |
| Lauren Sturges Fernandez |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 57

------

[**Table of Contents**](#toc)

**NEXTPLAT CORP AND SUBSIDIARIES**

---

| | |
|:---|:---|
| [Report of Independent Registered Public Accounting Firm](#report) RBSM LLP, New York, NY, (PCAOB ID. 587) | [F-2](#report) |
| [Consolidated Balance Sheets as of December 31, 2025 and 2024](#balance_sheets) | [F-3](#balance_sheets) |
| [Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2025 and 2024](#comprehensive_loss) | [F-4](#comprehensive_loss) |
| [Consolidated Statements of Equity for the Years Ended December 31, 2025 and 2024](#equity) | [F-5](#equity) |
| [Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024](#cash_flows) | [F-6](#cash_flows) |
| [Notes to Consolidated Financial Statements](#notes) | [F-7](#notes) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F-1

------

[**Table of Contents**](#toc)

---

| | |
|:---|:---|
| ![pic1.jpg](pic1.jpg) | <br> ***New York Office:***<br>805 Third Avenue<br> New York, NY 10022<br> 212.838-5100<br>***www.rbsmllp.com*** |

---

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Board of Directors and Stockholders of

NextPlat Corp and Subsidiaries

**Opinion on the Consolidated Financial Statements**

We have audited the accompanying consolidated balance sheets of NextPlat Corp and Subsidiaries (the "Company") as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

**Basis for Opinion**

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Critical Audit Matters**

The critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved especially challenging, subjective, or complex auditor judgments.

We determined that there are no critical audit matters.

---

| |
|:---|
| */s/* ***RBSM LLP*** |
| We have served as the Company's auditor since 2014. |
| New York, NY |
| March 31, 2026<br> PCAOB ID Number 587 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F-2

------

[**Table of Contents**](#toc)

**NEXTPLAT CORP AND SUBSIDIARIES**

**CONSOLIDATED BALANCE SHEETS**

**(In thousands, except shares and par value data)**

---

| | | |
|:---|:---|:---|
|  | ***December 31, 2025*** | ***December 31, 2024*** |
| **ASSETS** |  |  |
| **Current Assets** |  |  |
| Cash | $13709 | $19960 |
| Accounts receivable, net | 4014 | 4895 |
| Receivables - other | 1930 | 1331 |
| Inventory, net | 3396 | 4881 |
| Unbilled revenue | 292 | 237 |
| VAT receivable | 352 | 371 |
| Prepaid expenses | 463 | 404 |
| **Total Current Assets** | **24156** | **32079** |
| Property and equipment, net | 2505 | 3407 |
| Goodwill | 156 | 156 |
| Intangible assets, net | 422 | 524 |
| Operating right-of-use assets, net | 189 | 812 |
| Finance right-of-use assets, net |  | 5 |
| Deposits | 37 | 94 |
| Total Other Assets | 804 | 1591 |
| **Total Assets** | $**27465** | $**37077** |
| **LIABILITIES AND EQUITY** |  |  |
| **Current Liabilities** |  |  |
| Accounts payable and accrued expenses | $8265 | $7230 |
| Contract liabilities | 193 | 89 |
| Notes payable | 416 | 380 |
| Due to related party | 82 | 48 |
| Operating lease liabilities | 158 | 404 |
| Finance lease liabilities |  | 5 |
| Income taxes payable | 12 | 54 |
| **Total Current Liabilities** | **9126** | **8210** |
| **Long Term Liabilities** |  |  |
| Notes payable, net of current portion | 876 | 1032 |
| Operating lease liabilities, net of current portion | 41 | 438 |
| **Total Liabilities** | **10043** | **9680** |
| **Commitments and Contingencies** | **—** | **—** |
| **Equity** |  |  |
| Preferred stock ($0.0001 par value; 3,333,333 shares authorized; no shares issued or outstanding) |  |  |
| Common stock ($0.0001 par value; 50,000,000 shares authorized; 26,767,882 and 25,963,051 shares issued and outstanding as of December 31, 2025 and 2024, respectively) | 3 | 3 |
| Additional paid-in capital | 77586 | 75697 |
| Accumulated deficit | (60063) | (48351) |
| Accumulated other comprehensive loss | (118) | (66) |
| Treasury stock (at cost, 130,549 shares at December 31, 2025 and no shares at December 31, 2024, respectively) | (100) |  |
| Equity attributable to common stockholders | 17308 | 27283 |
| Equity attributable to noncontrolling interests | 114 | 114 |
| Total Equity | **17422** | **27397** |
| **Total Liabilities and Equity** | $**27465** | $**37077** |

---

See accompanying notes to consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F-3

------

[**Table of Contents**](#toc)

 **NEXTPLAT CORP AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

**(In thousands, except per share data)**

---

| | | |
|:---|:---|:---|
|  | ***Years Ended December 31,*** | ***Years Ended December 31,*** |
|  | ***2025*** | ***2024*** |
| Sales of products, net | $49665 | $55540 |
| Revenues from services | 4657 | 10542 |
| Revenue, net | 54322 | 66082 |
| Cost of products | 43374 | 49033 |
| Cost of services | 42 | 41 |
| Cost of revenue | 43416 | 49074 |
| Gross profit | 10906 | 17008 |
| Operating expenses: |  |  |
| Selling, general and administrative | 6043 | 6179 |
| Salaries, wages and payroll taxes | 10707 | 13303 |
| Impairment loss |  | 13653 |
| Professional fees | 2264 | 4401 |
| Depreciation and amortization | 540 | 788 |
| Intangible asset amortization | 102 | 1709 |
| Loss on settlement of litigation | 250 |  |
| Total operating expenses | 19906 | 40033 |
| Loss before other (income) expense | (9000) | (23025) |
| Other (income) expense: |  |  |
| Loss (gain) on sale or disposal of property and equipment | 213 | (94) |
| Interest expense | 64 | 81 |
| Interest earned | (358) | (731) |
| Contingent loss on settlement of litigation | 1750 |  |
| Asset write-off |  | 111 |
| Other income |  | (2) |
| Foreign currency exchange rate variance | (206) | 65 |
| Total other expense (income) | 1463 | (570) |
| Loss before income taxes | (10463) | (22455) |
| Income taxes |  | (71) |
| Net loss | (10463) | (22526) |
| Deemed dividend | (1249) |  |
| Net loss attributable to non-controlling interest |  | 9100 |
| Net loss attributable to common stockholders | $(11712) | $(13426) |
| Comprehensive loss: |  |  |
| Net loss | $(10463) | $(22526) |
| Foreign currency loss | (52) | (3) |
| Comprehensive loss | $(10515) | $(22529) |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | $(11712) | $(13426) |
| Weighted number of common shares outstanding – basic and diluted | 26535 | 20614 |
| Basic and diluted loss per share | $(0.44) | $(0.65) |

---

See accompanying notes to consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F-4

------

[**Table of Contents**](#toc)

 **NEXTPLAT CORP AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF EQUITY**

**YEARS ENDED December 31, 2025 AND 2024**

**(In thousands, except par value)**

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  | ***Accumulated*** |  |  |  |  |  |
|  | ***Common Stock*** | ***Common Stock*** | ***Additional*** |  | ***Other*** | ***Treasury Stock*** | ***Treasury Stock*** |  |  |  |
|  | ***$0.0001 Par Value*** | ***$0.0001 Par Value*** | ***Paid-in*** | ***Accumulated*** | ***Comprehensive*** | ***Cost*** | ***Cost*** | ***Stockholders'*** | ***Noncontrolling*** | ***Total*** |
|  | ***Shares*** | ***Amount*** | ***Capital*** | ***Deficit*** | ***Loss*** | ***Shares*** | ***Amount*** | ***Equity*** | ***Interests*** | ***Equity*** |
| Balance, December 31, 2023 | 18725 | $2 | $67170 | $(34925) | $(63) | *—* | $— | $32184 | $15903 | $48087 |
| Stock-based compensation in connection with options granted | *—* |  | 455 |  |  | *—* |  | 455 |  | 455 |
| Stock-based compensation in connection with restricted stock awards | 220 |  | 772 |  |  | *—* |  | 772 | 405 | 1177 |
| Capital contribution of noncontrolling interests | *-* |  |  |  |  | *—* |  |  | 122 | 122 |
| Issuance of common stock related to exercise of warrants | 48 |  | 85 |  |  | *—* |  | 85 |  | 85 |
| Issuance of common stock related to Progressive Care Merger | 6970 | 1 | 7215 |  |  | *—* |  | 7216 | (7216) |  |
| Comprehensive loss | *—* |  |  |  | (3) | *—* |  | (3) |  | (3) |
| Net loss | *—* |  |  | (13426) |  | *—* |  | (13426) | (9100) | (22526) |
| Balance, December 31, 2024 | 25963 | 3 | 75697 | (48351) | (66) | *—* |  | 27283 | 114 | 27397 |
| Stock-based compensation in connection with options granted | *—* |  | 11 |  |  | *—* |  | 11 |  | 11 |
| Stock-based compensation in connection with warrants granted | *—* |  | 44 |  |  | *—* |  | 44 |  | 44 |
| Stock-based compensation in connection with restricted stock awards | 805 |  | 585 |  |  | *—* |  | 585 |  | 585 |
| Shares repurchased | *—* |  |  |  |  | (131) | (100) | (100) |  | (100) |
| Comprehensive loss | *—* |  |  |  | (52) | *—* |  | (52) |  | (52) |
| Deemed dividend | *—* |  | 1249 | (1249) |  | *—* |  |  |  |  |
| Net loss | *—* |  |  | (10463) |  | *—* |  | (10463) |  | (10463) |
| Balance, December 31, 2025 | 26768 | $3 | $77586 | $(60063) | $(118) | (131) | $(100) | $17308 | $114 | $17422 |

---

See accompanying notes to consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F-5

------

[**Table of Contents**](#toc)

 **NEXTPLAT CORP AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In thousands)**

---

| | | |
|:---|:---|:---|
|  | ***Years Ended December 31,*** | ***Years Ended December 31,*** |
|  | ***2025*** | ***2024*** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |  |
| Cash received from e-Commerce Operations revenue | $18813 | $13544 |
| Cash received from Healthcare Operations revenue | 39638 | 57282 |
| Cash received from interest income | 358 | 987 |
| Cash received from other sources | 245 | 94 |
| Cash paid for inventory purchases and other costs of revenue | (47017) | (48863) |
| Cash paid for salaries and related expenses | (10310) | (11441) |
| Cash paid for other recurring operating expenses | (6919) | (13412) |
| Cash paid for other non-recurring expenses and merger costs | (839) | (3418) |
| Cash paid for interest expense | (64) | (81) |
| Cash paid for income taxes | (35) | (156) |
| Net cash used in operating activities | (6130) | (5464) |
| **CASH FLOWS FROM INVESTING ACTIVITIES:** |  |  |
| Purchase of property and equipment | (71) | (189) |
| Proceeds from sale or disposal of property and equipment | 234 | 94 |
| Cash acquired in acquisition of Outfitter Satellite subsidiary |  | 236 |
| Cash paid in acquisition of Outfitter Satellite subsidiary |  | (1094) |
| Net cash provided by (used in) investing activities | 163 | (953) |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |  |
| Repayments of notes payable | (120) | (111) |
| Acquisition of issued common stock held in treasury | (100) |  |
| Payments on finance lease liabilities | (5) | (24) |
| Proceeds from exercise of warrants |  | 85 |
| Capital contribution of non-controlling interest |  | 122 |
| Net cash (used in) provided by financing activities | (225) | 72 |
| Effect of exchange rate on cash | (59) | (2) |
| Net decrease in cash | (6251) | (6347) |
| Cash beginning of year | 19960 | 26307 |
| Cash end of year | $13709 | $19960 |
| **Reconciliation of net loss to cash flow used by operating activities** |  |  |
| Net loss | $(10463) | $(22526) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| Depreciation expense | 535 | 768 |
| Change in allowance for credit losses | (101) | (131) |
| Change in inventory reserve | 21 | 379 |
| Amortization of intangible assets | 102 | 1709 |
| Amortization of right-of-use assets - operating leases | 396 | 325 |
| Amortization of right-of-use assets - finance leases | 5 | 20 |
| Write-off of right-of-use asset |  | 111 |
| Impairment loss |  | 13653 |
| Stock-based compensation | 640 | 1632 |
| Loss (gain) on sale or disposal of property and equipment | 213 | (94) |
| Change in operating assets and liabilities: |  |  |
| Accounts receivable | 383 | 4745 |
| Inventories | 1464 | 12 |
| Unbilled revenue | (55) | (48) |
| Prepaid expense | (59) | 309 |
| Other assets |  | 256 |
| Deposits | 57 | (55) |
| VAT receivable | 19 | (29) |
| Accounts payable and accrued expenses | 1173 | (6035) |
| Operating lease liabilities | (522) | (427) |
| Income taxes payable | (42) | (85) |
| Contract liabilities | 104 | 47 |
| Net cash used in operating activities | $(6130) | $(5464) |

---

See accompanying notes to consolidated financial statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F-6

------

[**Table of Contents**](#toc)

**NEXTPLAT CORP AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

Unless the context requires otherwise, references to the "Company", "we", "us", "our", "our Company", or "our business" refer to NextPlat Corp and its subsidiaries.

**Note *1.* Organization and Nature of Operations.**

NextPlat Corp is a Nevada corporation (the "Company", "NextPlat", "we") reporting on the Nasdaq Capital Market exchange that has business segments operating in the e-Commerce and Healthcare sectors. It was incorporated in *1997* with executive offices located in Hallandale Beach, Florida.

**<u>e-Commerce Operations:</u>**

The Company operates *three* main e-Commerce websites as well as *25 third*-party e-Commerce storefronts on platforms such as Alibaba, Amazon, Mercado Libre, and Walmart. These e-Commerce venues form an effective global network serving thousands of consumers, enterprises, and governments. Additionally, we provide a comprehensive array of satellite enabled communication services and related equipment sales.

Our wholly owned subsidiary, Global Telesat Communications Limited ("GTC"), was formed under the laws of England and Wales in *2008.* GTC provides e-Commerce and satellite-enabled communication services on a global basis.

Our wholly owned subsidiary, Orbital Satcom Corp. ("Orbital Satcom"), a Nevada corporation, was formed on *November 14, 2014.* Orbital Satcom provides e-Commerce and satellite enabled communication services to customers in the U.S.

On *April 1, 2024,* NextPlat acquired 100% of the ownership interest of Outfitter Satellite, Inc., a Tennessee corporation ("Outfitter") in a stock purchase transaction. The Outfitter acquisition was completed to expand the Company's satellite enabled communication services in the U.S. Outfitter provides consumers, commercial and government customers with advanced satellite-based connectivity solutions from leading brands, including Iridium, Inmarsat and Globalstar.

*<u>Florida Sunshine Brands, LLC:</u>*

Florida Sunshine Brands, LLC ("Florida Sunshine") is a Florida limited liability company and incorporated *December 6, 2023.* Florida Sunshine operates under an operating agreement between NextPlat, with a 51% ownership, and Outer Brands FS, LLC, with a 49% ownership. Florida Sunshine's main objective is to source and sell vitamins and nutritional supplements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *7*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**<u>Healthcare Operations:</u>**

The Company's Healthcare segment operates through a wholly owned entity, Progressive Care, LLC, ("Progressive") a Nevada Limited Liability Company, which includes wholly owned subsidiaries, Pharmco, LLC ("Pharmco *901"*), Touchpoint RX, LLC doing business as Pharmco Rx *1002,* LLC ("Pharmco *1002"*), Family Physicians RX, Inc. doing business as PharmcoRx *1103* and PharmcoRx *1204* ("FPRX" or "Pharmco *1103"* and "Pharmco *1204"*) (pharmacy subsidiaries collectively referred to as "Pharmco"), and ClearMetrX Inc. ("ClearMetrX"). ClearMetrX is a personalized healthcare services and technology company that provides prescription pharmaceuticals and risk and data management services to healthcare organizations and providers.

Pharmco pharmacies deliver prescriptions to Florida's diverse population and currently holds Florida Community Pharmacy Permits at all Florida pharmacy locations. Pharmco *901* is a pharmacy located in Hallandale Beach, Florida, and is licensed as a non-resident pharmacy in the following states: Arizona, Colorado, Connecticut, Georgia, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Texas, and Utah.

Pharmco *1002* is a pharmacy located in Palm Springs, Florida that provides pharmacy services to Palm Beach, St. Lucie and Martin Counties, Florida. Progressive acquired all the ownership interests in Pharmco *1002* in a purchase agreement entered into on *July 1, 2018.*

FPRX is a pharmacy with locations in North Miami Beach and Orlando, Florida that provides pharmacy services to Miami-Dade County, Broward County, the Orlando/Tampa corridor, and the Treasure Coast of Florida. Progressive acquired all the ownership interests in FPRX in a purchase agreement entered into on *June 1, 2019.*

ClearMetrX was formed on *June 10, 2020* and provides *third*-party administration ("TPA") services to *340B* covered entities. ClearMetrX also provides data analytics and reporting services to support and improve care management for health care organizations.

RXMD Therapeutics was formed on *October 1, 2019.* RXMD Therapeutics has had *no* operating activity to date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *8*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *2.* Basis of Presentation and Principles of Consolidation**

The accompanying Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and pursuant to the rules and regulations of the Securities and Exchange Commission. The accompanying Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.

<u>Reclassifications</u>

Effective *January 1, 2025,* the Company early adopted Accounting Standards Update ("ASU") *2024*-*03,* "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic *220*-*40*): Disaggregation of Income Statement Expenses", on a retrospective basis, which resulted in reclassifications of certain expenses in the prior year period to conform to the current year presentation within cost of services, selling, general and administrative, salaries, wages and payroll taxes, and depreciation and amortization on the Consolidated Statements of Operations and Comprehensive Loss. The reclassification of these certain expenses did *not* impact net loss for the prior year period.

<u>Correction of Immaterial Misstatement</u>

During the year ended *December 31, 2025,* the Company recorded an adjustment to correct an error in estimate to its previously issued financial statements regarding performance bonus revenue in the amount of approximately $0.6 million. As of *December 31, 2024,* the Company understated receivables - other and sales of products by approximately $0.6 million. Although the Company revised the financial statements for the period ended *December 31, 2024,* based on an analysis of ASC *250* "Accounting Changes and Error Corrections", Staff Accounting Bulletin *99* "Materiality", and Staff Accounting Bulletin *108* "Considering the Effects of Prior Year Misstatements in Current Year Financial Statements", the Company has determined that this error was *not* material to the previously issued financial statements. Any corrections from the *2024* period that were made in the year ended *December 31, 2025* were *not* material.

***Business acquisition of Outfitter Satellite, Inc.***

On *March 25, 2024,* the Company entered into a Stock Purchase Agreement with James T. McKinley, pursuant to which the Company agreed to purchase all of the issued and outstanding shares of common stock of Outfitter. The closing of the transaction occurred on *April 1, 2024.* Outfitter is a wholly-owned subsidiary of NextPlat Corp.

Outfitter provides consumers, commercial, and government customers with advanced satellite-based connectivity solutions from leading brands, including Iridium, Inmarsat and Globalstar.

***Use of Estimates***

In preparing the Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the statements of financial condition, and revenues and expenses for the periods then ended. Actual results *may* differ significantly from those estimates. Significant estimates made by management include, but are *not* limited to, assumptions used to calculate stock-based compensation, fair value of net assets acquired in business combinations, common stock warrants and options issued for services, net realizable value of accounts receivables and other receivables, the useful lives of property and equipment and intangible assets, assumptions used in determining the potential impairment of long-lived assets, including intangible assets and goodwill, the estimate of the fair value of the lease liability and related right-of-use assets, inventory reserve estimates, and the estimates of the valuation allowance on deferred tax assets and corporate income taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *9*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *3.* Summary of Significant Accounting Policies**

The significant accounting policies of the Company are described below.

***Segment Reporting***

The Company evaluated segment reporting in accordance with Accounting Standards Codification ("ASC") Topic *280,* Segment Reporting, and concluded that the Company is comprised of two operating segments. This conclusion is based on the discrete operating results regularly reviewed by the chief operating decision maker ("CODM") to assess the performance of the business and to make resource allocations. These two operating segments also represent our two reportable segments: (i) e-Commerce Operations and (ii) Healthcare Operations.

***Business acquisitions***

The Company records business acquisitions using the acquisition method of accounting. All of the assets acquired, liabilities assumed, and contractual contingencies are recognized at their fair value on the acquisition date. The application of the acquisition method of accounting for business combinations requires management to make significant estimates and assumptions in the determination of the fair value of assets acquired and liabilities assumed in order to properly allocate purchase price consideration between assets that are depreciated and amortized and goodwill. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Acquisition-related expenses and restructuring costs are recognized separately from the business combination and are expensed as incurred. The Company uses a measurement period following the acquisition date to gather information that existed as of the acquisition date that is needed to determine the fair value of the assets acquired, liabilities assumed and equity interests. The measurement period ends once all information is obtained, but *no* later than *one* year from the acquisition date.

***Cash***

The Company places its cash with high credit quality financial institutions. The Company's accounts at these institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000. All cash amounts in excess of $250,000, approximately $1.1 million, are uninsured. The Company has a deposit placement agreement for Insured Cash Sweep Service ("ICS"). This service is a secure and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of *$250,000.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *10*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

***Accounts Receivable and Allowance for Credit Losses***

Trade accounts receivable are stated at amounts expected to be collected and primarily consist of amounts due from invoiced sales and reimbursements from *third*-party PBMs, insurance providers, and contracted facilities, based on contracted prices. Trade accounts receivable are unsecured and require *no* collateral. The Company maintains an allowance for credit losses based on its estimate of expected credit losses. The estimate is based on historical loss experience, current economic conditions, and reasonable and supportable forecasts, and considers factors such as the aging of receivables, payor mix, and specific customer credit risk characteristics. The Company periodically reviews the adequacy of the allowance through review of past due accounts and other relevant factors. Accounts receivable balances are written off against the allowance for credit losses when they are deemed uncollectible and all reasonable collection efforts have been exhausted.

***Inventory***

Inventories are valued at the lower of cost or net realizable value, using the *first*-in *first*-out cost method. The Company assesses the valuation of its inventories and reduces the carrying value of those inventories that are obsolete or in excess of the Company's forecasted usage to their estimated net realizable value. The Company estimates the net realizable value of such inventories based on analysis and assumptions including, but *not* limited to, historical usage, expected future demand and market requirements. A change to the carrying value of inventories is recorded to cost of products.

***Foreign Currency Translation***

The Company's reporting currency is U.S. Dollars. The accounts of *one* of the Company's subsidiaries, GTC, are maintained using the appropriate local currency, Great British Pound ("GBP"), as the functional currency. All assets and liabilities are translated into U.S. Dollars at balance sheet date, shareholders' equity is translated at historical rates and revenue and expense accounts are translated at the average exchange rate for the year or the reporting period. The translation adjustments are reported as a separate component of stockholders' equity, captioned as accumulated other comprehensive (loss) gain. Transaction gains and losses arising from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the Consolidated Statements of Operations and Comprehensive Loss.

---

| | | |
|:---|:---|:---|
|  | ***As of December 31, 2025*** | ***As of December 31, 2024*** |
| Closing rate $USD to GBP | $1.35 | $1.26 |
| Quarterly average rate $USD to GBP | $1.33 | $1.28 |
| Yearly average rate $USD to GBP | $1.32 | $1.28 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *11*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

***Revenue Recognition, Unbilled Revenue, and Contract Liabilities***

**<u>e-Commerce Operations:</u>**

The Company recognizes revenue from satellite services when earned, as services are rendered or delivered to customers. Equipment sales revenue is recognized when the equipment is delivered to the customer. Only equipment sales are subject to warranty. Historically, the Company has *not* incurred significant expenses for warranties. Equipment sales which have been prepaid, before the goods are shipped are recorded as contract liabilities and once shipped and delivered are recognized as revenue. The Company also records as contract liabilities, certain annual plans for airtime, which are paid in advance. Once airtime services are incurred, they are recognized as revenue. Unbilled revenue is recognized for airtime plans whereby the customer is invoiced for its data usage the following month after services are incurred.

The Company's customers generally purchase a combination of our products and services as part of a multiple element arrangement. The Company's assessment of which revenue recognition guidance is appropriate to account for each element in an arrangement can involve significant judgment. This assessment has a significant impact on the amount and timing of revenue recognition.

The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic *606,* Revenue from Contracts with Customers ("ASC *606"*), we perform the following *five* steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. The *five*-step model is applied to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services transferred to the customer. At contract inception, once the contract is determined to be within the scope of ASC *606,* we assess the goods or services promised within each contract and determine those that are performance obligations and assess whether each promised good or service is distinct. We then recognize revenue in the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Contract liabilities are shown separately in the consolidated balance sheets as current liabilities. At *December 31, 2025*, we had contract liabilities of approximately $0.2 million. At *December 31, 2024*, we had contract liabilities of approximately $0.1 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *12*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**<u>Healthcare Operations:</u>**

The Company provides prescription pharmaceuticals, virus related diagnostics and vaccinations, TPA services, and contracted pharmacy services for *340B* covered entities under the *340B* Drug Discount Pricing Program. Under the terms of the contracted pharmacy services for *340B* covered entities, the Company acts as a pass-through for reimbursements on prescription claims adjudicated on behalf of the *340B* covered entities in exchange for a dispensing fee per prescription.

The Company recognizes product revenue from prescriptions dispensed to patients (customers) at the time the drugs are physically delivered to a customer or when a customer picks up their prescription, which is the point in time when control transfers to the customer. *340B* dispensing fees are a component of *340B* contract revenue, which are recognized at the time the drugs are received by the patient, by either delivery or customer pick up. Each prescription claim is considered an arrangement with the customer and is a separate performance obligation. Payments are received directly from the customer at the point of sale, or the customers' insurance provider is billed electronically. For *third*-party medical insurance and other claims, authorization is obtained to ensure payment from the customer's insurance provider before the medication is dispensed to the customer. Authorization is obtained electronically and a corresponding authorization number is issued by the customer's insurance provider. The Company is the agent in all of the *340B* pharmacy dispensing service agreements transactions with *340B* covered entities and *not* the principal in the transactions. Thus, the Company only recognizes its net fee for the prescription dispensing transactions and *not* the gross billing and cost of goods sold for the drugs dispensed.

Billings for most prescription orders are with *third*-party payers, including Medicare, Medicaid, and insurance carriers. Customer returns are nominal.

The Company recognizes revenue from TPA services as it satisfies the performance obligations under the TPA contract with a *340B* covered entity. TPA services provided to covered entities include consulting services, accounting and reconciliation of contract pharmacy billings, and various compliance services. The covered entity simultaneously receives and consumes benefits as the Company performs services under the TPA contract. These services are capable of being distinct from *one* another, e.g., the covered entity *may* receive benefit from each separate service, but in the context of a TPA contract, the services are *not* distinct with the context of the TPA contract. Instead, the Company provides a significant service of integrating the services into a combined output that benefits the covered entity. Therefore, the Company considers the combined services to be a single performance obligation in each TPA contract.

As stated in the TPA agreements, the Company receives a fixed percentage which is applied to the gross pharmacy service billings over the contract period. The gross pharmacy service billings are estimated based on the number of prescriptions filled by the Pharmacy Service contractor multiplied by the reimbursement rates set by the insurance providers. The Company invoices the covered entities for TPA services on a semi-monthly basis and collections are within *24*-*45* days of invoicing.

ASC *606* provides a practical expedient wherein an entity *may* recognize revenue in the amount to which it has a right to invoice a customer if the entity has a right to consideration from the customer in an amount that corresponds directly with the value to the customer of the entity's performance completed to date. This expedient could be available, for example, for a service contract in which an entity bills a fixed amount for each hour of service provided. The Company believes that this practical expedient applies to its TPA contracts and we have elected this method in measuring revenue over the TPA contract term.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *13*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

***Cost of Products and Services***

Cost of revenue consists primarily of materials, airtime and overhead costs incurred internally and amounts incurred to contract manufacturers to produce our products, airtime and other implementation costs incurred to install our products and train customer personnel, and customer service and *third*-party original equipment manufacturer costs to provide continuing support to our customers. There are certain costs which are deferred and recorded as prepaids, until such revenue is recognized. Refer to revenue recognition above as to what constitutes deferred revenue.

Shipping and handling costs are included as a component of costs of product in the Company's Consolidated Statements of Operations and Comprehensive Loss because the Company includes in revenue the related costs that the Company bills its customers.

***Advertising***

Costs incurred for producing and communicating advertising for the Company are charged to operations as incurred. Advertising expense was approximately $0.2 million and $0.2 million for the years ended *December 31, 2025* and *2024*, respectively.

***Goodwill***

Goodwill represents the excess of the purchase price over the value assigned to net tangible and identifiable intangible assets. Valuation techniques consistent with the market approach, income approach, and/or cost approach are used to measure fair value. Goodwill and other indefinite-lived intangible assets are assessed annually for impairment in the *fourth* fiscal quarter and in interim periods if events or changes in circumstances indicate that the assets *may* be impaired.

***Intangible Assets***

Acquired intangible assets with finite lives other than goodwill are amortized over their useful lives. For intangible assets acquired in a business combination, the estimated fair values of the assets received are used to establish their recorded values. Acquired intangible assets other than goodwill are amortized over their useful lives unless the lives are determined to be indefinite. Valuation techniques consistent with the market approach, income approach, and/or cost approach are used to measure fair value. Intangible assets subject to amortization represent the fair value of tradenames and customer contracts acquired. In valuing these assets, the Company makes assumptions regarding useful lives and projected growth rates, and significant judgment is required. The Company periodically reviews its identifiable intangible assets for impairment as events or changes in circumstances indicate that the carrying amount of such assets *may not* be recoverable. If the carrying amounts of those assets exceed their respective fair values, additional impairment tests are performed to measure the amount of the impairment losses, if any.

Tradenames and customer contracts are amortized over 10 years. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount *may no* longer be recoverable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *14*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

***Property and Equipment***

Property and equipment are carried at historical cost less accumulated depreciation. Depreciation is based on the estimated service lives of the depreciable assets and is calculated using the straight-line method. Expenditures that increase the value or productive capacity of assets are capitalized. Fully depreciated assets are retained in the property and equipment, and accumulated depreciation accounts until they are removed from service. When property and equipment are retired, sold or otherwise disposed of, the asset's carrying amount and related accumulated depreciation are removed from the accounts and any gain or loss is included in operations. Repairs and maintenance are expensed as incurred.

The estimated useful lives of property and equipment are generally as follows:

---

| | | |
|:---|:---|:---|
|  | *Years* | *Years* |
| Building |  | 40 |
| Building improvements |  | *Remaining life of the building* |
| Leasehold improvements |  | *Lessor of the estimated useful life or life of the lease* |
| Office furniture and fixtures |  | 4-5 |
| Computer equipment |  | 3-4 |
| Rental equipment |  | 4 |
| Vehicles |  | 3-5 |
| Appliques |  | 10 |
| Website development |  | 2 |

---

***Impairment of Long-lived Assets***

The Company reviews its long-lived assets, comprised of property and equipment, right-of-use assets, and intangible assets, whenever events or changes in circumstances indicate that the carrying amount of an asset *may not* be recoverable and consider market participants in accordance with ASC Topic *360*-*10, Accounting for the Impairment or Disposal of Long-Lived Assets*. The Company evaluates the long-lived assets of the reporting units for impairment at the lowest asset group level for which individual cash flows can be identified. When evaluating long-lived assets for potential impairment, the carrying amount of the asset group is compared to the estimated future undiscounted cash flows. The impairment loss calculation compares the carrying amount of the assets to the fair value based on estimated discounted future cash flows. If required, an impairment loss is recorded for that portion of the asset's carrying value in excess of fair value. As of *December 31, 2025*, there were *no* indications that the carrying amounts of our long-lived assets exceeded their respective fair values. The Company recorded an impairment loss on long-lived assets for the Healthcare Operations segment, related to intangible assets, in the amount of approximately $12.8 million for the year ended *December 31, 2024.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *15*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

***Stock-based Compensation***

Stock-based compensation is accounted for based on the requirements of ASC Topic *718,* Compensation - Stock Compensation, which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The Company's determination of the fair value using the option-pricing model is affected by the stock price as well as assumptions regarding the number of highly subjective variables.

***Income Taxes***

The Company accounts for income taxes pursuant to the provision of ASC Topic *740*-*10,* Accounting for Income Taxes ("ASC *740*-*10"*), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach require the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than *not* that the net deferred asset will *not* be realized.

The Company follows the provision of ASC *740*-*10* related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there *may* be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC *740*-*10,* the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than *not* that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are *not* offset or aggregated with other positions.

Tax positions that meet the more likely than *not* recognition threshold are measured at the largest amount of tax benefit that is more than *50* percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

The Company believes its tax positions are all more likely than *not* to be upheld upon examination. As such, the Company has *not* recorded a liability for uncertain tax benefits.

The Company has adopted ASC Topic *740*-*10*-*25,* "Definition of Settlement," which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is *not* considered more likely than *not* to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for *three* years after they are filed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *16*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

***Leases***

Effective *January 1, 2019,* the Company accounts for its leases under ASC Topic *842,* Leases. Under this guidance, the Company determines if an arrangement contains a lease at inception based on whether or *not* the Company has the right to control the asset during the contract period and other facts and circumstances. Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right of use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred.

In calculating the right of use asset and lease liability, the Company has elected to combine lease and non-lease components. The Company excludes short-term leases having initial terms of *12* months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.

***Accumulated Other Comprehensive Income (Loss)***

Comprehensive income (loss) includes net income (loss) for the period and unrealized income (losses) from foreign currency translation adjustments.

***Earnings per Common Share***

Basic income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net loss per share does *not* include dilutive common stock equivalents in the weighted average shares outstanding as they would be anti-dilutive. In periods where the Company has a net loss, all dilutive securities are excluded. See Note *7* for more information on the computation of earnings per share.

***Related Party Transactions***

A party is considered to be related to the Company if the party directly or indirectly or through *one* or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company *may* deal if *one* party controls or can significantly influence the management or operating policies of the other to an extent that *one* of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in *one* of the transacting parties and can significantly influence the other to an extent that *one* or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party - see Note *22.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *17*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

***Recent Accounting Pronouncements***

***Accounting Pronouncements Recently Adopted***

In *November 2024,* the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") *2024*-*03,* "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic *220*-*40*): Disaggregation of Income Statement Expenses", ("ASU *2024*-*03"*), which is intended to enhance transparency into the nature and function of expenses. The amendments to Subtopic *220*-*40* require that on an annual and interim basis, entities disclose disaggregated operating expense information about specific categories, including purchases of inventory, employee compensation, depreciation, amortization and selling expense. The Company early adopted this ASU, effective *January 1, 2025,* on a retrospective basis. The amendments are presentation matter revisions and did *not* have an impact on the Company's financial condition, results of operations, or cash flows.

In *December 2023,* the FASB issued ASU *2023*-*09,* "Income Taxes (Topic *740*)—Improvements to Income Tax Disclosure" ("ASU *2023*-*09"*), which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements primarily relating to the rate reconciliation and income taxes paid. This includes a tabular reconciliation using both percentages and reporting currency amounts, covering various tax and reconciling items, and disaggregated summaries of income taxes paid during the period. ASU *2023*-*09* is required to be adopted for annual periods beginning after *December 15, 2024,* with early adoption permitted. The Company adopted this accounting standard update effective *January 1, 2025* and did *not* have an impact on the Company's financial condition, results of operations, or cash flows.

***Accounting Pronouncements Issued but *not* yet Adopted***

In *December 2025,* the FASB issued ASU *2025*-*11,* "Interim Reporting (Topic *270*): Narrow-Scope Improvements," which is intended to clarify and improve the guidance in Topic *270,* Interim Reporting. The amendments clarify the applicability of interim reporting guidance, the types of interim reporting, the form and content of interim financial statements and notes prepared in accordance with U.S. GAAP, and establish a principle for disclosing events and changes since the end of the last annual reporting period that have a material impact on the entity. The amendments are *not* intended to change the fundamental nature of interim reporting or expand or reduce current interim disclosure requirements. ASU *2025*-*11* is effective for interim reporting periods within annual reporting periods beginning after *December 15, 2027,* for public business entities, with early adoption permitted. The Company has *not* yet adopted ASU *2025*-*11* and does *not* expect the adoption of this ASU to have a material impact on its consolidated financial statements.

In *December 2025,* the FASB issued ASU *2025*-*12,* "Codification Improvements," which includes numerous amendments across a broad range of Topics to clarify existing guidance, correct errors, and otherwise improve the usability and consistency of the Accounting Standards Codification. Key areas addressed include clarifications to the diluted earnings per share calculation when a loss from continuing operations exists, clarification of disclosure requirements for lease receivables arising from certain leases, revisions to the reference amount for beneficial interests, and other technical improvements. ASU *2025*-*12* is effective for fiscal years beginning after *December 15, 2026,* with early adoption permitted. The Company does *not* expect the adoption of ASU *2025*-*12* to have a material impact on its consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *18*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

***Income Tax Legislation***

On *July 4, 2025,* the United States enacted the One Big Beautiful Bill Act ("OBBBA"), which included amendments to certain provisions of the Internal Revenue Code. OBBBA included provisions that affect research and development expenditures, bonus depreciation, the Section *163*(j) business interest expense limitation, and the calculation of the Corporate Alternative Minimum Tax. In addition, the OBBBA imposes a *1%* excise tax on certain stock repurchases, which is accounted for as a non-income tax expense and recognized within operating expenses when incurred.

In accordance with ASC *740,* Income Taxes, the Company evaluated at the enactment date the impact of the legislation on its income tax accounting, including the measurement of deferred tax assets and deferred tax liabilities and valuation allowance. Because the Company maintains a full valuation allowance against its net deferred tax assets, the enactment of the OBBBA did *not* have a material effect on the Company's consolidated financial statements for the year ended *December 31, 2025.*

***Subsequent Events***

The Company has evaluated subsequent events through the date of this filing, the date the consolidated financial statements were available to be issued. Management has determined that there are *no* subsequent events that require recognition or disclosure in the consolidated financial statements.

**Note *4.* Liquidity, Going Concern, and Management's Plans**

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred recurring operating losses and historically generated negative operating cash flows. These conditions initially raised substantial doubt about the Company's ability to continue as a going concern for the *twelve* months following the issuance of these consolidated financial statements.

Management has evaluated plans intended to mitigate these conditions, including expanding the Company's long-term care pharmacy operations, increasing *340B* contract pharmacy revenue, continuing the development of institutional medication fulfillment contracts, and optimizing operational efficiencies. Based on management's projections of operating results and cash flows, the Company's current liquidity position, and management's evaluation of its plans, management believes it is probable that these plans will be effectively implemented and will mitigate the conditions that initially raised substantial doubt about the Company's ability to continue as a going concern.

The consolidated financial statements do *not* include any adjustments that might result from the outcome of this uncertainty.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *19*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *5.* Fair Value**

Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following *three* levels of inputs that *may* be used to measure fair value:

<u>Level *1:*</u> Quoted prices in active markets for identical assets or liabilities.

<u>Level *2:*</u> Inputs other than Level *1* that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are *not* active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

<u>Level *3:*</u> Unobservable inputs that are supported by little or *no* market activity and that are significant to the fair value of the assets and liabilities.

The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments:

● *Cash, accounts receivable, receivables other, accounts payable and accrued liabilities, and contract liabilities:* The amounts reported in the accompanying Consolidated Balance Sheets approximate fair value due to their short-term nature.

● *Notes payable and lease liabilities:* The carrying amount of notes payable approximated fair value due to variable interest rates at customary terms and rates the Company could obtain in current financing. The carrying value of lease liabilities approximated fair value due to the implicit rate in the lease in relation to the Company's borrowing rate and the duration of the leases (Level *2* inputs).

<u>*Identifiable Intangible Assets*</u>

The initial recognition of the Outfitter identifiable intangible assets, resulting from the acquisition on *April 1, 2024,* were measured using Level *3* inputs. The fair value at the date of acquisition was approximately $0.6 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *20*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *6.* Revenue**

The following table disaggregates net revenues by categories (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | ***Year Ended December 31, 2025*** | ***Year Ended December 31, 2025*** | ***Year Ended December 31, 2025*** |
|  | ***e-Commerce Operations*** | ***Healthcare Operations*** | ***Total*** |
| e-Commerce revenue | $14608 | $— | $14608 |
| Pharmacy prescription and other revenue, net of PBM fees |  | 35704 | 35704 |
| Pharmacy 340B contract revenue |  | 4010 | 4010 |
| Revenues, net | $14608 | $39714 | $54322 |

---

---

| | | | |
|:---|:---|:---|:---|
|  | ***Year Ended December 31, 2024*** | ***Year Ended December 31, 2024*** | ***Year Ended December 31, 2024*** |
|  | ***e-Commerce Operations*** | ***Healthcare Operations*** | ***Total*** |
| e-Commerce revenue | $13791 | $— | $13791 |
| Pharmacy prescription and other revenue, net of PBM fees |  | 41907 | 41907 |
| Pharmacy 340B contract revenue |  | 10384 | 10384 |
| Revenues, net | $13791 | $52291 | $66082 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *21*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *7.* Earnings (Loss) per Share**

Net income (loss) per common share is calculated in accordance with ASC Topic *260:* Earnings per Share ("ASC *260"*). Basic income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net loss per share does *not* include dilutive common stock equivalents in the weighted average shares outstanding as they would be anti-dilutive.

The components of basic and diluted EPS were as follows (in thousands, except per share data). For all periods presented, the Company incurred a net loss causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in diluted loss per common share and basic loss per common share being equivalent.

---

| | | |
|:---|:---|:---|
|  | ***Years Ended December 31,*** | ***Years Ended December 31,*** |
|  | ***2025*** | ***2024*** |
| Net loss attributable to common stockholders | $(11712) | $(13426) |
| Basic weighted average common shares outstanding | 26535 | 20614 |
| Potentially dilutive common shares |  |  |
| Diluted weighted average common shares outstanding | 26535 | 20614 |
| Basic weighted average loss per common share | $(0.44) | $(0.65) |
| Diluted weighted average loss per common share | $(0.44) | $(0.65) |
| Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: |  |  |
| Stock options |  | 13 |
| Common stock purchase warrants |  |  |
|  |  | 13 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *22*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *8.* Accounts Receivable, net**

Accounts receivable, net consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***December 31, 2025*** | ***December 31, 2024*** |
| Gross accounts receivable – trade | $4054 | $5036 |
| Less: allowance for credit losses | (40) | (141) |
| Accounts receivable – trade, net | $4014 | $4895 |

---

The Company decreased the allowance for credit losses in the amount of approximately $0.1 million and $0.1 million for the years ended *December 31, 2025* and *2024*, respectively.

Accounts receivable - trade, net for the Company as of *January 1, 2024* was approximately $8.9 million.

**Note *9.* Receivables - Other**

Receivables - other consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***December 31, 2025*** | ***December 31, 2024*** |
| Performance bonuses | $1369 | $1187 |
| Customers | 472 | 115 |
| Other | 89 | 29 |
|  | $1930 | $1331 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *23*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *10.* Inventory**

Inventory, net consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***December 31, 2025*** | ***December 31, 2024*** |
| Finished goods | $3814 | $5320 |
| Less reserve for obsolete inventory | (418) | (439) |
| Total | $3396 | $4881 |

---

**Note *11.* Property and Equipment, net**

Property and equipment consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***December 31, 2025*** | ***December 31, 2024*** |
| Appliques | $2160 | $2160 |
| Building | 2116 | 2116 |
| Website development | 618 | 615 |
| Office furniture and fixtures | 575 | 564 |
| Land | 184 | 184 |
| Leasehold improvements | 129 | 177 |
| Rental equipment | 128 | 87 |
| Computer equipment | 122 | 119 |
| Vehicles |  | 645 |
| Property and equipment gross | 6032 | 6667 |
| Less: accumulated depreciation | (3527) | (3260) |
| Property and equipment, net | $2505 | $3407 |

---

Depreciation expense was approximately $0.5 million and $0.8 million for the years ended *December 31, 2025* and *2024*, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *24*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *12.* Goodwill and Intangible Assets, net**

***Goodwill***

Goodwill was approximately $0.2 million at *December 31, 2025* and *December 31, 2024.* There were no changes in the carrying amount of goodwill during the year ended *December 31, 2025.* The Company performed its goodwill impairment assessment during the year ended *December 31, 2025* and determined that there were no indications of impairment.

***Intangible Assets***

Intangible assets, net as of *December 31, 2025* and *2024* related to Outfitter and consisted of the following (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | ***December 31, 2025*** | ***December 31, 2025*** | ***December 31, 2025*** |
|  | ***Gross amount*** | ***Accumulated amortization*** | ***Net Amount*** |
| Customer Contracts | $665 | $(395) | $270 |
| Trade names | 185 | (33) | 152 |
| Total intangible assets | $850 | $(428) | $422 |

---

---

| | | | |
|:---|:---|:---|:---|
|  | ***December 31, 2024*** | ***December 31, 2024*** | ***December 31, 2024*** |
|  | ***Gross amount*** | ***Accumulated amortization*** | ***Net Amount*** |
| Customer Contracts | $665 | $(312) | $353 |
| Trade names | 185 | (14) | 171 |
| Total intangible assets | $850 | $(326) | $524 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *25*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

A summary of the changes to the gross carrying amount, accumulated amortization, and net book value of total intangible assets by reporting unit during the periods presented is as follows (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | ***e-Commerce Operations*** | ***Healthcare Operations*** | ***Total*** |
| Balances as December 31, 2024: |  |  |  |
| Gross amount | $850 | $— | $850 |
| Accumulated amortization | (326) |  | (326) |
| Net amount | 524 |  | 524 |
| Changes during the year ended December 31, 2025: |  |  |  |
| Amortization expense | (102) |  | (102) |
| Net amount | (102) |  | (102) |
| Balances at December 31, 2025: |  |  |  |
| Gross amount | 850 |  | 850 |
| Accumulated amortization | (428) |  | (428) |
| Net amount | $422 | $— | $422 |

---

For the years ended *December 31, 2025* and *2024*, the Company recognized amortization expense of approximately $0.1 million and $1.7 million, respectively.

The following table represents the total estimate for future amortization of intangible assets for the *five* succeeding years and thereafter as of *December 31, 2025* (in thousands):

---

| | |
|:---|:---|
| Year | *Amount* |
| 2026 | $102 |
| 2027 | 102 |
| 2028 | 102 |
| 2029 | 39 |
| 2030 | 18 |
| Thereafter | 59 |
| Total | $422 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *26*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *13.* Accounts Payable and Accrued Expenses**

Accounts payable and accrued expenses consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***December 31, 2025*** | ***December 31, 2024*** |
| Accounts payable | $5812 | $6596 |
| Accrued litigation | 1750 |  |
| Accrued wages and payroll liabilities | 340 | 269 |
| Customer deposits payable | 72 | 96 |
| Accrued other liabilities | 291 | 269 |
| Total | $8265 | $7230 |

---

**Note *14.* Notes Payable**

Notes payable consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***December 31, 2025*** | ***December 31, 2024*** |
| A. Mortgage note payable - commercial bank - collateralized | $956 | $1050 |
| B. Note payable - uncollateralized | 25 | 25 |
| C. Notes payable - collateralized | 78 | 234 |
| Insurance premiums financing | 233 | 103 |
| Subtotal | 1292 | 1412 |
| Less: current portion of notes payable | (416) | (380) |
| Long-term portion of notes payable | $876 | $1032 |

---

(A) Mortgage Note Payable – collateralized

In *2018,* Pharmco closed on the purchase of land and building located at *400* Ansin Boulevard, Hallandale Beach, Florida. The purchase price was financed in part through a mortgage note and security agreement entered into with a commercial lender in the amount of $1,530,000. The promissory note is collateralized by the land and building, bears interest at a fixed rate of 4.75% per annum, matures on *December 14, 2028* and is subject to a prepayment penalty. Principal and interest are repaid through 119 regular payments of $11,901 that began in *January 2019,* with the final payment of all principal and accrued interest *not* yet paid on *December 14, 2028.* Note repayment is guaranteed by Progressive Care. The carrying value of the land and building was approximately $2.2 million as of *December 31, 2025.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *27*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(B) Note Payable – Uncollateralized

As of *December 31, 2025*, the uncollateralized note payable represents a non-interest-bearing loan that is due on demand from an investor.

(C) Notes Payable – Collateralized

On *July 16, 2020 (*the "Issue Date"), GTC, entered into a Coronavirus Interruption Loan Agreement ("Debenture") by and among the Company and HSBC UK Bank PLC (the "Lender") for an amount of £250,000, or USD $338,343 at an exchange rate of GBP: USD of 1.3533720. The Debenture bears interest beginning *July 16, 2021,* at a rate of 4.0% per annum over the Bank of England Base Rate (0.1% as of *July 16, 2020),* payable monthly on the outstanding principal amount of the Debenture. The Debenture has a term of six years from the drawdown date and is scheduled to mature on *July 15, 2026 (*the "Maturity Date"). Voluntary prepayments are allowed with *five* business days' written notice and the amount of the prepayment is equal to 10% or more of the limit or, if less, the balance of the debenture. The Debenture is secured by all GTC's assets as well as a guarantee by the UK government. The Debenture includes customary events of default, including, among others: (i) non-payment of amounts due thereunder, (ii) non-compliance with covenants thereunder, (iii) bankruptcy or insolvency (each, an "Event of Default"). Upon the occurrence of an Event of Default, the Debenture becomes payable upon demand. The balance outstanding on the note payable was approximately $39,000 and $132,000 as of *December 31, 2025* and *2024*, respectively.

In *July 2022,* Progressive Care entered into a note obligation with a commercial lender, the proceeds from which were used to purchase pharmacy equipment in the amount of approximately $90,000. The terms of the promissory note payable require 60 monthly payments of $1,859, including interest at 8.78% starting *January 2023.* The balance outstanding on the note payable was approximately $39,000 and $58,000 as of *December 31, 2025* and *2024*, respectively.

Principal outstanding as of *December 31, 2025*, is expected to be repayable as follows (in thousands):

---

| | |
|:---|:---|
| **Year** | ***Amount*** |
| 2026 | $416 |
| 2027 | 123 |
| 2028 | 753 |
| Thereafter |  |
| Total | $1292 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *28*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *15.* Equity**

***Common Stock***

We have authorized 50,000,000 shares of $0.0001 par value common stock. As of *December 31, 2025* and *2024*, 26,767,882 and 25,963,051 shares, respectively, were issued and outstanding. On *October 1, 2024,* the Merger became effective and Progressive Care, Inc. merged with and into Progressive Care, LLC, a wholly owned subsidiary of NextPlat. In connection with the Merger, each share of Progressive Care common stock that was issued and outstanding immediately prior to the effective time of the Merger was converted into 1.4865 shares of NextPlat common stock.

***Listing on the Nasdaq Capital Market***

Our common stock and warrants have been trading on the Nasdaq Capital Market under the symbols "NXPL" and "NXPLW," respectively, since *January 21, 2022.* Prior to *January 21, 2022,* our common stock and warrants were traded on the Nasdaq Capital Market under the symbols "OSAT" and "OSATW," respectively.

**Note *16.* Warrants**

***Amendment to PIPE Warrants***

On *November 5, 2025,* the Company entered into a Universal Amendment to PIPE Warrants (the "Amendment") with holders of the Company's Common Stock Purchase Warrants (the "Warrants") representing greater than *fifty* percent of the outstanding Warrants (based on the number of underlying warrant shares). The Warrants were originally issued pursuant to a Securities Purchase Agreement dated *December 8, 2022,* and provided for an exercise period ending on *December 14, 2025.* Pursuant to the Amendment, the exercise period of each Warrant was extended by 24 months, such that the Warrants will now expire on *December 14, 2027,* instead of *December 14, 2025.* All other terms and conditions of the Warrants remain unchanged and in full force and effect.

The 4,575,429 Warrants were originally classified as equity instruments within stockholders' equity. The Company modified 4,421,879 of the outstanding freestanding Warrants and determined the modification resulted in an incremental increase in fair value of approximately $1.2 million, calculated using the Black-Scholes model immediately before and after the modification. As the modification was considered an inducement to holders to retain their investment, the incremental value of approximately $1.2 million was recognized as an increase of additional paid-in capital and recorded as a deemed dividend, impacting net income attributable to common stockholders for the period. The modified warrants remain classified as equity instruments in stockholders' equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *29*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

***Underwriter Warrants***

In *June 2021,* the Company issued 144,000 warrants to Maxim Group LLC, the underwriter (the "Underwriter Warrants") in connection with the *June 2021* Public Offering (*"June* Offering"). The Underwriter Warrants expire five years from the effective date of the *June* Offering and are exercisable at a per share price equal to $5.50 per share, or 110% of the public offering price per unit in the *June* Offering.

As of *December 31, 2025* and *2024*, there were 144,000 Underwriter Warrants issued and outstanding, respectively.

***Progressive Care Merger*****W***arrants*

On *October 1, 2024,* as a result of the Progressive Care merger with NextPlat (the "Merger"), 650,515 warrants to purchase Progressive Care common stock were outstanding and unexercised immediately prior to the effective time of the Merger automatically converted into a warrant to purchase shares of NextPlat common stock with each such warrant having and being subject to the same terms and conditions (including vesting and exercisability terms) as were applicable to such Progressive Care warrant immediately before the effective time.

***Placement Agent Warrants***

In *December 2022,* pursuant to the *December 2021* Offering, the Company issued 549,051 warrants to purchase shares of Common Stock with an exercise price of $1.75 per share, to its Placement Agent Dawson James Securities Inc. The Placement Agent Warrants are exercisable at any time and from time to time during the three-year period commencing on the *six*-month anniversary of the closing date.

Additionally, as a result of the Progressive Care merger with NextPlat, 637,984 placement agent warrants to purchase Progressive Care common stock were outstanding and unexercised immediately prior to the effective time of the Merger automatically converted into a warrant to purchase shares of NextPlat common stock with each such warrant having and being subject to the same terms and conditions (including vesting and exercisability terms) as were applicable to such Progressive Care warrant immediately before the effective time.

As of *December 31, 2025* and *2024*, there were 1,187,035 Placement Agent Warrants issued and outstanding, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *30*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

***Stock-Based Compensation Warrants***

During the year ended *December 31, 2025,* the Company granted 50,000 warrants as stock-based compensations valued at approximately $0.88 per warrant, using a Black-Scholes option pricing model with the following assumptions: stock price of $0.88 per share (based on closing price of the Company's common stock on the date of grant), volatility of 200%, expected term of seven years, and a risk free interest rate of 3.88%. There were no stock-based compensation warrants issued for the year ended *December 31, 2024.* As of *December 31, 2025* and *2024*, there were 70,000 and 20,000 Stock-Based Compensation Warrants issued and outstanding, respectively.

A summary of the status of the Company's total outstanding warrants and changes during the year ended *December 31, 2025* is as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | ***Number of Warrants*** | ***Weighted Average Exercise Price*** | ***Weighted Average Remaining Contractual Life (Years)*** |
| Balance at January 1, 2024 | 7569572 | $2.85 | 2.15 |
| Granted (1) | 1288498 | 2.01 | 1.93 |
| Exercised | (48550) | 1.75 | *—* |
| Balance outstanding and exercisable at December 31, 2024 | 8809520 | $2.73 | 1.26 |
| Balance at January 1, 2025 | 8809520 | $2.73 | 1.26 |
| Granted | 50000 | 0.88 | 6.86 |
| Exercised |  |  | *—* |
| Balance outstanding and exercisable at December 31, 2025 | 8859520 | $2.89 | 1.34 |

---

------

(*1*) Warrants issued related to the Progressive Care Merger on *October 1, 2024.*

As of *December 31, 2025*, and *December 31, 2024*, there were 8,859,520 and 8,809,520 warrants outstanding, respectively.

As of *December 31, 2024*, the Company had registered warrants of 2,386,092 of the 8,809,520 warrants issued and outstanding.

As of *December 31, 2025*, the Company had registered warrants of 2,386,092 of the 8,859,520 warrants issued and outstanding.

The Company determined that the warrants do *not* meet the definition of liability under FASB ASC Topic *480* and therefore classified the warrants as equity instruments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *31*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *17.* Stock-Based compensation**

Stock-based compensation expense is recorded in selling, general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss. For the years ended *December 31, 2025* and *2024*, stock-based compensation expense was approximately $0.6 million and $1.6 million, respectively. There were no income tax benefits recognized from stock-based compensation during the years ended *December 31, 2024* and *2023* due to cumulative losses and valuation allowances.

***Stock Award Plans***

The Company maintains stock incentive plans to attract, motivate and retain management, key employees, directors, and consultants. These plans provide for discretionary awards of, among others, stock options, stock awards, stock unit awards, and stock appreciation rights to participants (collectively, share-based awards).

***Restricted Stock Awards***

The following table summarizes our restricted stock awards activity:

---

| | | |
|:---|:---|:---|
|  | ***Number of Units*** | ***Weighted Average Grant Date Fair Value*** |
| Outstanding as of December 31, 2023 | 225000 | $4.33 |
| Vested | (220000) | 5.03 |
| Forfeited | (5000) | 5.37 |
| Outstanding as of December 31, 2024 |  |  |
| Granted | 1086581 | 0.71 |
| Vested | (804831) | 0.73 |
| Forfeited |  |  |
| Outstanding as of December 31, 2025 | 281750 | $0.65 |

---

As of *December 31, 2025*, there was approximately $0.3 million of net unrecognized compensation cost related to unvested stock-based compensation to be recognized over the remaining weighted average period of one year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *32*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

***Stock Options***

Stock options outstanding at *December 31, 2025* and *2024*, as disclosed in the below table, have approximately $0 and $3,000 of intrinsic value, respectively.

A summary of the status of the Company's outstanding stock options and changes during the years ended *December 31, 2025* and *2024*, is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Number of Options*** | ***Weighted Average Exercise Price*** | ***Weighted Average Grant Date Fair Value*** | ***Weighted Average Remaining Contractual Life (Years)*** |
| Balance at January 1, 2024 | 2245333 | $3.63 | $2.88 | 4.26 |
| Granted (1) | 480088 | 1.78 | 1.30 | 7.60 |
| Cancelled | (250000) | 5.35 | *—* | *—* |
| Balance outstanding at December 31, 2024 | 2475421 | $3.10 | $2.54 | 4.35 |
| Options exercisable at December 31, 2024 | 2453752 | $3.11 | $2.55 | 4.36 |
| Balance at January 1, 2025 | 2475421 | $3.10 | $2.54 | 4.35 |
| Granted | *—* | *—* | *—* | *—* |
| Exercised | *—* | *—* | *—* | *—* |
| Cancelled | *—* | *—* | *—* | *—* |
| Expired | (30000) | 2.46 | 2.46 | *—* |
| Balance outstanding at December 31, 2025 | 2445421 | $3.10 | $2.54 | 3.40 |
| Options exercisable at December 31, 2025 | 2445421 | $3.10 | $2.54 | 3.40 |

---

------

(*1*) Stock options granted as a result of the Progressive Care Merger on *October 1, 2024.*

On *October 1, 2024,* the Merger became effective and Progressive Care merged with and into Merger Sub and thereby became a wholly owned subsidiary of NextPlat. In connection with the Merger, each share of Progressive Care common stock that was issued and outstanding immediately prior to the effective time of the Merger was converted into 1.4865 shares of NextPlat common stock, and each warrant to purchase Progressive Care common stock that was outstanding and unexercised immediately prior to the effective time of the Merger automatically converted into a warrant to purchase shares of NextPlat common stock with each such warrant having and being subject to the same terms and conditions (including vesting and exercisability terms) as were applicable to such Progressive Care warrant immediately before the effective time.

There were no stock options granted during the year ended *December 31, 2025*. As of *December 31, 2025*, all stock options were fully vested.

For the year ended *December 31, 2024*, the Company granted 480,088 stock options valued at approximately $1.30 per option, using a Black-Scholes option pricing model with the following assumptions: stock price of $1.30 per share (based on closing price of the Company's common stock on the date of grant), volatility of 236% - 240%, expected term of 7 to 8 years and a risk free interest rate of 3.61% to 3.64%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *33*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *18.* Income Taxes**

The Company accounts for income taxes under ASC Topic *740:* Income Taxes which requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry forwards. ASC Topic *740* additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets.

The components of earnings (loss) before income taxes for the years ended *December 31, 2025* and *2024* were as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***Years Ended December 31,*** | ***Years Ended December 31,*** |
|  | ***2025*** | ***2024*** |
| Net loss before income taxes: |  |  |
| Domestic | $(10584) | $(22681) |
| Foreign | 121 | 226 |
|  | $(10463) | $(22455) |

---

Income tax provision consisted of the following for the years ended *December 31, 2025* and *2024* (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***Years Ended December 31,*** | ***Years Ended December 31,*** |
|  | ***2025*** | ***2024*** |
| Income tax provision: |  |  |
| Current: |  |  |
| Federal | $— | $— |
| State |  |  |
| Foreign |  | 71 |
| Total current |  | 71 |
| Deferred: |  |  |
| Federal |  |  |
| State |  |  |
| Foreign |  |  |
| Total deferred |  |  |
| Total income tax provision | $— | $71 |

---

The Company's wholly owned subsidiary, GTC, is a United Kingdom ("UK") Limited Company and files tax returns in the UK. Its estimated tax liability for *December 31, 2025* and *2024* is approximately $0 and $56,000, respectively. The estimated tax liability of $56,000 differs from the estimated tax expense of approximately $71,000 due to true-up adjustments of approximately $15,000 that were recorded in *2024.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *34*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

The Company adopted ASU *2023*-*09* for the year ended *December 31, 2025.* A reconciliation of the income tax provision by applying the statutory United States federal income tax rate to loss before income taxes is as follows (dollars in thousands):

---

| | | |
|:---|:---|:---|
|  | ***Year Ended December 31, 2025*** | ***Year Ended December 31, 2025*** |
|  | ***Amount*** | ***Rate*** |
| U.S. federal statutory tax rate | $(2223) | 21% |
| State tax rate, net of federal effect | (445) | 4% |
| Change in valuation allowance | 2551 | (24)% |
| Nontaxable or nondeductible items | 38 | (0)% |
| Other adjustments | 79 | (1)% |
| Income tax provision | $— | —% |

---

A reconciliation of the income tax provision by applying the statutory United States federal income tax rate to income loss before income taxes is as follows, prior to the adoption of ASU *2023*-*09:*

---

| | |
|:---|:---|
|  | ***Year Ended December 31, 2024*** |
| Federal income tax provision at statutory rate | $(1666) |
| Deferred state income taxes, net | (293) |
| Provision true-up adjustments | 72 |
| Foreign taxes at rate different than US Taxes | 71 |
| Permanent differences | 142 |
| Other true-ups | 4 |
| Change in valuation allowance | 1741 |
| Income tax provision | $71 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *35*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Deferred tax assets and liabilities are provided for significant income and expense items recognized in different years for tax and financial reporting purposes. Temporary differences, which give rise to a net deferred tax asset is as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***December 31, 2025*** | ***December 31, 2024*** |
| Deferred tax assets: |  |  |
| Net operating loss carryforward | $11741 | $9625 |
| Property plant and equipment and intangibles asset | 313 | 280 |
| Equity method investment loss | 806 | 806 |
| Accounts receivable | 26 | 33 |
| Inventory | 27 | 17 |
| Right-of-use assets | 35 | 171 |
| Accrued loss contingency | 444 |  |
| Stock-based compensation | 4181 | 4177 |
| Interest limitation | 619 | 619 |
| Total deferred tax assets | 18192 | 15728 |
| Deferred tax liabilities: |  |  |
| Book basis of intangible assets in excess of tax basis | 208 | 150 |
| Lease liabilities | 36 | 181 |
| Total deferred tax liabilities | 244 | 331 |
| Net deferred tax asset before valuation allowance | 17948 | 15397 |
| Less: valuation allowance | (17948) | (15397) |
| Net deferred tax asset | $— | $— |

---

The Company has a total net operating loss carryforward ("NOL carryforward") of approximately $46.6 million at *December 31, 2025*. The NOL carryforward consists of approximately $30.1 million from NextPlat Corp and approximately $16.5 million from Progressive Care LLC. Out of the approximately $46.6 million NOL carryforward, approximately $6.3 million will begin to expire in *2032* and approximately $40.3 million will have an indefinite life. The Company has *not* performed an IRC Section *382* analysis of the Progressive Care NOL carryforward, so it is *not* known as this time the amount of the NOL carryforward available to offset NextPlat future taxable income. IRC Section *382* imposes a limitation on a company to use historical NOLs and certain other tax attributes in the event of an ownership change.

After consideration of all the evidence, both positive and negative, management has recorded a full valuation allowance at *December 31, 2025* and *2024*, due to the uncertainty of realizing the deferred income tax assets. The change in the valuation allowance for *2025* was an increase of approximately $2.6 million.

The Company is subject to taxation in the U.S. and various states and foreign jurisdictions. U.S. federal income tax returns for 2022 and after remain open to examination. Generally, foreign income tax returns after 2021 remain open to examination. *No* income tax returns are currently under examination. As of *December 31, 2025* and *2024*, the Company does not have any unrecognized tax benefits, and continues to monitor its current and prior tax positions for any changes. The Company recognizes penalties and interest related to unrecognized tax benefits as income tax expense. For the years ended *December 31, 2025* and *2024*, there were no penalties or interest recorded in income tax expense.

During the years ended *December 31, 2025* and *2024,* the Company made cash payments for foreign income taxes of approximately $35,000 and $0.2 million, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *36*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *19.* Leases**

The Company has entered into a number of lease arrangements under which the Company is the lessee. These leases are classified as operating leases. In addition, the Company has elected the short-term lease practical expedient in ASC Topic *842* related to real estate leases with terms of *one* year. The following is a summary of the Company's lease arrangements.

***Finance Lease Agreements***

In *May 2018,* Progressive Care entered into a finance lease obligation to purchase pharmacy equipment with a cost of approximately $115,000. The terms of the lease agreement require monthly payments of approximately $1,700 plus applicable tax over 84 months ending *March 2025* including interest at the rate of 6%.

***Operating Lease Agreements***

On *December 2, 2021,* NextPlat Corp. entered into a 62-month operating lease for approximately 4,141 square feet of office space located in Florida (the "Florida Lease"). The lease commenced upon occupancy on *June 13, 2022* and was scheduled to expire on *August 31, 2027.* Initial annual base rent was approximately $186,000, subject to 3% annual increases. The Florida Lease did *not* require contingent rental payments, impose financial restrictions, or contain any residual value guarantees. On *November 11, 2025,* the Company entered into a lease termination agreement with the landlord to terminate the Florida Lease prior to its contractual expiration date. Pursuant to the termination agreement, the Company was required to pay an early termination fee of approximately $120,000. In accordance with ASC *842,* the Company accounted for the termination agreement as a lease modification that resulted in termination of the lease. Upon execution of the termination agreement, the Company remeasured the lease liability and derecognized the related ROU asset. The difference between (i) the carrying amounts of the lease liability and ROU asset and (ii) the termination payment was recognized in the Consolidated Statements of Operations and Comprehensive Loss during the year ended *December 31, 2025.* The $120,000 termination fee is included in operating expenses within the Consolidated Statements of Operations and Comprehensive Loss. Following the termination, the Company has *no* remaining obligations under the Florida Lease.

The Company leases office and warehouse facilities located in Poole, England. The Company previously leased approximately 2,660 square feet of office and warehouse space under a lease arrangement with annual rent of approximately £30,000 (approximately $37,100 based on an average exchange rate of 1.24 GBP to USD). The lease was renewed on *October 6, 2022* and expired on *October 31, 2023,* and was subsequently renewed for an additional twelve-month term. On *August 1, 2024,* the Company relocated from its previous Poole, England facility and entered into a new operating lease for office and warehouse space at a new location in Poole, England (the "Poole Lease"). The relocation resulted in termination of the prior lease agreement. The Poole Lease has a three-year term commencing *August 1, 2024* and expiring on *July 31, 2027.* Annual base rent under the Poole Lease is approximately £14,000 through *July 31, 2025,* approximately £30,000 through *July 31, 2026,* and approximately £26,000 through *July 31, 2027.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *37*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Outfitter leases office space located at *2727* Old Elm Hill Pike, Nashville, Tennessee (the "Nashville Lease"). The lease commenced in *April 2024* and originally had a contractual expiration date of *April 2026.* The lease agreement required monthly lease payments of approximately $4,800. In *December 2025,* the Company executed a First Amendment to the lease agreement extending the lease term through *April 1, 2027* and revising lease payments effective *January 1, 2026.* In accordance with ASC *842,* the amendment was evaluated as a lease modification. As the modification extended the lease term and revised future lease payments without granting an additional right-of-use separate from the original lease, the Company accounted for the amendment as a modification of the existing operating lease. Accordingly, the Company remeasured the operating lease liability as of the modification date using a revised discount rate, with a corresponding adjustment recorded to the related right-of-use asset.

Progressive Care entered into a lease agreement for its Orlando pharmacy in *August 2020.* The term of the lease is 66 months with a termination date of *February 2026.* The lease agreement calls for monthly payments that began in *February 2021,* of $4,310, with an escalating payment schedule each year thereafter.

Progressive Care leases its North Miami Beach pharmacy location under an operating lease agreement with a lease commencement date in *September 2021.* The term of the lease is 60 months with a termination date in *August 2026.* The lease calls for monthly payments of $5,237, with an escalating payment schedule each year thereafter.

Variable expenses generally represent the Company's share of the landlord's operating expenses.

Right-of-use assets for operating leases are periodically reduced by impairment losses. We use the long-lived assets impairment guidance in ASC Subtopic *360*-*10,* Property, Plant, and Equipment – Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. For the year ended *December 31, 2024,* the Company recorded approximately $0.1 million of impairment loss related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and *not* returning to service in the future. There were *no* impairments related to the write-down of right-of-use assets for the year ended *December 31, 2025.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; We monitor for events or changes in circumstances that require a reassessment of *one* of our leases. When a reassessment results in the re-measurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in profit or loss.

We recognized lease costs associated with all leases as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***Years Ended December 31,*** | ***Years Ended December 31,*** |
|  | ***2025*** | ***2024*** |
| Operating lease cost: |  |  |
| Fixed rent expense | $486 | $603 |
| Variable rent expense | 182 | 65 |
| Finance lease cost: |  |  |
| Amortization of right-of-use assets | 5 | 20 |
| Interest expense |  | 1 |
| Total Lease Costs | $673 | $689 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *38*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Supplemental cash flow information related to leases was as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***Years Ended December 31,*** | ***Years Ended December 31,*** |
|  | ***2025*** | ***2024*** |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |
| Operating cash flows from operating leases | $522 | $427 |
| Financing cash flows from finance leases | 5 | 24 |
| Total cash paid for lease liabilities | $527 | $451 |

---

Supplemental balance sheet information related to leases was as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***December 31, 2025*** | ***December 31, 2024*** |
| <u>Operating leases:</u> |  |  |
| Operating lease right-of-use assets, net | $189 | $812 |
| Operating lease liabilities: |  |  |
| Current portion | 158 | 404 |
| Long-term portion | 41 | 438 |
|  | $199 | $842 |
| Weighted average remaining lease term (years) | 1.14 | 2.25 |
| Weighted average discount rate | 5% | 4% |
| <u>Finance leases:</u> |  |  |
| Finance lease right-of-use assets, net | $— | $5 |
| Finance lease liabilities: |  |  |
| Current portion |  | 5 |
| Long-term portion |  |  |
|  | $— | $5 |
| Weighted average remaining lease term (years) | *—* | 0.24 |
| Weighted average discount rate | *—* | 6% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *39*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Future minimum lease payments are as follows (in thousands):

---

| | | | |
|:---|:---|:---|:---|
| **Years Ending December 31,** | ***Finance Lease*** | ***Operating Lease*** | ***Total Future Lease Commitments*** |
| 2026 | $– $| 163 | $163 |
| 2027 | – | 40 | 40 |
| 2028 | – |  |  |
| 2029 | – |  |  |
| 2030 | – |  |  |
| Total lease payments to be paid | – | 203 | 203 |
| Less: future interest expense | – | (4) | (4) |
| Lease liabilities | – | 199 | 199 |
| Less: current maturities | – | (158) | (158) |
| Long-term portion of lease liabilities | $– $| 41 | $41 |

---

**Note *20.* Reportable Segments**

The Company has two reportable segments: (i) e-Commerce Operations, which involves acquiring and leasing, primarily an e-commerce platform to collaborate with businesses to optimize their ability to sell their goods online, domestically, and internationally, and enabling customers and partners to optimize their e-commerce presence and revenue, and other related businesses and (ii) Healthcare Operations, which provides TPA, data management, COVID-*19* related diagnostics and vaccinations, prescription pharmaceuticals, compounded medications, telepharmacy services, anti-retroviral medications, medication therapy management, the supply of prescription medications to long-term care facilities, medication adherence packaging, contracted pharmacy services for *340B* covered entities under the *340B* Drug Discount Pricing Program, and health practice risk management. This organizational structure aligns with how the Company's CODMs manage the business, including resource allocation and performance assessment, and further aligns with the Company's product categories and the key markets the Company serves.

The CODMs include the Company's Chief Executive Officer and Chief Financial Officer.

The CODMs do *not* review segment assets and segment expenses at a level different than what is reported in the Company's Consolidated Balance Sheets and Consolidated Statements of Operations and Comprehensive Loss. While the Company believes there are synergies between the *two* reportable segments, the segments are managed separately because each requires different business strategies. Accounting policies associated with our operating segments are generally the same as those described in Note *1.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *40*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

The following tables provide information about the Company's reportable segments (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Year Ended December 31, 2025** | ***e-Commerce Operations*** | ***Healthcare Operations*** | ***Eliminations*** | ***Total*** |
| e-Commerce revenue | $14608 | $— | $— | $14608 |
| Pharmacy prescription and other revenue, net of PBM fees |  | 35704 |  | 35704 |
| Pharmacy 340B contract revenue |  | 4010 |  | 4010 |
| **Revenues, net** | 14608 | 39714 |  | 54322 |
| **Expenses:** |  |  |  |  |
| Cost of revenue | 11251 | 32165 |  | 43416 |
| Selling, general and administrative | 2958 | 3085 |  | 6043 |
| Salaries, wages and payroll taxes | 2905 | 7802 |  | 10707 |
| Professional fees | 1510 | 754 |  | 2264 |
| Depreciation and amortization | 278 | 262 |  | 540 |
| Intangible asset amortization | 102 |  |  | 102 |
| Loss on settlement of litigation |  | 250 |  | 250 |
| Total expenses | 19004 | 44318 |  | 63322 |
| Operating loss | (4396) | (4604) |  | (9000) |
| Interest expense | 7 | 57 |  | 64 |
| Other expense | 434 | 965 |  | 1399 |
| Loss before income taxes | (4837) | (5626) |  | (10463) |
| Income taxes |  |  |  |  |
| Net loss | $(4837) | $(5626) | $— | $(10463) |
| **Year Ended December 31, 2024** | ***e-Commerce Operations*** | ***Healthcare Operations*** | ***Eliminations*** | ***Total*** |
| e-Commerce revenue | $13791 | $— | $— | $13791 |
| Pharmacy prescription and other revenue, net of PBM fees |  | 41907 |  | 41907 |
| Pharmacy 340B contract revenue |  | 10384 |  | 10384 |
| **Revenues, net** | 13791 | 52291 |  | 66082 |
| **Expenses:** |  |  |  |  |
| Cost of revenue | 10356 | 38718 |  | 49074 |
| Selling, general and administrative | 2907 | 3272 |  | 6179 |
| Salaries, wages and payroll taxes | 3599 | 9704 |  | 13303 |
| Impairment loss |  | 13653 |  | 13653 |
| Professional fees | 2900 | 1741 | (240) | 4401 |
| Depreciation and amortization | 438 | 350 |  | 788 |
| Intangible asset amortization | 101 | 1608 |  | 1709 |
| Total expenses | 20301 | 69046 | (240) | 89107 |
| Operating loss | (6510) | (16755) | 240 | (23025) |
| Interest expense | 13 | 68 |  | 81 |
| Other (income) expense | (647) | (244) | 240 | (651) |
| Loss before income taxes | (5876) | (16579) |  | (22455) |
| Income taxes | (71) |  |  | (71) |
| **Net loss** | $(5947) | $(16579) | $— | $(22526) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **e-Commerce Operations** | **Healthcare Operations** | **Eliminations** | **Total** |
| Total assets as of December 31, 2025 | $12748 | $14717 | $– $| 27465 |
| Total assets as of December 31, 2024 | $19044 | $18033 | $– $| 37077 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *41*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *21.* Commitments and Contingencies**

***Litigation***

On *March 17, 2025,* a former employee of Pharmco LLC, a wholly owned subsidiary of the Company, filed a lawsuit against Pharmco LLC, asserting claims under the Equal Employment Opportunity Commission (EEOC) regulations. On *October 14, 2025,* the Company reached a Settlement Agreement with the plaintiff to resolve all claims. The settlement was fully covered by the Company's insurance policy, and the insurer remitted payment directly to the plaintiff on the Company's behalf.

On *October 28, 2024,* Alan Jay Weisberg, the former Chief Executive Officer and Chairman of Progressive Care Inc. ("RXMD"), filed a putative class action suit on behalf of himself and all other former RXMD stockholders against NextPlat, Charles M. Fernandez, the former Chief Executive Officer and director of NextPlat, and Rodney Barreto, a director of NextPlat. The complaint purports to allege a breach of fiduciary duty by NextPlat and Messrs. Fernandez and Barreto in connection with the merger of RXMD with and into a wholly owned subsidiary of NextPlat (the "Merger"), which Merger was completed on *October 1, 2024* following approval by the stockholders of each of NextPlat and RXMD in stockholder meetings held on *September 13, 2024* by NextPlat and RXMD, respectively. Among other things, the complaint asserts that the consideration paid to Mr. Weisberg and the other RXMD stockholders in connection with the Merger was insufficient. The monetary relief requested in the complaint includes compensatory and rescissory damages in an unspecified dollar amount. The complaint is pending in the Court of Chancery of the State of Delaware. The caption is *Alan Jay Weisberg v. Charles M. Fernandez, Rodney Barreto and Nextplat Corp.,* and the case number is C.A. *No. 20. 24*-*1097*-MTZ.

The Company believes the claims asserted in the action are without merit and intends to continue to vigorously defend against the lawsuit. The Company has filed a motion to dismiss the complaint. Although the parties have engaged in discussions regarding a potential resolution of the matter, *no* agreement has been reached and there can be *no* assurance that the matter will be resolved on acceptable terms or at all. Based on currently available information and after consultation with legal counsel, management determined that a loss associated with this matter is probable and reasonably estimable in accordance with applicable accounting guidance. Accordingly, as of *December 31, 2025,* the Company recorded an accrual of approximately $1.75 million, which represents management's current estimate of loss exposure and corresponds to the Company's applicable insurance retention under its directors' and officers' liability insurance coverage. Due to the significant and unusual nature of the contingent loss accrual, the Company classified the associated expense within other (expense) income instead of operating expenses (as with other legal settlements) as to *not* distort operating losses. The ultimate outcome of the matter remains uncertain, and the actual loss could differ materially from the amount accrued. Any such difference could have a material effect on the Company's consolidated financial condition, results of operations, or cash flows in the period in which the matter is resolved.

On *June 17, 2024,* Progressive Care was notified of a potential claim that a former employee (the "Claimant") allegedly suffered a loss due to an alleged breach by Progressive Care of an employment contract with the Claimant. On *November 7, 2025,* Progressive Care entered into a Settlement Agreement (the "Settlement Agreement") with the Claimant to resolve all disputes related to the employment and the arbitration proceeding. Pursuant to the Settlement Agreement, Progressive Care paid the Claimant a total sum of $150,000 within *seven* days of execution. In addition, Progressive Care transferred to the Claimant 128,205 shares of NextPlat common stock valued at $100,000. The Settlement Agreement provides the Claimant with a *one*-time reverse stock-split protection mechanism, whereby, if the aggregate value of the transferred shares declines by more than *20%* within *sixty* calendar days following a reverse stock split, Progressive Care will issue additional shares of NextPlat common stock to the Claimant to restore the aggregate value to the pre-split level, with such shares to be issued within *ten* days after the *sixty*-day period. The settlement amount of $250,000 is included in "Loss on settlement of litigation" in the Consolidated Statements of Operations and Comprehensive Loss.

From time to time, the Company *may* become involved in litigation relating to claims arising out of our operations in the normal course of business. Other than the matter described above, the Company is *not* currently involved in any pending legal proceeding, claims or litigation, and to the best of our knowledge, *no* governmental authority is contemplating any proceeding to which the Company is a party or to which any of the Company's properties is subject, which would reasonably be likely to have a material adverse effect on the Company's business, financial condition, operating results, and cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *42*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

**Note *22.* Related Party Transactions**

The Company uses an American Express account for Orbital Satcom and an American Express account for GTC, both in the name of the Company's Chief Executive Officer, who personally guarantees the balance owed. As of *December 31, 2025*, the accounts payable due to related party includes amounts due to the Company's Chief Executive Officer. Total related party payments due as of *December 31, 2025* and *December 31, 2024* were $11,000 and $18,000, respectively. Those related party payables are non-interest bearing and due on demand.

During the year ended *December 31, 2025*, the Company employed and paid wages to *one* employee related to the Company's Chief Executive Officer and *one* employee related to the Company's Chief Financial Officer.

During the year ended *December 31, 2025,* the Company employed and paid wages to the spouse of the Company's late Chief Executive Officer, Charles M. Fernandez, as Chief of Staff and Special Assistant to the Chairman of the Board. The Company terminated Mrs. Fernandez's employment with the Company on *August 13, 2025.*

**Note *23.* Concentrations**

**<u>e-Commerce Operations</u> <u>concentrations:</u>**

***Customers:***

Amazon accounted for 31.1% and 32.8% of the Company's net revenues during the years ended *December 31, 2025* and *2024*, respectively. *No* other customer accounted for *10%* or more of the Company's net revenues for either period.

***Suppliers:***

The following table sets forth information as to each supplier that accounted for *10%* or more of the Company's purchases for the years ended *December 31, 2025* and *2024* (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the Years Ended December 31,*** | ***For the Years Ended December 31,*** | ***For the Years Ended December 31,*** | ***For the Years Ended December 31,*** |
|  | ***2025*** | ***2025*** | ***2024*** | ***2024*** |
|  | ***Amount*** | ***% of Total Purchases*** | ***Amount*** | ***% of Total Purchases*** |
| Iridium Satellite | $2738 | 22% | $1602 | 17% |
| Garmin | $1882 | 15% | $1242 | 13% |
| Globalstar Europe | $1373 | 11% | $975 | 10% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F- *43*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEXTPLAT CORP AND SUBSIDIARIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

***Geographic**:*

The following table sets forth net revenue as to each geographic location, for the years ended *December 31, 2025* and *2024* (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Years Ended December 31,*** | ***Years Ended December 31,*** | ***Years Ended December 31,*** | ***Years Ended December 31,*** |
|  | ***2025*** | ***2025*** | ***2024*** | ***2024*** |
|  | ***Amount*** | ***% of Total*** | ***Amount*** | ***% of Total*** |
| Europe | $7451 | 51% | $6812 | 49% |
| North America | 4683 | 32% | 4529 | 33% |
| Asia and Pacific | 1968 | 13% | 1720 | 12% |
| Africa | 462 | 3% | 683 | 5% |
| South America | 44 | *nm* | 47 | *nm* |
|  | $14608 | 100% | $13791 | 100% |

---

**<u>Healthcare Operations</u> <u>concentrations:</u>**

***Suppliers:***

Progressive had significant concentrations with one vendor, McKesson. The purchases from this significant vendor were approximately 98.0% of total vendor purchases for the year ended *December 31, 2025*.

***Customers:***

Progressive's trade receivables are primarily from prescription medications billed to various insurance providers. Ultimately, the insured is responsible for payment should the insurance company *not* reimburse Progressive Care.

Reimbursements from the top *three* significant PBMs were as follows:

---

| | |
|:---|:---|
|  | **Year Ended December 31, 2025** |
| A | 31% |
| B | 18% |
| C | 15% |

---

---

| | |
|:---|:---|
|  | **Year Ended December 31, 2024** |
| A | 29% |
| B | 23% |
| C | 20% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; F-44

## Exhibit 19.1

**Exhibit 19.1**

![ex_939006img001.jpg](ex_939006img001.jpg)

**NEXTPLAT CORP & SUBSIDIARIES**

**INSIDER TRADING POLICY**

&nbsp;&nbsp;&nbsp;&nbsp;**I.** **PURPOSE** 

NextPlat Corp (the "<u>Company</u>") has adopted this Insider Trading Policy (this "<u>Policy</u>") to help its directors, officers and employees comply with insider trading laws and to prevent even the appearance of improper insider trading.

&nbsp;&nbsp;&nbsp;&nbsp;**II.** **SCOPE** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.** This Policy applies to all directors, officers and employees of the Company, as well as to their respective family members and others in their households (collectively referred to as " <u>Insiders</u> "), and any other individuals the Compliance Officer (defined in Section V. below) may designate as Insiders because they have access to material nonpublic information concerning the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** Except as set forth explicitly below, this Policy applies to any and all transactions in the Company's securities, including transactions in common stock, options, preferred stock, restricted stock, restricted stock units, and any other type of securities that the Company may issue. This Policy applies to such securities regardless of whether they are held in a brokerage account, a 401(k) or similar account, through an employee stock purchase plan, or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;**III.** **SPECIFIC GUIDANCE** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.** **Buying, Selling, and other Trading Activity Transactions.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. All Insider trading transactions are required to be pre-approved by the Compliance Officer prior to the trading activity in accordance with the following procedures:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Individual notifies the Compliance Officer in writing (via email), at least three business days prior to the proposed trade(s), of the amount (dollars or shares) and nature of the proposed trade(s), and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. the individual has certified to the Compliance Officer in writing, no more than three business days prior to the proposed trade(s), that he or she is not aware of material nonpublic information regarding the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The notice and certification required by this section shall be given using the form attached hereto as <u>Exhibit A</u>. The Compliance Officer will designate the expiration date of the approved trade notice (typically four trading days after the proposed trade date).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>No Obligation to Approve Trades</u>. The existence of the foregoing approval procedures does not in any way obligate the Compliance Officer (or in the case of any trade by the Compliance Officer, the Chief Executive Officer or the Chief Financial Officer of the Company) to approve any trades requested by any Insiders or the Compliance Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** **The Trading Window.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Trading Only While Trading Window is Open</u>. Insiders may buy, sell or trade in Company securities only while the Company's trading window is open. In general, the Company's trading window opens after the close of trading on the second full trading day following the Company's public announcement of quarterly earnings and remains open through the last trading day of the third calendar month of the then-current fiscal quarter. The Company's trading window is subject to additional blackout periods at the discretion of the Compliance Officer. See <u>Exhibit B</u> for the current year trading window calendar.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.** **Generally Prohibited Activities.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Trading in Company Securities</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. No Insider may buy, sell or otherwise trade in Company securities while aware of material nonpublic information concerning the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. No Insider may buy, sell or otherwise trade in Company securities during any trading blackout period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Tipping</u>. Providing material nonpublic information to another person who may trade or advise others to trade on the basis of that information is known as "tipping" and is illegal. Therefore, no Insider may "tip" or provide material nonpublic information concerning the Company to any person other than a director, officer or employee of the Company, unless required as part of that Insider's regular duties for the Company and authorized by the Compliance Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Giving Trading Advice</u>. No Insider may give trading advice of any kind about the Company to anyone, whether or not such Insider is aware of material nonpublic information about the Company, except that Insiders should advise other Insiders not to trade if such trading might violate the law or this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Engaging in Short Sales</u>. No Insider may engage in short sales of Company securities. A short sale is the sale of a security that the seller does not own at the time of the trade.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Engaging in Derivative Transactions</u>. No Insider may engage in transactions in puts, calls or other derivative instruments that relate to or involve Company securities. Such transactions are, in effect, bets on short-term movements in the Company's stock price and therefore create the appearance that the transaction is based on nonpublic information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Hedging</u>. No Insider may engage in hedging transactions involving Company securities, including forward sale or purchase contracts, equity swaps, collars or exchange funds. Such transactions are speculative in nature and therefore create the appearance that the transaction is based on nonpublic information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Trading on Margin or Pledging</u>. No Insider may hold Company securities in a margin account or pledge (or hypothecate) Company securities as collateral for a loan. Margin sales or foreclosure sales may occur at a time when the Insider is aware of material nonpublic information or otherwise is not permitted to trade in Company securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Trading in Securities of Other Companies</u>. No Insider may, while in possession of material nonpublic information about any other public company gained in the course of employment with the Company, (a) trade in the securities of the other public company, (b) "tip" or disclose such material nonpublic information concerning that company to anyone, or (c) give trading advice of any kind to anyone concerning the other public company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**D.** **Exceptions.** 

The prohibited activities above do not apply to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Exercises of stock options or similar equity awards or the surrender of shares to the Company in payment of the stock option exercise price or in satisfaction of any tax withholding obligations, provided that any securities acquired pursuant to such exercise *may not be sold*  **** ** while the Insider is in possession of material nonpublic information or subject to a special trading blackout.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Other purchases of securities from the Company or sales of securities to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Purchases or sales made pursuant to a Rule 10b5-1 plan that is adopted and operated in compliance with the terms of this Policy. See Section VII.

&nbsp;&nbsp;&nbsp;&nbsp;**IV.** **DETERMINING WHETHER INFORMATION IS MATERIAL AND NONPUBLIC** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.** **Definition of** "**Material** "**Information.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. There is no bright line test for determining whether particulate information is material. Such a determination depends on the facts and circumstances unique to each situation and cannot be made solely based on the potential financial impact of the information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. In general, information about the Company should be considered "material" if:

&nbsp;&nbsp;&nbsp;&nbsp;● A reasonable investor would consider the information significant when deciding whether to buy or sell Company securities; or

&nbsp;&nbsp;&nbsp;&nbsp;● The information, if disclosed, could be viewed by a reasonable investor as having significantly altered the total mix of information available in the marketplace about the Company.

Put simply, if the information could reasonably be expected to affect the price of the Company's stock, it should be considered material.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. It is important to remember that whether information is material will be viewed by enforcement authorities with the benefit of hindsight. In other words, if the price of the Company's stock changed as a result of the information having been made public, it will likely be considered material by enforcement authorities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. While it is not possible to identify every type of information that could be deemed to be "material," the following matters ordinarily should be considered material:

&nbsp;&nbsp;&nbsp;&nbsp;● Financial performance, especially quarterly and year-end earnings or significant changes in financial performance or liquidity.

&nbsp;&nbsp;&nbsp;&nbsp;● Potential significant mergers and acquisitions or the sale of significant assets or subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;● New major contracts, orders, suppliers, customers, or finance sources, or the loss thereof.

&nbsp;&nbsp;&nbsp;&nbsp;● Major discoveries or significant changes or developments in products or product lines, research or technologies.

&nbsp;&nbsp;&nbsp;&nbsp;● Significant changes or developments in supplies or inventory, including significant product defects, recalls or product returns.

&nbsp;&nbsp;&nbsp;&nbsp;● Stock splits, public or private securities/debt offerings, or changes in dividend policies or amounts.

&nbsp;&nbsp;&nbsp;&nbsp;● Significant changes in senior management.

&nbsp;&nbsp;&nbsp;&nbsp;● Actual or threatened major litigation, or the resolution of such litigation.

&nbsp;&nbsp;&nbsp;&nbsp;● An imminent change in the Company's credit rating by a rating agency.

&nbsp;&nbsp;&nbsp;&nbsp;● The contents of forthcoming publications that may affect the market price of Company securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** **Definition of** "**Nonpublic** "**Information.** 

Information is "nonpublic" if it has not been disseminated to investors through a widely circulated news or wire service (such as Dow Jones, Bloomberg, PR Newswire, etc.) or through a public filing with the Securities and Exchange Commission (the "SEC"). For the purposes of this Policy, information will not be considered public until after the close of trading on the second full trading day following the Company's widespread public release of the information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.** **Consult the Compliance Officer for Guidance.** 

Any Insider who is unsure whether the information that he or she possesses is material or nonpublic should consult the Compliance Officer for guidance before trading in any Company securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**D.** **Hardship Cases.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Hardship Trades</u>. The Compliance Officer may, on a case-by-case basis, authorize trading in Company securities outside of an applicable trading window due to financial hardship or other hardships only after:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. the individual trading has notified the Compliance Officer in writing of the circumstances of the hardship and the amount and nature of the proposed trade(s), and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. the individual trading has certified to the Compliance Officer in writing no earlier than two business days prior to the proposed trade(s) that he or she is not aware of material nonpublic information concerning the Company.

&nbsp;&nbsp;&nbsp;&nbsp;**V.** **COMPLIANCE OFFICER** 

The Company has designated its Chief Compliance Officer, or any individual designated by the Chief Compliance Officer, as the individual responsible for ensuring compliance with this Policy (the "<u>Compliance Officer</u>"). The duties of the Compliance Officer include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.** Administering this Policy and monitoring and enforcing compliance with all Policy provisions and procedures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** Responding to all inquiries relating to this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.** Reviewing and either approving or denying all proposed trades by Insiders in accordance with the procedures set forth in Section V.C.1 above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**D.** After discussing with the blackout assessment team, designating and announcing special trading blackout periods during which certain Insiders may not trade in Company securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**E.** Providing copies of this Policy and other appropriate materials to all new Insiders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**F.** Administering, monitoring and enforcing compliance with all federal and state insider trading laws and regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**G.** Assisting in the preparation and filing of all required SEC reports relating to insider trading in Company securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**H.** Revising the Policy as necessary to reflect changes in federal or state insider trading laws and regulations, or as otherwise deemed necessary or appropriate.

The Compliance Officer may designate one or more individuals who may perform the Compliance Officer's duties in the event that the Compliance Officer is unable or unavailable to perform such duties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Compliance Officer Trades</u>. If the Compliance Officer desires to complete any trades involving Company securities, he or she must first obtain the approval of the Chief Executive Officer of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;**VI.** **RULE 10b5-1 TRADING PLANS** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.** **General Information.** 

Under Rule 10b5-1 of the Securities Exchange Act of 1934, an individual has an affirmative defense against an allegation of insider trading if he or she demonstrates that the purchase, sale or trade in question took place pursuant to a binding contract, specific instruction or written plan that was put into place before he or she became aware of material nonpublic information. Such contracts, irrevocable instructions and plans are commonly referred to as Rule 10b5-1 plans.

Rule 10b5-1 plans have the obvious advantage of protecting against insider trading liability. However, they also require advance commitments regarding the amounts, prices and timing of purchases or sales of Company securities and thus limit flexibility and discretion. In addition, once a Rule 10b5-1 plan has been adopted, it is generally not permissible to amend or modify such plan.

Accordingly, while some individuals may find Rule 10b5-1 plans attractive, they may not be suitable for all Insiders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** **Specific Requirements.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Pre-Approval</u>. For a Rule 10b5-1 plan to serve as an adequate defense against an allegation of insider trading, a number of legal requirements must be satisfied. Accordingly, anyone wishing to establish a Rule 10b5-1 plan must first receive approval from the Compliance Officer or his or her designee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Material Nonpublic Information and Special Blackouts</u>. An individual desiring to enter into a Rule 10b5-1 plan must enter into the plan at a time when he or she is not aware of any material nonpublic information about the Company or otherwise subject to a special trading blackout.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Trading Window</u>. Insiders may only establish a Rule 10b5-1 plan when the Company's trading window is open.

&nbsp;&nbsp;&nbsp;&nbsp;**VII.** **POTENTIAL PENALTIES AND DISCIPLINARY SANCTIONS** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.** **Civil and Criminal Penalties.** 

The consequences of prohibited insider trading or tipping can be severe. Persons violating insider trading or tipping rules may be required to disgorge the profit made or the loss avoided by the trading, pay the loss suffered by the person who purchased securities from or sold securities to the Insider or tippee, pay significant civil and/or criminal penalties, and serve a lengthy jail term. The Company in such circumstances may also be required to pay major civil or criminal penalties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** **Company Discipline.** 

Violation of this Policy or federal or state insider trading or tipping laws by any Insider may, in the case of a director, subject the director to dismissal proceedings and, in the case of an officer or employee, subject the officer or employee to disciplinary action by the Company up to and including termination for cause.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.** **Reporting of Violations.** 

Any Insider who violates this Policy or any federal or state law governing insider trading or tipping or knows of any such violation by any other Insider, must report the violation immediately to the Compliance Officer. Upon determining that any such violation has occurred, the Compliance Officer, in consultation with the Company's Chair of the Audit Committee of the Board, will determine whether the Company should release any material nonpublic information, and, when required by applicable law, shall cause the Company to report the violation to the SEC or other appropriate governmental authority.

&nbsp;&nbsp;&nbsp;&nbsp;**VIII.** **MISCELLANEOUS** 

This Policy will be delivered to all directors, officers, employees and designated outsiders upon its adoption by the Company and to all new directors, officers, employees and designated outsiders at the start of their employment or relationship with the Company.

Upon first receiving a copy of this Policy or any revised versions, all directors, officers, and employees must sign an acknowledgment that he or she has received a copy of this Policy and agrees to comply with its terms.

This Policy will renew annually and must be acknowledged and signed by all directors, officers, and employees.

------

## Exhibit 21.1

**Exhibit 21.1**

 <u>**NEXTPLAT CORP AND SUBSIDIARIES**</u>

**List of Subsidiaries**

---

| | |
|:---|:---|
| **Subsidiary** | **State or Other Jurisdiction of Incorporation** |
| ClearMetrX, Inc. | Florida |
| Family Physicians RX, Inc. (doing business as PharmcoRx 1103 and Pharmcorx 1204) | Florida |
| Global Telesat Communications Limited | England and Wales |
| Orbital Satcom Corp. | Nevada |
| Outfitter Satellite, Inc. | Tennessee |
| Pharmco, LLC (doing business as Pharmcorx and Pharmcorx LTC) | Florida |
| Progressive Care LLC | Nevada |
| RXMD Therapeutics, Inc. | Florida |
| Touchpoint RX, LLC (doing business as Pharmco Rx 1002, LLC) | Florida |
| Outfitter Satellite, Inc. | Tennessee |

---

------

## Exhibit 23.1

**Exhibit 23.1**

---

| | |
|:---|:---|
| ![a01.jpg](a01.jpg) | ***New York Office:*** <br>805 Third Avenue <br> 14th floor <br> New York, NY 10022 <br> 212.838-5100 <br>***www.rbsmllp.com*** |

---

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in this Annual Report on Form 10-K of NextPlat Corp. and subsidiaries (the "Company") as of and for the years ended December 31, 2025 and 2024 of our report dated March 31, 2026 included in its Registration Statements on Form S-3 (No. 333-272809 and 333-292211) and Form S-8 (File No. 333-280655, 333-287913 and 333-293095) relating to the consolidated financial statements.

/s/ RBSM LLP

We have served as the Company's auditor since 2014.

New York, New York

March 31, 2026

------

## Exhibit 31.1

**Exhibit 31.1**

**<u>CERTIFICATIONS</u>**

I, David Phipps, certify that:

1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2025, of NextPlat Corp;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: March 31, 2026 | /s/ David Phipps |
|  | David Phipps |
|  | Chief Executive Officer and President |
|  | (Principal Executive Officer) |

---

------

## Exhibit 31.2

**Exhibit 31.2**

**<u>CERTIFICATIONS</u>**

I, Amanda Ferrio, certify that:

1. I have reviewed this annual report on Form 10-K for the year ended December 31, 2025, of NextPlat Corp;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: March 31, 2026 | /s/ Amanda Ferrio |
|  | Amanda Ferrio  |
|  | Chief Financial Officer |
|  | (Principal Financial and Accounting Officer) |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of NextPlat Corp (the "Company") on Form 10-K for the fiscal year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), David Phipps, Chief Executive Officer and President of the Company, and Amanda Ferrio, Chief Financial Officer of the Company, each certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: March 31, 2026 | By:  | /s/ David Phipps |
|  |  | David Phipps  |
|  |  | Chief Executive Officer and President |
|  |  | (Principal Executive Officer)  |

---

---

| | | |
|:---|:---|:---|
| Date: March 31, 2026  | By:  | /s/ Amanda Ferrio |
|  |  | Amanda Ferrio |
|  |  | Chief Financial Officer  |
|  |  | (Principal Financial and Accounting Officer) |

---

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request

------